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Lauren Michele Federici 
ELUCIDATING TRIGGERS AND NEUROCHEMICAL CIRCUITS UNDERLYING 
HOT FLASHES IN AN OVARIECTOMY MODEL OF MENOPAUSE 
 
Menopausal symptoms, primarily hot flashes, are a pressing clinical 
problem for both naturally menopausal women and breast and ovarian cancer 
patients, with a high societal and personal cost.  Hot flashes are poorly 
understood, and animal modeling has been scarce, which has substantially 
hindered the development of non-hormonal treatments.  An emerging factor in 
the hot flash experience is the role of anxiety and stress-related stimuli, which 
have repeatedly been shown to influence the bother, frequency, and severity of 
hot flashes.  Causal relationships are difficult to determine in a clinical setting, 
and the use of animal models offers the ability to elucidate causality and 
mechanisms.  The first part of this work details the development and validation of 
novel animal models of hot flashes using clinically relevant triggers (i.e., 
compounds or stimuli that cause hot flashes in clinical settings), which also 
increase anxiety symptoms.  These studies revealed that these triggers elicited 
strong (7-9 °C) and rapid hot flash-associated increases in tail skin temperature 
in rats.  In a surgical ovariectomy rat model of menopause, which typically exhibit 
anxiety-like behavior, hot flash provocation revealed an ovariectomy-dependent 
vulnerability, which was attenuated by estrogen replacement in tested models.  
An examination of the neural circuitry in response to the most robust flushing 
compound revealed increased cellular activity in key thermoregulatory and 
emotionally relevant areas.  The orexin neuropeptide system was hyperactive 
and presented as a novel target; pretreatment with selective and dual orexin 
receptor antagonists significantly diminished or eliminated, respectively, the 
response to a hot flash provocation in ovariectomized rats.  The insertion/deletion 
polymorphism of the serotonin transporter has been linked to increased anxiety-
associated traits in humans, and subsequent studies prolonged hot flashes in 
SERT+/- rats, which also caused hot flashes in highly symptomatic women.  
These studies indicate the orexin system may be a novel non-hormonal 
 v   
treatment target, and future studies will determine the therapeutic importance of 
orexin receptor antagonists for menopausal symptoms.  
 
Anantha Shekhar, M.D., Ph.D., Chair 
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Part I:  Overview of Menopause, Hot Flashes, Estrogen, and Therapeutics 
 
1.1. Menopause and Hot Flashes  
 
1.1.1.  Naturally occurring menopause 
Menopause occurs as a consequence of the natural course of aging in 
women, wherein the ovarian follicular cells degenerate and cease to produce sex 
steroid hormones, especially estradiol.  With the extensive data garnered through 
the advent of large-scale studies that have followed thousands of women 
prospectively, menopause can be broken down into many stages based on 
menstrual bleeding patterns that were recently updated (as summarized by the 
Society of Reproductive Aging Workshop +10 [ten years after the initial meeting; 
STRAW+10)(Harlow et al., 2012)].  Generally, the perimenopause stage refers to 
the time period wherein menstrual cycles of a previously predictable length (the 
number of days between cycles) become subtly aberrant, and during this time a 
woman approaches the ‘menopausal transition’.  In the early perimenopausal 
stage, cycle lengths must be ≥7 days different for 10 consecutive months; the 
late perimenopause stage is marked by a period of amenorrhea that lasts for 60 
or more days.  The final menstrual period (FMP) is defined as the ‘0’ point on the 
continuum, and at that point a woman enters the postmenopause, which is 
subdivided into early postmenopause and late postmenopause stages.  
Interestingly, the endocrine correlates are not the defining criterion; but rather 
supportive, as the bleeding pattern data has been verified across many cultures 
where reliable hormonal measurements were not always available.  Throughout 
the reproductive years, follicle stimulating hormone (FSH), inhibin-B, and anti-
Mullerian hormone (AMH) are low, and FSH begins to rise in the late 
reproductive stage until it surpasses 25 IU/L in the late menopausal transition 
(before stabilizing in the postmenopause years).  Inhibin-B and AMH drop to very 
low levels in the late postmenopause stage. 
The loss of ovarian function during menopause leads to symptoms 
associated with disrupted autonomic tone (e.g., hot flashes and racing heart), 
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sleep disruption, weight gain, and alterations in mood.  Of these symptoms, hot 
flashes are the most problematic, and begin in the late perimenopause and early 
postmenopause stages.  Thus menopause is perhaps every bit as emotionally 
and physically wrenching as puberty, which is the onset of reproductive viability.  
In the United States and other western cultures, the typical onset of menopause 
occurs at a median age of 51.3 (Dratva et al., 2009).  This is a time of life already 
burgeoning with change and transitions such as children maturing and leaving 
the household and/or caring for elderly parents, and as discussed in section 
2.3.2., this may contribute to anxiety and stress which are now becoming 
recognized as prominent risk factors for more severe and problematic hot 
flashes.  Additionally, early onset of naturally occurring menopause is associated 
with more severe menopausal symptoms (Kuh et al., 1997).  
 
1.1.2.  Surgical and pharmacological menopause 
For some women, menopause comes at a relatively young age and 
abruptly following surgical or pharmacological disruption of sex hormone activity.  
Surgically induced menopause occurs following ovarian removal (oophorectomy), 
which can be done to treat benign conditions, like cysts, or to treat or prevent 
ovarian cancer.  In particularly high-risk women, like those with a family history of 
breast cancer and certain genetic mutations (e.g., BRCA1, BRCA2), 
oophorectomy is also done to treat or prevent estrogen receptor positive breast 
cancer.  Pharmacologically induced menopause occurs following estrogen 
inhibition therapies (EIT) to treat estrogen receptor positive breast cancer.  
Selective estrogen receptor modulators (SERM; e.g., tamoxifen) are estrogen 
antagonists in breast tissue, and aromatase inhibitors (AI) prevent the conversion 
of androgens into estrogens.  These compounds are commonly prescribed for 
cancer treatment, but also for prevention in high-risk women, similar to 
prophylactic oophorectomy.  Additional health complications arising from surgical 
menopause (above and beyond natural menopause) are listed in Table 1, and 
include a diverse array of symptoms, such as increased risk of Parkinsonism, 
increased mood disruption, and many cardiovascular and metabolic problems. 
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Table 1.  Menopausal Symptoms Exacerbated by Oophorectomy.  Menopause induced 
through surgery (oophorectomy) leads to increased adverse health outcomes, of both 
short and long-term duration, relative to naturally-occurring menopause.  The nature of 
the conditions is varied, and includes classical menopausal symptoms like hot flashes, 
but also neurological disease and disease affecting peripheral organ systems. 
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1.1.3.  Menopause Symptoms 
1.1.3a.  Brief recapitulation of menopause symptoms 
While there is no one defining universal menopausal experience, the 
constellation of symptoms is fairly consistent across cultures and includes a 
variety of physical and psychological/psychiatric perturbations.  The cardinal 
symptom, hot flashes and night sweats, are discussed in greater detail in the 
following paragraph.  Briefly, the symptoms that typically receive less attention 
include affective changes and mood disruption, such as anxiety and depression.  
This can include an increased number of anxiety and depressive symptoms (but 
not enough to warrant a clinical diagnosis) as well as meeting sufficient criteria 
for  a diagnosis.  Weight gain, sleep disturbances, fatigue, osteoporosis, and 
genitourinary syndrome (previously known as vulvovaginal atrophy) and sexual 
dysfunction are common complaints at the menopause.  Cognitive loss, 
independent of aging, is also frequently reported.   
 
1.1.3b.  Hot flash sensation  
In addition to irregular menstruation, the hallmark of the menopausal 
transition is the hot flash (more commonly hot flush in the U.K.), which consists of 
an intense sensation of heat sweeping across the body and is often, but not 
always, accompanied by sweating (see Fig. 1).  It is often relatively restrained to 
the face and neck region, but can cover the entire body [though rarely the dorsal 
(backside) surface (Voda, 1981)].  Figure 1 represents a body diagram where a 
woman has drawn where the hot flash occurs.  Cultural or ethnic differences in 
physical localization of the experience of the flush have been described, such 
that Mexican women identify hot flashes on the neck and arms/hands whereas 
Caucasian women (historically, the major population of most menopausal 
studies) report sensations mostly on the face and chest (Sievert et al., 2002).   
 
1.1.3c.  Hot flashes are associated with cutaneous vasomotor responses 
Physiologically, hot flashes consist of objectively measurable signs:  
increased  
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Figure 1.  Body Diagram of a Hot Flash.  ‘X’ indicates the origins of the hot flash, and 
arrows demonstrate the spread.  Note the differences between the frontal/ventral and 
back/dorsal perspectives.  Modified from (Sievert et al., 2007). 
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skin temperature, increased cutaneous blood flow, mild tachycardia, decreased 
core body temperature, and decreased skin resistance or increased skin 
conductance/sweating (Kronenberg, 1990; Low et al., 2008).  In addition to all of 
the objectively measurable events, what usually defines a hot flash is the 
subjective labeling of these signs as a hot flash.  Often, this is indicated by a 
button press (in laboratory studies) or in an electronic diary (for long-term 
observations).  Despite this subjectivity, the physiology tends to correlate with 
subjective measures quite well, as illustrated in Fig. 2.  Lastly, psychological 
symptoms at the time of the flush include feelings of anxiety and/or 
embarrassment, which may depend on the individual and social context in which 
the flash occurs, such as in the workplace versus at home.  Anecdotally, some 
women describe severe anxiety during hot flashes that are consistent with an 
“escape” response, such as feeling the need to leave the store during grocery 
shopping.   
 
1.2. Burden of Hot Flashes 
 
1.2.1.  Incidence and duration of symptoms 
The incidence of hot flashes is striking; in both the U.S. and U.K., up to 
90% of women report them (Williams et al., 2008; Hunter et al., 2012).  While the 
long-held assumption was that hot flashes last only a short time around the 
menopausal transition, recent systematic studies demonstrated that hot flashes 
occur for much longer than a year or two.  An earlier meta-analysis demonstrated 
that the median duration of hot flashes is four years (Politi et al., 2008); in 2011, 
Freeman reported a median duration of 10.2 years for moderate-to-severe hot 
flashes for women in the Penn Ovarian Aging Study (Freeman et al., 2011).  The 
Study of Women’s Health Across the Nation (SWAN) corroborated both studies, 
finding a median duration of 7.4 years for hot flashes overall, but persistence of 
up to 14 years (Avis et al., 2015).  While hot flashes eventually subside for the 
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Figure 2.  Physiological Recordings of a Hot Flash.  The top panel illustrates the 
subjective sensation of a hot flash (as indicated with a button press) and its close 
temporal relationship with increased finger blood flow and finger temperature at the 
onset of the hot flash.  Note the high ambient temperature; this was likely elevated to 
increase the probability of a hot flash.  The bottom panel illustrates skin sympathetic 
nerve activity just precedes the onset of a hot flash (subjective sensation), which also 
correlates very well with sweat responses in the chest and foot.  Upper panel adapted 
from Kronenberg, 1990, and lower panel adapted from Low et al., 2008.   
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majority of women, a small subset (10-15%) experience hot flashes for ten years 
or more or even for the remainder of their lives; a recent survey of 85-year old 
women reported 16% (still) experienced vasomotor symptoms (Vikstrom et al., 
2013).   
 
1.2.2.  Healthcare and economic costs 
Perhaps unsurprisingly, hot flashes are the primary menopausal symptom 
women seek medical treatment for, resulting in substantial direct and indirect 
healthcare costs.  Until recently, the economic burden of vasomotor symptoms 
had been murky, though thought to be high, given that over 2 million women 
enter menopause annually (United States Department of Labor), and work ability 
has been reported as inversely related to climacteric symptoms (Geukes et al., 
2012).  In a retrospective study of over 35,000 women, Kleinman and colleagues 
found increased:  direct medical and pharmacy costs, sick leave costs, and sick 
leave days among women with diagnosed menopausal symptoms (relative to 
control women matched on a number of parameters).  Their estimates of hourly 
and annual productivity were 12.2 and 10.9% lower, respectively, for women with 
menopausal symptoms (Kleinman et al., 2013).  In an analysis of 252,273 
menopausal women (with symptoms but not utilizing treatment) using insurance 
database entries, Sarrel and colleagues estimated the cost of untreated 
vasomotor symptoms in excess of $375 million annually (Sarrel et al., 2015).  
Similarly, this figure includes both direct and indirect costs; specifically, these 
women had 82% more physician visits (all causes), 121% more VMS-related 
physician visits, and 57% more work productivity loss days.  With regard to 
severity of symptoms and work, women with severe or moderate VMS 
experience greater presenteeism, or working while sick (which is associated with 
decreased productivity), than women with mild VMS (24.28 and 14.3%, 
respectively, for severe and moderate VMS compared to 4.33% for women with 
mild VMS).  In terms of dollars, these percentages translate to an increased cost 
from $1100 (mild symptoms) to $6500 (severe symptoms) per woman [2009 US 
dollars (Whiteley et al., 2013)]. 
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1.3.  Relationship Between Hot Flashes and Estrogen 
 
 Although dramatic loss of estrogen during menopause is the major 
contributing factor leading to hot flashes and other menopausal symptoms (e.g., 
weight gain, sleep disruption, and changes in mood/anxiety and cognition), the 
exact mechanisms have yet to be fully understood.  Estrogens are a complex 
family of molecules of several different types with varying affinities for their 
nuclear and membrane associated receptors.  In this section, I will discuss the 
types of estrogens, estrogen receptors (types and localization with respect to 
function), and evidence of estrogen’s critical role in hot flashes. 
 
1.3.1.  Types of estrogens  
 It is virtually impossible to discuss hot flashes without a mention of 
estrogens, whose replacement was the standard of care for VMS and is still the 
only known compound to substantively relieve hot flashes (albeit at high doses).  
These steroid hormones are synthesized from cholesterol precursors, and the 
enzyme aromatase converts androgens into estrogens.  Estrogens are 
delineated among three major classes:  estrone (E1), estradiol (E2), and estriol 
(E3).  Estrone is the primary circulating estrogen after menopause produced 
largely by the adrenal glands; it is the least potent agonist of the estrogen 
receptor.  Estradiol, the “estrogen” that most colloquial and even scientific 
language refers to, is the primary circulating estrogen for non-pregnant, 
reproductive-age females and is the most potent of these molecules.  Estriol, is 
exclusively produced during pregnancy, and has potency intermediate of estrone 
and estradiol.  Throughout this document, estrogen refers to estradiol unless 
explicitly differentiated. 
 
1.3.2.  Types of estrogen receptors, locations, and function 
 Estrogen receptors (ER) fall into two classes:  classical nuclear receptors 
and more recently discovered membranous receptors.  The nuclear receptors, 
ERα and ERβ, are transcribed from genes on different chromosomes (in 
 10
humans; ERα on 6q25.1 and ERβ on 15a23.2) and have three and four known 
isoforms, respectively (Jia et al., 2015).  Functionally, an ER consists of three 
domains:  1) the NH2-terminal domain; 2) the DNA-binding domain; 3) the 
COOH-terminal ligand-binding domain.  The DNA-binding domains are 97% 
conserved between the two receptors, and enter the nucleus to regulate gene 
transcription by binding to estrogen response elements (DNA sequences).  Their 
temporal responsiveness is relatively slow, in comparison to a membrane 
receptor or ion channel, for example.  ERs are widely distributed in the peripheral 
tissues of the rat, with high expression of ERα and ERβ in the ovary and uterus; 
high expression of ERα in the pituitary, kidney, and adrenals; moderate 
expression of ERβ in the uterus, bladder, and lung; low expression of ERβ in the 
pituitary, thymus, and spinal cord; and high expression of ERβ in the ovary 
(Kuiper et al., 1997). 
Prior to the discovery of a second ER (ERβ), in situ hybridization studies 
of female rats revealed that ER mRNA transcripts were widely distributed 
throughout the brain, with dense expression in many amygdaloid and 
hypothalamic nuclei and less expression in the brainstem, septal areas, 
thalamus, and cerebellum (Simerly et al., 1990).  Later studies revealed that ER 
expression varied over the estrus cycle, and that ovariectomy lead to increased 
ER expression (Shughrue et al., 1992).  An initial characterization of ERβ 
compared to ERα revealed some restricted localization of the β receptor; 
specifically, it is expressed (virtually) exclusively in the supraoptic nucleus and 
paraventricular nucleus (Shughrue et al., 1996).  Additionally, ERβ is expressed 
in the medial preoptic, anterior periventricular, arcuate, medial mammillary 
nucleus, and bed nucleus of the stria terminalis.  Within the paraventricular 
nucleus, in situ hybridization combined with immunohistochemistry revealed that 
these neurons were largely (60-80%) positive for corticotrophin releasing factor 
(Laflamme et al., 1998).  Osterlund and colleagues further found specific 
differences of expression of the two receptors within subnuclei of the amygdala 
(Osterlund et al., 1998). The expression of these receptors in hypothalamic 
nuclei strongly suggests a key role in regulating sexual, reproductive, stress-
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responsive, and homeostatic physiological processes and behaviors, whereas 
the amygdaloid expression indicates an essential role in emotional regulation.  
The other known estrogen receptor is a membranous receptor called 
GPER (G-protein coupled estrogen receptor 1, formerly GPR30) and has been 
found in breast tumors in women and is linked to invasive cancers (Filardo et al., 
2006).  As the name suggests, it is a 7-transmembrane, Gq-protein coupled 
receptor.  It follows that GPER mediates fast, non-genomic effects of estradiol, 
and activation with a GPER-specific ligand increases intracellular calcium 
(Brailoiu et al., 2007).  Distribution patterns of GPER parallel ERβ to some 
extent, with high expression in the supraoptic nucleus and paraventricular 
nucleus (Brailoiu et al., 2007; Hazell et al., 2009).  GPER is also found in the 
forebrain, anterior pituitary, hippocampus, and brainstem nuclei that regulate the 
autonomic nervous system (area postrema, dorsal motor nucleus of the vagus, 
nucleus of the solitary tract, and nucleus ambiguous) and in some peripheral 
tissues (renal pelvis, adrenal medulla, and ovary) of the rat (Brailoiu et al., 2007; 
Hazell et al., 2009).  As there is a specific antibody for this receptor, double 
immunohistochemical studies have identified that a significant proportion of 
GPER+ cells are also immunoreactive for either oxytocin or vasopressin in the 
hypothalamus (Brailoiu et al., 2007; Hazell et al., 2009).  Similar to the classical 
receptors, GPER may also have a specific subcellular distribution, as one study 
demonstrated specific localization to the Golgi apparatus and endoplasmic 
reticulum (Matsuda et al., 2008).  Again, the high expression of GPER in 
hypothalamic and autonomic nuclei suggests a prominent role for estrogen’s 
regulation of homeostatic function. 
Interestingly, more recent work has revealed that the classical ‘nuclear’ 
receptors can also mediate fast membranous effects.  Currently, both ERα and 
ERβ have been shown to couple with metabotropic glutamate receptors 
(mGluRs) through scaffolding proteins called caveolins [see review by (Meitzen 
and Mermelstein, 2011)].  Caveolin 1 links ERα to Group I mGluRs (mGluR1 or 
mGluR5), which are presynaptically localized, excitatory, Gq-coupled receptors.  
Gq signaling initiates the cleavage of phosphatidylinositol 4,5-bisphosphonate 
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(PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) by 
Phospholipase C (PLC).  IP3 can stimulate intracellular calcium release from the 
endoplasmic reticulum, whereas DAG can increase cAMP production through the 
stimulation of adenylyl cyclase (via DAG-dependent protein kinase/PKG).  cAMP 
can then bind to the cAMP response element (CRE) in the genome to modulate 
gene transcription.  cAMP can also regulate ion channels (such as G-protein 
inward rectifying potassium [GIRK] channels, which control intracellular 
excitability) or modulate proteins [(review by (Kelly and Rønnekleiv, 2015)].  
Conversely, caveolin 3 can link ERα and ERβ to Group II mGluRs (mGluR2 or 
mGluR3), which are inhibitory and both pre- and postsynaptically localized.  
These receptors are linked to Gi proteins, which inhibits adenylyl cyclase and 
cAMP production, consequently decreasing the activity of cAMP-dependent 
protein kinase (PKA).  Through either membranous signaling pathway, estrogen 
can affect cellular excitability and gene transcription, even in the absence of an 
estrogen response element (ERE).  
 
1.3.3.  Estrogen inhibition  
Estrogen disruption, either surgical or pharmacological, unequivocally 
leads to hot flashes.  Women who have had an oöphorectomy experience severe 
menopausal symptoms, including depression and anxiety, and have greater 
moderate-to-severe and prolonged hot flashes when compared to naturally 
menopausal women (Gallicchio et al., 2006b; Rocca et al., 2008; Benshushan et 
al., 2009).  Young, premenopausal women prescribed adjuvant endocrine 
therapies (AET) for cancer treatment (SERMs, AIs) frequently experience hot 
flashes [35.7-42.5% for AI, 69% for tamoxifen use (Carpenter et al., 1998)], and 
the majority of these women rate their hot flashes as severe (59%).  In fact, 
studies have documented that the hot flashes resulting from SERM treatment is 
so severe that many patients discontinue taking these medications, which leads 
to increased mortality (Hershman et al., 2011; Murphy et al., 2012; Kemp et al., 
2014).   
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1.3.4.  Relationship between estrogen levels and hot flashes 
Yet, the relationship between hot flashes and estrogen outside of an 
estrogen inhibition context is not as simple as it would appear.  Estradiol levels in 
premenopausal women fluctuate across the menstrual cycle, and range from 
approximately 60 to 100 pg/ml (Rothman et al., 2011), as shown in Fig. 3.  As a 
woman transitions into perimenopause, estradiol levels fluctuate around normal 
premenopausal values before dropping precipitously about one year before the 
final menstrual period (Burger et al., 1999).  Estradiol levels then further 
decrease in the years following the final menstrual period, and ultimately are 
about 90% decreased from premenopausal values.  The correlations between 
estradiol levels and the presence or absence of hot flashes have not always 
been the most straightforward, as numerous early studies failed to find consistent 
or even any positive relationships between these measures [for review, see 
(Whiteman et al., 2003)].  Notably, these were small, cross-sectional studies, and 
much larger (i.e. sufficiently powered) and longitudinal studies (typically 200 
women or more) have revealed stronger and more consistent relationships 
between hot flashes and estrogen levels, such that low levels of estrogen were 
significantly associated with hot flashes (Gold et al., 2000; Avis et al., 2001a; 
Gallicchio et al., 2006b, 2015; Alexander et al., 2010).  An additional 
consideration is the methodologies used to assess estrogen levels.  Traditional 
methods have used immunoassays (i.e, radioimmunoassays), and are plagued 
by nonspecificity because the antibodies employed have difficulty in separating 
estradiol and estrone (Labrie et al., 2015).  Furthermore, they are relatively 
insensitive, and the low levels of estradiol in the postmenopause stage are often 
around the limits of detection of some assays.  More sophisticated methods (e.g., 
liquid chromatography tandem mass spectrometry; LC-MS/MS) are more suited 
to separate these compounds and accurately assess low levels.  Despite the 
outstanding question regarding how estrogen loss contributes to hot  
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Figure 3.  Levels of Estradiol and Follicle Stimulating Hormone Across the Lifespan.  
Estradiol (E2) and Follicle Stimulating Hormone (FSH) are graphed according to 
measurements across a regular menstrual cycle in a cohort of young women [early 
follicular phase (EFP), mid-cycle (MC), and mid-luteal phase (MLP)] and in early 
menopausal (less than five years after the final menstrual period) and late menopausal 
women (five years or more after the final menstrual period).  Data points represent group 
averages ± SEM; n=14,9, and 10, respectively for premenopausal, early and late 
menopausal participants.  Overall, there is a 90% reduction in E2 from premenopausal to 
post-menopause, and E2 continues to decrease in the postmenopausal years.  Graph is 
adapted from Rothman et al., 2011 Steroids.   
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flash generation and how its replacement ameliorates most hot flashes, estrogen 
clearly plays a very important role.  Numerous studies of premenopausal (and 
therefore having largely normal endocrine profiles) cancer patients treated with 
estrogen inhibition therapies demonstrate that estrogen antagonism causes hot 
flashes.  However, caution should be taken in interpreting studies that have 
quantified estrogens using immunoassays, and thus this represents another area 
for potential improvement in studying women’s health.   
 
1.3.5.  Estrogen withdrawal is necessary 
Despite more recent findings (with more sophisticated and sensitive 
assays), absolute levels of estrogen appear insufficient to cause or permit hot 
flashes or even prevent them.  Seminal papers long reported that estrogen 
withdrawal is required for hot flashes, as pre-pubertal girls (with low levels of 
estrogen) do not experience hot flashes, and women with developmental defects 
that never go through puberty (i.e., those with hypothalamic amenorrhea) 
experience hot flashes only after withdrawing from estrogen therapy (Yen et al., 
1972b).  And while high doses of estrogen ameliorate hot flashes, after 
discontinuing ERT, most women will experience hot flashes again regardless of 
tapering or not (Haskell, 2004).  In recent years, the advent of non-hormonal 
therapies has helped to provide a broader perspective on hot flashes that is less 
estrogen-centric. 
 
1.3.6.  Progesterone 
 Although much research in women’s health has focused on estrogens, 
given their ability to reduce hot flashes, progesterone has shown promise as a 
therapy, both through correlational analyses and hormone replacement studies.  
A large-scale genetic study found low levels of progesterone were significantly 
associated with recent, severe, and frequent hot flashes in women who 
experienced hot flashes compared to women who have not experienced hot 
flashes (Schilling et al., 2007).  Recently, Gallicchio reported that higher estradiol 
and progesterone levels significantly decreased the odds of all hot flash 
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measurements in a cohort of younger mid-life women (Gallicchio et al., 2015).  
Progesterone replacement was equally able to reduce hot flashes compared to 
conjugated equine estrogens in a cohort of premenopausal women that 
underwent oophorectomy for benign disease in an intervention trial (Prior et al., 
2007), and significantly reduced vasomotor symptoms in postmenopausal 
women, including within a subset with severe symptoms (Hitchcock and Prior, 
2012; Prior and Hitchcock, 2012).  
 
1.4.  Therapeutic Options for Hot Flash Amelioration 
 
1.4.1.  Decline of estrogen replacement therapy 
 In the last 15 years, estrogen has been the subject of much controversy 
for reasons that have little to do with its efficacy as a hot flash remedy, for which 
it is about 75% effective (reduction in the number of hot flashes) according to a 
detailed Cochrane analysis (Maclennan et al., 2004).  The early landmark study 
in hormone replacement trials, the Women’s Health Initiative [WHI; (Rossouw et 
al., 2002)], demonstrated increased risk for cardiovascular events, stroke, and 
breast cancer in women taking estrogen (with or without progesterone) 
replacement.  Unfortunately, there were significant problems with the design of 
these studies, as more than half the WHI cohort had been post-menopausal for 
ten years or more before re-exposure to estrogen and/or progesterone.  This is 
pertinent in the context of the critical window hypothesis of estrogen, which 
attempts to resolve some of the discrepant results between estrogen’s protective 
and deleterious effects, see (Maki, 2013).  This idea contends that while 
circulating estrogen levels are within a normal range, estrogen replacement may 
be beneficial.  But once estrogen levels reach a nadir, replacement may have 
harmful effects (or at least failure to benefit).  [There is some evidence of this in 
preclinical literature; following ovariectomy, estrogen treatment cannot induce an 
increase in long-term potentiation (long-lasting increases in synaptic strength) 
after a certain length of time before initiating estradiol treatment (Smith et al., 
2010)].  A subsequent re-analysis of the WHI data stratified by both age and time 
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since menopause before starting hormone therapy revealed non-significant 
trends towards a protective effect of hormone therapy regarding coronary heart 
disease for women less than 10 years from menopause, though increased risk of 
stroke was unaffected by age since menopause (Rossouw et al., 2007).  
Consequently, many women who would have otherwise sought ERT did not.  
Strikingly, breast cancer incidence declined approximately 6.7-10% (Clarke et al., 
2006; Ravdin et al., 2007) in the United States, and similar decrease was found 
in Germany, paralleling a decline in prescriptions for estrogen or hormone 
therapy (Katalinic and Rawal, 2008).  These findings and the intense media 
attention they garnered precipitated a demand for non-hormonal alternative 
treatments for hot flashes.  As a result, current guidelines for hormone therapy 
state that the lowest effective dose should be used for the shortest period of time 
(North American Menopause Society position statement).  Lower doses of 
estrogen are still efficacious compared to placebo, but less so than higher doses 
(Utian et al., 2001).   
 
1.4.2.  Alternative treatment options 
1.4.2a.  Serotonin & norepinephrine reuptake inhibitors 
To date, there are two commonly used non-hormonal treatments for VMS, 
selective serotonin and/or norepinephrine reuptake inhibitors (SSRI; SNRI, 
respectively) which increase the synaptic concentration of these 
neurotransmitters by inhibiting their respective transporter(s) and the reuptake 
processes.  However, their effects take at least 1-3 weeks, and it is thought that 
they work through complex compensatory mechanisms to produce their 
therapeutic effect [and elucidating such mechanisms is still an outstanding 
research question (see review by (Stahl, 1998)].  There is only one non-hormonal 
FDA-approved compound with a hot flash indication; paroxetine mesylate (Paxil) 
at 7.5 mg/day, (marketed as Brisdelle®), a dose less than prescribed for any 
psychiatric indication (which typically start at 20 mg) (Simon et al., 2013).  Other 
drugs in this class and related classes are often prescribed for vasomotor 
symptoms, but such use is “off label” (because that compound is not specifically 
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approved for hot flashes) and, while legal, may not be reimbursed by insurance 
companies.  The response rates for all of these compounds are marginally 
greater than placebo (for a graphical representation, see Fig. 9); for example, 
paroxetine reduced hot flashes from 10 to 5 (median per day) whereas placebo 
reduced hot flashes from 10 to 5.9 per day (Simon et al., 2013).  This pattern is 
typical amongst SS/NRIs, and hot flash trials in general have very high placebo 
response rates.  Furthermore, these treatments present many side effects, like 
gastrointestinal distress and sexual dysfunction (Handley and Williams, 2015).   
 
1.4.2b.  GABA 
Currently, there is one non-hormonal treatment strategy, gabapentin 
(Neurontin), for hot flashes that may target the non-monoamine neurotransmitter 
GABA (ϒ-aminobutyric acid, the predominant fast inhibitory neurotransmitter).  
This structural analogue of GABA is currently used for neuropathic pain and 
seizures, in addition to many off-label uses.  A few groups reported that 
gabapentin (200-2400 mg) ameliorates hot flashes comparably to estrogen 
treatment with respect to both hot flash frequency and severity (Reddy et al., 
2006; Aguirre et al., 2010; Allameh et al., 2013).  Gabapentin seems to be safe 
and relatively effective in hot flashes induced by oöphorectomy or tamoxifen 
therapy for breast cancer (Loprinzi et al., 2002b; Pandya et al., 2005).  GABA’s 
receptors and gabapentin’s pharmacology is discussed in greater detail in 
section 2.5.3. 
 
1.4.2c.  Non-pharmacological treatment options 
A plethora of non-hormonal and alternative therapies have been evaluated 
for menopausal symptoms, including several plant-based estrogenic compounds 
(phytoestrogens) like soy (or isolated soy derivatives like S-equol), black cohosh, 
and red clover; overall, these interventions largely failed to have any effect on 
reducing VMS (Roberts and Lethaby, 2014).  The modern panacea, exercise, 
has similarly failed to have overall demonstrated efficacy (Daley et al., 2015a, 
2015b), and twelve weeks of yoga instruction and practice was no more effective 
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than usual care in reducing vasomotor symptoms frequency or bother, though did 
improve insomnia symptoms (Newton et al., 2014).  
 
1.4.3.  Importance of treating hot flashes 
For cancer patients, non-hormonal therapies are the only viable option as 
ERT is virtually always contraindicated.  However, SSRI administration in the 
context of tamoxifen treatment may additionally be contraindicated.  Tamoxifen is 
a prodrug that requires enzymatic conversion into its active metabolite, endoxifen 
(4-hydroxy-N-desmethyl-tamoxifen), which is responsible for most of the 
pharmacological activity of the molecule (Dickschen et al., 2012).  Activity of the 
cytochrome P450 superfamily member CYP2D6 is required for this 
biotransformation, and, as shown in Fig. 4, several SSRIs, including paroxetine, 
are potent and irreversible inhibitors of this enzyme.  Stearns and colleagues 
(2003) demonstrated that paroxetine can lower plasma levels of endoxifen by up 
to 64% (Stearns et al., 2003b).  Additional studies have documented increased 
mortality with tamoxifen and SSRI co-therapy, and a longer duration of overlap 
was associated with increased mortality (Kelly et al., 2010).  Despite these 
findings, a recent study in the Netherlands found that CYP2D6-inhibiting SSRIs 
were still over-prescribed to patients taking tamoxifen (Binkhorst et al., 2013).  
Since many women are poor or intermediate tamoxifenendoxifen metabolizers 
(Goetz et al., 2007), clinical trials investigating the effectiveness of endoxifen 
hydrochloride as a treatment are currently underway (www.clinicaltrials.gov 
identifier NCT02311933).  Clearly, the development of endoxifen would 
circumvent the problem in prescribing SSRIs to these patients.  However, ‘good’ 
metabolizer status (of tamoxifen into endoxifen) and higher blood levels of 
endoxifen are positively related to hot flashes and have been shown to predict 
hot flashes and their severity (Goetz et al., 2005; Lorizio et al., 2012;).  
Therefore, even with the successful development of endoxifen therapy, it seems 
likely that this could lead to more hot flashes in the oncology population and 
increase demand for more effective, non-hormonal treatments for hot flashes.  
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Figure 4.  Metabolic Pathway of Tamoxifen.  As indicated by the gray arrows, tamoxifen 
is metabolized into its active metabolite, endoxifen by the enzymes CYP3A4/5 and 
others and CYP2D6.  CYP2D6 is required for the conversion of both NDM-tamoxifen 
and 4OH-tamoxifen into endoxifen, which is the metabolite responsible for tamoxifen’s 
pharmacological activity.  SSRIs, including paroxetine, are potent inhibitors of this 
enzyme, and can lower blood levels of endoxifen by up to 64%.  Clinical trials are 
currently being conducted to determine if endoxifen hydrochloride is as effective as 
tamoxifen, and may circumvent the problem in prescribing SSRIs, yet may also 
precipitate an increased demand for effective hot flash treatments from this population of 
women.  
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Part II:  Risk Factors for Hot Flashes 
  
2.1.  Classical Risk Factors  
 
 Risk factors for hot flashes are numerous, but have only been extensively 
characterized in large, diverse cohorts in more recent years.  A careful 
delineation of factors that increase or decrease the probability and severity of hot 
flashes can reveal additional clues about their mechanisms that may lead to 
novel treatments.  Early studies linked hot flashes most clearly to menopause 
stage; i.e., perimenopausal women are the most vulnerable.  However, with the 
discoveries of several prospective, population-based, multi-ethnic, and multi-site 
studies, additional risk factors are becoming more apparent.  This section will 
cover some of the key risk factors related to the experience of vasomotor 
symptoms, including smoking, obesity, race or ethnic background and also 
includes a discussion of emerging genetic factors, stress, and anxiety. 
 
2.1.1.  Cigarette smoking 
 Results from several studies have consistently indicated a role for 
cigarette smoking and the experience of vasomotor symptoms.  In a sample of 
233 peri- and postmenopausal women, smoking was positively associated with 
hot flashes (OR = 2.0), and smokers reported significant bother due to hot 
flashes in the 454 women enrolled in the Massachusetts Women’s Health Study 
(Avis et al., 1997; Staropoli et al., 1998).  Initial results from the SWAN confirmed 
these early findings (OR = 1.21-1.78) (Gold et al., 2000).  A cross-sectional study 
of 1,087 women reported significantly increased odds of reporting both 
moderate-to-severe and daily hot flashes among current smokers compared to 
former smokers (Whiteman et al., 2003).  While most reports have examined 
intensity and/or frequency of VMS, smoking had no effect on the duration of hot 
flashes in women followed in the Penn Ovarian Aging Study cohort (Freeman et 
al., 2011).  Cross-culturally, the positive association between smoking and hot 
flashes has been relatively consistent as well in very large studies (Sabia et al., 
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2008; Gjelsvik et al., 2011; Hunter et al., 2012).  However, studies of Finnish and 
Portuguese women failed to find any association between smoking and VMS 
(Moilanen et al., 2010; Pimenta et al., 2011).  
Furthermore, it is well-established that smokers reach menopause 
approximately 1.7 years before nonsmokers (McKinlay et al., 1985).  Cigarette 
smoke may impact the ability of aromatase to produce estrogens, in addition to 
being potentially directly toxic to the ovaries (Mattison et al., 1983).  
Mechanistically, there are several ways in which cigarette smoking could be 
affecting (decreasing) hormone levels, and it is possible that this relationship 
mediates the observed effect of smoking on hot flash experience, though several 
reports, detailed below, do not support this idea.  Gallicchio and coworkers 
reported a significant positive association between cigarette smoking and greater 
experience of any and more severe hot flashes in a case-control study of 653 
women that retained significance even when controlling for estradiol and estrone 
levels, suggesting a mechanism independent from sex steroids (Gallicchio et al., 
2005, 2006a).  Later results from the same sample indicated that current 
smokers had higher androstenedione and progesterone levels and a higher 
androgen to estrogen ratio than “never smokers”, yet controlling for these 
hormone levels did not change the association between cigarette smoking and 
the probability of experiencing hot flashes (Cochran et al., 2008).  
Recent work indicates the relationships observed between cigarette 
smoking and increased hot flashes may be mediated by interactions between 
gene variants (polymorphisms) and ethnic background.  An investigation of the 
interaction of gene variants with smoking status on hot flash symptoms revealed 
European-American (EA) women homozygous for the COMT Val158Met variant 
had increased risk of hot flashes, and heavy smokers with such variant 
experienced more frequent moderate to severe hot flashes (Butts et al., 2012).  
EA smokers with the CYP1B1*3 variant also experienced more frequent 
moderate to severe hot flashes, and African-American smokers with the CYP1A2 
variant were more likely to report hot flashes as well.  
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2.1.2.  Obesity and body composition  
Similar to smoking, obesity has shown strong associations with hot 
flashes, though its relationship appears complex and possibly menopausal stage-
dependent.  Initially, small studies observed that thinner women (Erlik et al., 
1982) experienced more hot flashes, and thus the “thin hypothesis” was posited.  
This purported that body fat was protective against hot flashes based on the 
contention that thinner women have less body fat to be aromatized (peripherally) 
into estrogens (predominantly estrone).  This idea directly competes with the 
“thermoregulatory hypothesis”, which posits that women with more body fat 
would be at increased risk of hot flashes due to the heat-retaining/insulating 
properties of adipose tissue.  It is still unclear exactly what may be correct, and 
both mechanisms may be contributing to hot flash pathology.  In a study of Dutch 
women, those aged 40-44 in the highest quartile of body mass index (BMI; 
calculated by weight in kilograms divided by height in meters squared; normal is 
<25 kg/m2, overweight 25.1-29.9, obese >30) and waist-to-hip ratio (measure of 
abdominal adiposity) report significantly more hot flashes, even when controlling 
for age than postmenopausal comparison women (den Tonkelaar et al., 1996).  
Additionally, Wilbur and Gold both demonstrated women with a higher BMI had 
more hot flashes (Wilbur et al., 1998; Gold et al., 2000, 2006).  An increased risk 
of daily hot flashes was reported for women with high BMI only in pre- and 
perimenopausal women; BMI greater than 30 kg/m2 impacted the risk of 
moderate to severe hot flashes in postmenopausal women (Whiteman et al., 
2003).  In 2004, Hyde Riley and coworkers showed that perimenopausal women 
with a BMI greater than 25 kg/m2 had increased odds of reporting hot flashes 
(OR = 2.0) after controlling for multiple factors; yet in postmenopausal women, 
BMI was not significantly associated with hot flashes (Hyde Riley et al., 2004).  
Gallicchio et al. (2005) report that severely obese women (BMI ≥ 35.0) had 
increased odds of any and more severe hot flashes as they transitioned through 
the menopause, but later found that controlling for estrogens, progesterone, and 
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sex hormone binding globulin negated that effect (Gallicchio et al., 2005; 
Schilling et al., 2007).   
 Importantly, BMI is a relatively crude measure, and does not distinguish 
between adipose tissue and lean mass, and so it is possible that persons with 
significant muscle mass may be classified as overweight (e.g., football players).  
Furthermore, self-reported measures of weight are particularly prone to 
inaccuracies and have been demonstrated specifically in this population (Lawlor 
et al., 2002; Engstrom et al., 2003).  Therefore, objective verification of weight or 
body composition is highly desirable.  The SWAN utilized bioelectrical impedance 
analysis to determine percentage of body fat in a multiethnic/racial sample, and 
the patterns uncovered have been illuminating.  First, in 2008, Thurston and 
colleagues reported a significant positive association between percentage of 
body fat and hot flash experience (self-report), which were maintained even 
when controlling for FSH, estradiol, and free estradiol (estradiol not bound to sex 
hormone-binding globulin) (Thurston et al., 2008c).  Using data gathered as part 
of the SWAN Heart Study, Thurston et al., (2008b) also reported that abdominal 
adiposity specifically was positively associated with hot flashes, and this effect 
was mediated by subcutaneous rather than visceral adiposity (fat distributed 
directly under the skin versus beneath the abdominal musculature).  These 
associations were maintained after controlling for FSH and free and bound 
estradiol (Thurston et al., 2008d).  Furthermore, increasing body fat over time 
was associated with greater odds of reporting hot flashes even when controlling 
for the aforementioned hormones (Thurston et al., 2011).  Importantly, obesity is 
modifiable risk factor, and a pilot study of a behavioral weight loss intervention in 
women with hot flashes demonstrated a significant reduction in self-reported hot 
flashes, with trends for reduction on diary and physiological measures (the study 
was not designed or powered to determine the effects of weight loss on hot 
flashes per se) (Thurston et al., 2015).   
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2.1.3.  Race and ethnic background 
 Several reports have consistently indicated racial/ethnic differences in the 
reported experiences of hot flashes.  In the SWAN, women of Chinese and 
Japanese ancestry in the United States reported all menopausal symptoms less 
than Caucasians, who reported less symptoms than African-Americans (Gold et 
al., 2000).  In the Hilo Women’s Health Study of Japanese-Americans and 
European-Americans in Hilo, Hawaii, Japanese-American women were less likely 
to report both hot flashes and night sweats and were more likely to report 
symptoms as mild when they were experienced, even after controlling for soy 
consumption (which contains phytoestrogens that weakly activate estrogen 
receptors) (Sievert et al., 2007).  However, later research using [objective] 
ambulatory and laboratory monitoring found no differences in subjective or 
objective hot flashes between Japanese-American and European-American 
women in Hilo (Brown et al., 2009).  Over the duration of the SWAN, African-
American women continued to report more hot flashes than the other ethnic and 
racial groups studied (Gold et al., 2006), consistent with Miller and colleagues’ 
case-control study, which found that African-American women had increased risk 
of hot flashes with greater severity and longer duration than Caucasian women 
(Miller et al., 2006).  In a study of 216 African-American and Caucasian women, 
race accounted for 10% of the variance in experience of vasomotor symptoms; 
again, African-Americans experienced more VMS and reported their symptoms 
as more bothersome (Appling et al., 2007).  In a SWAN report of vasomotor 
symptom bother, perhaps a more nuanced view of hot flashes, African-American 
race was associated with significant bother from VMS (Thurston et al., 2008b).  
Importantly, above and beyond frequency and bother, VMS seemed to last 
longer overall for African-American women compared to other groups, with a 
median duration of 10.1 years (Avis et al., 2015), echoing Freeman’s POAS 
conclusions regarding African-American race as a significant hot flash predictor 
(Freeman et al., 2011).  The precise mechanisms that may be responsible for a 
racial discrepancy in hot flash experience have not been determined, but there 
may be genetic differences as outlined below. 
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2.2.  Genetic contributions 
  
Considering the discrepancies between estrogen levels and hot flash 
symptoms, several groups have proposed the idea that it may be how estrogens 
are metabolized or interact with certain polymorphisms/protein variants within 
tissues that lends itself to a meaningful clinical outcome.  Subtle differences in 
receptors and/or synthetic and/or catabolic enzymes could affect this.  The most 
obvious targets for consideration of this concept are the classical (nuclear) 
estrogen receptors, α and β (ERα, ERβ).  Estrogen receptors are transcription 
factors that dimerize upon estrogen binding and then enter the nucleus to 
regulate gene expression at estrogen response elements.  Polymorphisms within 
the genes that encode these receptors have been studied in the context of hot 
flash symptomatology, along with metabolic enzymes, are discussed in this 
section.   
 
2.2.1.  ESR1/ERα 
The first report of a significant association with ERα comes from a study of 
177 postmenopausal Mexican women that examined two single nucleotide 
polymorphisms (SNP) within ERα (Malacara et al., 2004).  Significant 
associations were found only for hot flashes and vaginal dryness; hot flashes 
were lower for the Pp genotype (PvuII site of ERα or rs2234693).  It is unclear 
how meaningful the measure of hot flashes were in this report, as the authors 
only state “hot flashes were measured by the presence of acute, localized short-
lasting sensations of skin warming…symptoms were registered by yes = 1 or no 
= 0”.  In the SWAN Genetics Study (examining African-American, Caucasian, 
and Chinese-American women), no significant associations of hot flashes within 
this SNP were found, but statistical significance for reduced hot flashes in the AG 
genotype for another ESR1 SNP, rs9340799 (XbaI site) was found in Caucasian 
women whose BMI was <25 (normal weight) (Crandall et al., 2006).  For 
Caucasian women with the AG genotype and a BMI >= 30, this genotype 
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increased the odds ratio of VMS reporting by 2.6.  Results from the Seattle 
Midlife Women’s Health Study failed to find any association with hot flashes with 
either polymorphism (Woods et al., 2006b), consistent with a study of 290 
Mexican women (Aguilar-Zavala et al., 2012).  In premenopausal women, the 
XbaI GG and PvuII CC genotypes were associated with significantly more hot 
flashes before tamoxifen treatment; after tamoxifen initiation, the only group that 
showed a genotype-dependent change was postmenopausal women who were 
both XbaI GG and PvuII CC genotype (Jin et al., 2008).   
 
2.2.2.  ESR2/ERβ  
 Takeo and colleagues (2005) reported that CA dinucleotide repeats in 
intron 5 of ESR2 were associated with increased risk of vasomotor symptoms 
and premenstrual symptoms in 51 postmenopausal Japanese women (Takeo et 
al., 2005).  Women with the short/short genotype had a 7-fold increased risk of 
vasomotor symptoms, 13-fold increased risk of psychological symptoms and 7.6-
fold increased risk of premenstrual symptoms, and women with the extremely 
short/long genotype had increased risk of both symptoms and depression, 
though the magnitude of the increased risk is unclear.  In a cohort of 297 women 
taking tamoxifen for breast cancer, women with the ESR2-02 AA genotype were 
significantly less likely to develop hot flashes compared to GG or AG carriers (Jin 
et al., 2008). 
 
2.2.3.  Sex steroid metabolic enzymes 
Additional areas of investigation include the anabolic and catabolic 
enzymes for sex steroid hormones, including several members of the cytochrome 
P450 (CYP) superfamily and catechol-o-methyl transferase (COMT), which 
degrades dopamine, norepinephrine, and epinephrine and converts estrogen into 
a hydroxy estrone.   
Aromatase (CYP19) converts testosterone into estradiol.  Results from the 
multi-ethnic Seattle Midlife Women’s Health Study found a significant association 
between the 11r polymorphism in this gene and more frequent and severe hot 
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flashes in women in the middle and late menopause transition stages as well as 
experiencing hot flashes in post-menopause (Woods et al., 2006b).  The 
sulfotransferase SULT1A1 catalyzes the conversion of estradiol into a sulfated 
form; a polymorphism (Met223Val or rs1081030) in this gene was significantly 
associated with increased risk of hot flashes in European-American women in the 
Penn Ovarian Aging Study (POAS) (Rebbeck et al., 2010). 
 Estrogen elimination occurs largely through oxidation by attachment of 
hydroxyl groups.  The enzyme CYP1B1 metabolizes estradiol and estrone into 
catechol estrogens (4-hydroxy estrogens), and a polymorphism at amino acid 
432 exists (valineleucine or rs1056836).  Conflicting reports find both increased 
and decreased risk of hot flashes that may be race-dependent.  In a community 
study of midlife women (total n=612), Visvanathan and coworkers found that 
women carrying this mutation were at a 30% increased risk of moderate to 
severe hot flashes and a 27% increased risk of having hot flashes for one year or 
more; risk ratios for experiencing any or weekly hot flashes were of borderline 
statistical significance (Visvanathan et al., 2005).  Schilling and coworkers (2007) 
corroborated these findings.  For African-American women in the SWAN 
Genetics Study, heterozygosity at this locus significantly decreased the odds of 
reporting hot flashes (Crandall et al., 2006), which agrees with the results of 
African-American women in the POAS, where again this genotype significantly 
decreased the odds ratio of hot flashes (Rebbeck et al., 2010).  An additional 
pathway involving CYP1A1 mediates 2-hydroxylation of estrogens, and a 
polymorphism (rs2606345) AC genotype decreased the odds of Chinese women 
reporting hot flashes (Crandall et al., 2006).  The 4- and 2-hydroxy versions of 
estradiol and estrone have different potencies, such that 4-OH estrogens still 
have significant biological activity whereas the 2-OH estrogens only weakly 
activate estrogen receptors.   
A polymorphism in 3-β-hydroxysteroid dehydrogenase (3βHSD), which 
catalyzes several reactions (including the synthesis of progesterone from 
pregnenolone, 17-α-progesterone from 17-α-pregnenolone, DHEA to 
androstenedione, and androstrenediol to testosterone) was associated with a 
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significantly increased risk of moderate to severe hot flashes (Schilling et al., 
2007).  Three polymorphisms in 17β-hydroxysteroid dehydrogenase, which 
interconvert estradiol and estrone (rs615942, TG genotype; rs592389, TG 
genotype; rs2830, AG genotype) were associated with decreased odds of 
reporting hot flashes in Caucasian women in the SWAN (Crandall et al., 2006).   
 Overall, these studies have identified some additional genetic risk factors 
for hot flashes, but between-study or cohort effects are sometimes diametrically 
opposed.  Several sources of variability could account for these discrepancies, 
including characteristics of the study sample (i.e. race/ethnic background, age, 
inclusion/exclusion criteria), and definition and methodology of assessing hot 
flashes and consistency between assays.  Additionally, some studies are quite 
small, and extrapolation of meaning from such sizes is problematic.  Despite 
these potential hindrances, the investigation into the genetics underlying hot 
flashes continues to point toward estrogen as a key hormone in hot flash 
pathology, though these findings are understandably biased by a priori 
hypotheses.  Understanding the intricacies and mechanisms in these pathways 
will be essential to fully realizing effective non-hormonal treatment strategies.   
 
2.2.4.  Serotonin transporter 
 The serotonin transporter [SERT/5-HTT, encoded by SLC6A4 gene] 
removes serotonin from the synaptic cleft and has a variable n-terminal domain 
repeat polymorphism (44 base-pair insertion/deletion) in the promoter region 
known as the 5-HTTLPR, leading to a long ‘l’ and short ‘s’ allele (Heils et al., 
1996).  The ‘s’ allele leads to reduced transcriptional efficacy, and therefore, less 
SERT expression (Lesch et al., 1996).  The s/s or s/l genotype has been 
associated with many neuropsychiatric conditions, including depression and 
anxiety (Lesch et al., 1996; Gonda et al., 2007, 2009).  Increased anxiety has 
been linked to the presence and severity of vasomotor symptoms and is one of 
the strongest predictors of hot flashes and is discussed in great detail in section 
2.4 (Freeman et al., 2005).  Recently, a significant positive association between 
severity of climacteric symptoms and the ‘s’ allele was found in a study of Polish 
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women using the Blatt-Kupperman Menopausal Index (Grochans et al., 2013).  In 
a study of Mexican women, the ‘s’ allele was correlated with increased cigarette 
smoking, a known risk factor for VMS (Aguilar-Zavala et al., 2012).  The 
effectiveness of SSRIs for hot flashes in relation to SERT genotype has not been 
demonstrated yet; however, s/s carriers have been shown to have a poor 
response to SSRIs for other conditions (Stein et al., 2006).  The effectiveness 
and tolerability of SSRIs for hot flashes may be related to 5-HTTLPR genotype 
such that s/s carriers are at greater risk for treatment-emergent side effects 
(Perlis et al., 2003), and this genotype may mediate some of the discontinuation 
observed in SSRI trials for hot flashes. 
 
2.3.  Role of stress  
 
In 1936, Hans Selye called stress the “non-specific response of the body 
to any demand for change.”  More recently, stress is conceptualized as a state of 
threatened homeostasis (Bonnavion et al., 2015).  In the vernacular, stress is 
often incorrectly vilified to indicate a negative event or circumstance, like the 
stress brought on by an illness or death.  Stressors can be both positive and/or 
negative (such as the birth of a child or a move) and can be qualitatively 
categorized as they relate to social roles, family, etc.  A more appropriate view is 
that there exists an optimal level of stress, “eustress”, and both too much or little 
stress is deleterious.  The role of stress, as defined in many ways, in menopause 
has been examined primarily using self-report, survey instruments.  There are a 
few laboratory studies that examined the effects of induced stressors on 
menopausal symptoms.   
 
2.3.1.  Stress in early life 
Stress experienced in early childhood and adolescence has been linked to 
the later development of numerous psychiatric conditions and poorer health 
outcomes, including schizophrenia, anxiety, depression, and cardiovascular 
disease, to name but a few.  High levels of stress can dysregulate the 
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hypothalamic-pituitary adrenal (HPA) axis, which ultimately releases 
glucocorticoids from the adrenal gland and suppresses energy-intensive 
processes in the immune system.  Increased cortisol secretion has been linked to 
hot flash pathology, and 24 hour urinary cortisol levels explained 32.5% of the 
variance in scores on the Greene Climacteric Scale (Cagnacci et al., 2011), and 
both ACTH and cortisol levels have shown increases following hot flashes 
(Meldrum et al., 1984; Cignarelli et al., 1989).  It seems plausible that stress that 
may alter the responsiveness of the HPA axis might have a role in the later 
experience of hot flashes, despite having occurred decades earlier.  In the 
Mental Health sub-study of the SWAN, (n=332, conducted only at the Pittsburgh 
site, so participants were Caucasian and African-American only), Thurston and 
colleagues (2008) assessed the role of early life stress and vasomotor symptoms 
(Thurston et al., 2008a) (the first and only report in the literature to date).  
Childhood abuse and neglect were measured by the 28-item short form of the 
Childhood Trauma Questionnaire, which has five subscales (emotional abuse, 
physical abuse, emotional neglect, sexual abuse, and physical neglect).  
Approximately 38% of the sample reported one of the five dimensions of abuse.  
Childhood abuse (all five dimensions) was significantly positively correlated with 
VMS (both hot flashes and/or night sweats) reporting in multivariate models that 
controlled for age, race, BMI, smoking, educational attainment, menopause 
status, and depressive symptoms.  Challenge tests (i.e., ACTH or CRF 
administration) can be used to assess the function of the HPA axis, and adult 
female survivors of childhood abuse have shown hypersensitivity to such 
measures (Heim et al., 2001).  While not all women experience childhood abuse, 
the role such experiences may play in modifying the HPA axis could provide 
clues to the etiology of hot flashes, even if only in a particular subgroup.   
 
2.3.2.  Stress in mid-life 
 Many groups have found that stress increases across the menopause 
transition.  In 1981, Cooke and Greene reported increased total life stress from 
pre-menopause (n=21, defined by age as 25-34) to early menopause (n=33, 
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defined by ages 35-44) that was due almost entirely to ‘exit stress’, or the stress 
one has when a person/persons leave his/her “social field”; in this study, due 
largely to deaths (Cooke and Greene, 1981).  Gannon, Hansel, and Goodwin 
(1987) studied ten symptomatic women, mean age 55.5 (range 50-63) using a 
hot flash card to ascertain relationships between hot flash parameters and daily 
stress, using a version of The Hassles Scale (measure of 117 “microstressors”) 
(Gannon et al., 1987).  Overall, stress accounted for 55% of the variance in hot 
flash frequency.  They also found statistically significant positive correlations 
(r=0.31—0.74) between daily stress and hot flash frequency in 5/10 women; 
significant correlations (0.37, 0.43) between daily stress and HF intensity for two 
subjects (one different from previous group); three subjects had significant 
correlations between hassles and hot flash duration (r=0.30—0.42).  In a study of 
19 symptomatic Japanese women and 44 matched controls, the severity of 
climacteric symptoms, as measured by the Simplified Menopausal Index, 
significantly positively correlated (0.51) with stress, as measured by the Life 
Event Inventory (Igarashi et al., 2000).  They noted that the patient group was 
more likely to utilize avoidance-oriented coping for menopausal complaints, 
which was also positively correlated with the severity of climacteric symptoms.  
Binfa and colleagues (2004) found that perimenopausal women (n=46, 15.3% of 
the sample) had higher stress scores as measured by the Cooper Questionnaire, 
but this was not due to an increase in negative life events, family dysfunction, or 
poor social support (Binfa et al., 2004).  Furthermore, they found that 
perimenopausal women also had increased climacteric symptoms as measured 
with the Greene scale.  A critical limitation of the above studies is their relatively 
small numbers of participants.  In 2004, results from the SWAN cohort found that 
perceived stress was significantly positively and independently associated with 
vasomotor symptoms (OR=1.4; 95% confidence interval 1.2—1.6, p < 0.0001) 
(Gold et al., 2004), and greater perceived stress significantly impacted the 
duration of experiencing vasomotor symptoms for SWAN participants (Avis et al., 
2015).   
 
 33
2.3.3.  Experimental stress 
Similar to early studies of ambient temperature, initial studies of hot 
flashes and stress were correlational and self-reported, even with the use of 
validated surveys.  Swartzman and coworkers (1990) performed the first 
laboratory study using physiological monitoring to determine if stressors had a 
causal role in hot flashes (Swartzman et al., 1990).  After a habituation session, 
symptomatic postmenopausal women (n=21, age 37-71, 20/21 naturally 
menopausal, 1 surgically menopausal) were exposed to a variety of stressors at 
a rate of 2-3 per hour.  These stressors included loud noises, physical exercises, 
paced arithmetic, watching a stressful film, recalling a stressful situation, etc.; a 
non-stress session (counterbalanced design) included watching films or reading 
magazines.  During the stress session, 47% more objective and 57% more 
subjective flushes were recorded (with the same flush report bias in both 
conditions).  Anxiety, as measured by the State-Trait Anxiety Inventory, was the 
same before both sessions, and did not correlate with either flush rate. 
 
2.4.  Role of Anxiety Symptoms 
 
2.4.1.  Prevalence of anxiety across the menopause transition 
 Increased symptoms of anxiety during the menopause transition have 
been reported by several large prospective studies.  In the initial SWAN 
screening/eligibility interview, the majority of women interviewed endorsed feeling 
tense or nervous (51.9%) or irritable or grouchy (51.6%) in the last two weeks 
(yes or no) (Avis et al., 2001b).  These symptoms were part of a 15-item list of 
symptoms used in SWAN measures (at all visits), and is important to distinguish 
that it is not a standardized measure of anxiety or a diagnosis of an anxiety 
disorder per se, but that these items reflect common symptoms of anxiety more 
broadly defined.  Psychological distress, defined as self-reported feelings of 
tension/nervousness, irritability/grouchiness, and “feeling blue” during the past 
two weeks was similarly found to increase across the menopause transition in 
the SWAN cohort (Bromberger et al., 2001).  Overall, 24.1% of women in the 
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study endorsed psychological distress, though 28.9% of early perimenopausal 
women reported these symptoms compared to only 20.9% of premenopausal 
women and 22% of post-menopausal women.  “Persistent mood disturbance”, 
operationally defined as indicating nervousness/tension or irritability/grouchiness 
on at least six days in the last two weeks, was found as a consequence of the 
menopausal transition (Bromberger et al., 2013).  When controlling for typical 
confounding factors including vasomotor symptoms and sleep disturbance, 10% 
of the women studied (1473 + 1688) indicated “taking medication for nervous 
conditions”, and 16.1% of perimenopausal women (n=1473) indicated feeling 
irritable compared to only 11.4% of premenopausal women (n=1688).  A similar 
pattern for feelings of nervousness was found; 18.4% of perimenopausal women 
endorsed this symptom compared to only 12.0% of premenopausal women, 
while “feeling blue” was not affected by the transition in this study.  Finally, in 
2013 Bromberger and coworkers reported that anxiety, as measured by 1) 
irritability; 2) tension/nervousness; 3) feeling fearful for no reason; and 4) heart 
racing or pounding (the latter two being symptoms of anxiety or panic), was likely 
to increase for women with low baseline levels of anxiety as they transitioned into 
the perimenopause or postmenopause stages.  For women with high baseline 
levels of anxiety, menopause stage was not associated with high levels of 
anxiety, and controlled for “upsetting life events, financial strain, fair/poor 
perceived health, and vasomotor symptoms”.   
 
2.4.2.  Anxiety and menopause across cultures 
 Importantly, findings of increased anxiety at menopause appear to hold 
across cultures and ethnic groups and do not appear a consequence of reporting 
bias.  Significantly higher anxiety and depression in both peri- and 
postmenopausal women, as assessed with the Hospital Anxiety and Depression 
Scale (HADS), which has seven anxiety items and seven depression items, were 
reported in women studied in Norway through The Health Survey of Nord-
Trondelag County (HUNT-II) (Tangen and Mykletun, 2008).  Both peri- and 
postmenopausal women had increased scores compared to both premenopausal 
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women (premenopausal women n=3632, score 4.54; perimenopausal women 
n=355, score 5.03; postmenopausal women n=2396, score 4.81).  Importantly, it 
is possible that women with high levels of anxiety are more likely to report or 
even over-report hot flashes in studies that rely on self-report, potentially 
confounding results.  While concordance between objective and subjective 
measures of hot flashes is relatively low (average 29%), in a systematic review 
(Mann and Hunter, 2011) a study of 140 peri- and post-menopausal women 
found that anxiety was less likely to cause a woman to under-report hot flashes 
but not more likely to cause over-reporting of hot flashes (Stefanopoulou and 
Hunter, 2014).   
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Part III:  Physiology of Hot Flashes 
 
3.1.  Basic Concepts in Thermoregulation 
 
3.1.1.  The importance of being endothermic 
 Humans are endothermic, that is, we generate our own heat through 
metabolism and are not reliant on solar energy to maintain body temperature.  
This long-held state of affairs affords us our choice of environment, and comes 
with several mechanisms to defend against threats to maintaining an appropriate 
core temperature (37 °C).  Without a relative constancy of internal temperature, 
enzymatic function suffers, and death can result from excessive internal 
temperature.  To clarify, core body temperature/internal temperature refers to the 
temperature of the brain, spinal cord, internal organs, and large veins, whereas 
“shell” temperature is used to distinguish the temperature of the skin.  Normally, 
in humans, skin temperature is 3-4 °C lower than core temperature.  The 
maintenance of core body temperature comes from the balance between heat 
production and heat dissipation, each of which consist of multiple contributing 
processes affected by a wide variety of factors.   
 
3.1.2.  Thermodynamics:  Basics of heat transfer 
 Heat transfer occurs in four major ways:  conduction, convection, 
radiation, and evaporation.  Conduction is the direct transfer of heat from one 
source to another, and always occurs down a thermal gradient (from hot to cold).  
This occurs frequently, as often a human body is the warmest object in a room 
(with notable exceptions, like kitchens or mechanical rooms) and touching an 
object will result in heat loss from the person to the object.  Conversely, when the 
object is hotter than the person touching it, heat transfers from the object to the 
person.  Convection is the transfer of heat through a current, in either a gaseous 
or liquid state, and a faster flow rate of the liquid or gas will move more heat.  
This is easily felt on a warm day with a slight breeze.  Radiation is the transfer of 
heat from bodies that are not in contact through electromagnetic waves—i.e., the 
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sun.  Evaporation is the loss of heat through the physical transformation of water 
from a liquid to gaseous state—i.e., sweating.   
 
3.1.2a.  Heat loss mechanisms 
 Humans possess two major ways of rapidly losing heat:  cutaneous 
vasodilation and sweating.  Cutaneous vasodilation expands the diameter of 
blood vessels near the surface of the body, which allows for more heat to pass 
through the skin and escape.  In particular, specialized areas of the skin (acral 
skin), including the feet, hands, nose, and ears, possess ateriovenous 
anastomoses.  These are shunting systems that mix arterial and venous blood in 
a large network, and the high surface area to volume ratio of these appendages 
facilitates heat loss.  In the rat, cutaneous vasodilation is the major mechanism to 
defend against heat stress, and, as shown in the following experiment, surface 
warming through vasodilation prevents core temperature increases (Fig. 5).  This 
mechanism is only effective if the ambient temperature is less than the skin 
temperature—therefore, at ambient temperatures in excess of 37 °C, heat 
transfer through vasodilation cannot occur because the thermal gradient is in the 
wrong direction.  Evaporative cooling produced through sweating works in 
conjunction with vasodilation to further cool the body.  Again, there is an 
environmental limit; as relative humidity increases, evaporation is impeded, and 
cooling slows or is even physically impossible in this situation.   
 
3.1.2b.  Heat preserving and generating mechanisms   
 The primary mechanism to save heat from loss to the environment is to 
constrict surface cutaneous blood vessels and shunt the blood towards the body 
core, which results in an even greater difference between internal and skin 
temperature.  The largest and most typical source of heat production comes as a 
by-product of overall metabolism, and other sources of heat production include 
shivering and non-shivering thermogenesis.  Shivering thermogenesis occurs by 
non-voluntary contractions of skeletal muscle that do not produce movement.  
Non-shivering thermogenesis occurs in specialized adipose tissue called brown 
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adipose tissue (BAT).  The relative importance of BAT in adult thermogenesis is 
contentious, though its importance for neonates is undisputed, as infants cannot 
shiver.  Essentially, BAT is enriched in mitochondria, and themogenin/uncoupling 
protein-1 disconnects the mitochondria from generating ATP so that it just 
generates heat.  Lastly, the contraction of muscles that innervate hair follicles in 
glabrous skin cause piloerection and increases the surface area of the skin.  At 
best, this is a minor contributor/strategy to conserve heat, and is likely a vestige 
of humans’ evolutionary past.  
 
3.1.2c.  Behavioral strategies 
 While humans can survive from episodes of severely decreased core body 
temperature, internal temperature can only increase a few degrees before 
becoming fatal, as enzymes only function within a certain temperature range (the 
upper limit of which is already close to normal internal temperature).  For this 
reason, behavioral strategies are perhaps best understood in the context of the 
link between emotions and survival.  It is not only logical but elegant to select for 
mechanisms that provide strong motivational salience to effect change to prevent 
heat stress or cold stress.  Despite the existence of physiological mechanisms to 
cope with temperature change, behavioral strategies are at least as important 
and more frequently employed to defend against temperature change.  This can 
easily be seen in heat or cold avoidance or warmth-seeking behavior depending 
on the state of the animal.  Examples abound—keeping houses, workplaces, and 
vehicles at a comfortable temperature, drinking cold or hot drinks, wearing 
temperature-appropriate clothing and shoes, etc.  Menopausal women are 
especially known for behavioral thermoregulation, such as the use of fans and 
air-conditioning to ameliorate the perception of heat that comes with hot flashes.  
Indeed, environmental cooling is just one source of indirect costs of menopausal 
care (Utian, 2005). 
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Figure 5.  Ambient Temperature-Induced Cutaneous Vasomotor Response Preserves 
Normothermia.  Adult male rats were placed in a box with a heat lamp above the 
surface, and tail skin temperature was measured with a thermistor.  Over a period of 10 
minutes, ambient temperature was increased approximately 5 °C from ~21 °C to 26 °C.  
a) Tail skin temperature increased significantly and rapidly from a baseline value of 
approximately 24 °C to 35 °C, while b) core temperature did not change (temperature 
changes as depicted in the right panel are not significant).   
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3.1.3.  General thermosensory pathway  
 How then, does the detection of temperature occur, which is clearly a very 
basic and critical sensory survival function?  Temperature sensation occurs when 
a receptor in the periphery is activated by thermal energy, which falls into four 
categories:  cold, cool, warm, and hot.  The ‘cold’ and ‘hot’ categories also have 
overlap with noxious/painful sensations, as these temperature ranges can signal 
the potential for acute tissue damage; i.e. freezing or burning.  Thermal receptors 
are free nerve endings (several types to be described subsequently) that 
propagate signals along dorsal root ganglion neurons encoding thermal 
information along small diameter, relatively slowly conducting unmyelinated C 
fibers and lightly myelinated Aδ fibers to detect warmth and cold, respectively.  
Second order neurons in the dorsal horn decussate at the spinal cord level and 
form the anterolateral system, and have both direct and indirect projection 
pathways.  A direct projection through the spinothalamic system relays 
information concerning the body position where the temperature information is 
being sensed, whereas branches emerge that relay thermal information to the 
hypothalamus through the spinoreticular pathway (via the reticular formation in 
the medulla and pons).   
 Specific receptors for thermal sensation largely include the transient 
receptor potential family (TRP) receptors, all of which are nonselective cation 
channels that are permeable to Na+, K+, and Ca2+ that consequently depolarize 
the neuron.  Three subfamilies are relevant for thermoregulation and are known 
as “thermoTRPs”:  the vanilloid (TRPV), melastatin (TRPM), and ankyrin (TRPA) 
groups (Romanovsky, 2007).  TRPV1-4 and TRPM2, 4, and 5 are warm sensors, 
whereas TRPM8 transmits cold signals.  TRPV4 is activated by a range of 
approximately 20-35 °C, whereas TRPV3 is activated at a warmer range of 
temperatures, approximately 32-37 °C, and are probably the most relevant in 
terms of hot flashes; animals that lack TRPV4 have altered thermal sensation 
(Lee et al., 2005).  These receptors rapidly desensitize to a constant 
temperature, and are more readily activated by changes in temperature.  
Importantly, while these are typically conceptualized as sensing external 
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temperature, such as the temperature of objects or hot or cold air, these 
receptors also mediate temperature sensation from changes within the body 
itself, which can result from activation of efferent heat loss pathways (i.e. 
cutaneous vasodilation during a hot flash or exercise or heat stress; see Fig. 7).  
Therefore, in the case of a hot flash, the sensation of heat on the face, chest, or 
elsewhere on the body, is relayed and transduced through these receptors.  (As 
mentioned previously, the hot flash is not a phantom sensation—skin 
temperature objectively increases during the episode.  However, this does not 
preclude the possibility that thermal receptors could be activated in the absence 
of thermal changes and produce a “thermal hallucination”).  Though several of 
these receptors have been shown to be regulated by estradiol, including TRPV1 
(Pohóczky et al., 2016), TRPM2 (Hiroi et al., 2013; Ahn et al., 2014), and TRMP8 
(Chodon et al., 2010), there are no reports yet demonstrating any specific 
polymorphisms or gain or loss of function in menopause and resulting hot 
flashes.  This represents another potentially illuminative area of investigation and 
gap in knowledge in hot flash research.   
 
3.2.  Triggers of Hot Flashes 
  
As follows from the perspective of thermoregulation, the cutaneous 
vasodilation that occurs during hot flashes (and thus leads to the sensation of 
heat) is a heat loss mechanism.  However, as this section will detail, thermal 
changes, whether in the environment or in the body itself, are only weakly linked 
to hot flashes, and why these heat dissipation responses are occurring remains 
enigmatic (at least from a purely thermoregulatory view).  This section will 
describe the role of temperature in triggering hot flashes, including self-reported 
relationships between ambient temperature, and experimental studies of 
manipulating ambient temperature and direct heating paradigms.  The potentially 
causal role of elevated core body temperature is also discussed.  
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3.2.1.  Ambient temperature:  Self-report 
Perhaps due to the obvious presentation of hot flashes as a primarily 
thermosensory event, the most commonly assumed or accepted precipitant is 
“warm” ambient temperature.  Some early studies provided correlational 
evidence that external/environmental temperature modulated hot flash frequency, 
intensity, or severity [hot flash parameters].  In a sample of 500 weather-sensitive 
women in Jerusalem, the arrival of the Sharav, or change to hot dry heat, 
increased hot flashes and chills (Sulman et al., 1975).  Soon after, Coope (1978) 
studied 31 women (mean age 53; range 40-67) that experienced hot flashes 
(with or without heart palpitations) and insomnia (Coope et al., 1978).  Using self-
report hot flash cards, they determined the number of hot flashes per day 
significantly positively correlated with both the maximum and minimum daily 
temperatures (0.700 and 0.425, respectively).  In 1981, 3 corroborated these 
findings in tracking his wife’s hot flashes for 100 days over multiple seasons 
(Molnar, 1981), and found a strong positive correlation (0.68) for number of hot 
flashes per day and the mean daily temperature.  However, a later group only 
found a significant positive correlation between hot flash parameters and daily 
temperature for one of ten women (Gannon et al., 1987).  Similarly, Voda (1981) 
found no relationship between hot flash frequency and temperature variation in a 
study of 1041 self-reported hot flashes, despite reports from participants that they 
“thought” they had more hot flashes in warmer weather (Voda, 1981).  Only one 
participant, whose hot flashes were analyzed for six months, demonstrated a 
relationship with ambient temperature; for her, hot flash length was directly 
related to temperature.  A more recent study following 372 women in the United 
Arab Emirates (a hyper-arid climate) failed to find any association of seasonal 
variation with hot flash prevalence, frequency, or problem rating (Stefanopoulou 
et al., 2014a), mirroring a study of 717 women in India that also failed to find any 
association between hot flashes and seasonal temperature variation 
(Stefanopoulou et al., 2014b). 
It is curious that the results of the previous studies are so discrepant, and 
perhaps these results were due to wide variability in the populations studied.  In a 
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diary measure of 39 breast cancer survivors (mean age 52.6) experiencing hot 
flashes (mostly due to tamoxifen treatment), a group that likely consists of 
women with a more similar experience, Stubbs and coworkers (2008) 
investigated what participants thought as a proximal cause to the flush (Stubbs et 
al., 2008).  This was a self-report measure in response to the question, “What 
events affected your symptoms?”  Only a small proportion of the responses were 
temperature-related; of the 1,008 hot flashes reported, 2% indicated hot drinks, 
6% indicated a hot environment, and 0.2% indicated a hot shower or bath.  Of 
course, one cannot rule out the possibility that these response patterns were not 
specific to breast cancer treatment.   
 
3.2.2.  Ambient temperature:  Systematic manipulations 
 As will become a consistent theme in hot flash research, self-report can be 
notoriously faulty, and, while difficult, controlled laboratory investigations can be 
highly informative.  Kronenberg and Barnard (1992) systematically manipulated 
ambient temperature and used physiological monitoring to objectively measure 
hot flashes in six women experiencing ten or more hot flashes per day (ten per 
day is still the accepted criterion for “frequent” hot flashes as suggested by the 
FDA for hot flash intervention trials); five of the six participants were 
postmenopausal while one was perimenopausal (Kronenberg and Barnard, 
1992).  Their laboratory study utilized a cool, 19 °C ambient temperature or 
warm, 31 °C temperature; all subjects were exposed to an 8-hour session in both 
conditions.  In the 12 experimental sessions, they recorded 93 hot flashes; 75 
occurred in the warm condition while only 18 occurred in the cool condition.  Hot 
flash frequency and intensity were significantly greater in the warm room, though 
duration did not reach statistical significance.  The warm temperature in this 
study is quite warm (not very far from normal skin temperature values), and the 
lack of a control group of asymptomatic women precludes comparison between 
the experiences of these presumably different groups.  It may have been that the 
same objective signs using physiological monitoring would be present, but the 
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symptomatic women label this experience as a hot flash, whereas the 
asymptomatic women merely report feeling warmer than usual. 
 Indeed, work in this laboratory (performed during an IBMG rotation by Jill 
Badin) revealed that ambient temperature-induced flushing does not differ 
between ovariectomized (OVEX) and intact female rats (shown in Fig. 6).  A 
gradual warming protocol (using a shielded heat lamp to increase ambient 
temperature over a 30 minute period) caused an increase in tail skin temperature 
from a baseline of 25 °C to about 33 °C, yet there was no difference in the 
response between these groups.  An OVEX group given chronic E2 replacement 
appeared to have a baseline shift downward about 0.5 °C and TST increased 
about 2.5 °C less.  This data is especially meaningful in light of work discussed in 
section 3.2.1, as it suggests that ambient temperature fluctuations may not be 
causally relevant to hot flashes. 
 
3.2.3.  Direct heating paradigms 
 In contrast to manipulating air temperature, a few groups have used direct 
heating of the body to provoke and study hot flashes.  Sturdee and coworkers 
(1978) used a direct heating paradigm to evoke flushing in menopausal women 
and compared their physiological responses to premenopausal women (Sturdee 
et al., 1978).  Using warm water bottles and blankets, they elicited 18 flushes in 
seven of eight menopausal women studied, and the flushes were accompanied 
by increased skin temperature (1 °C), a statistically significant tachycardia 
(increase from 71±3 beats per minute to 86±4 bpm) at the onset of the flush, and 
decreased skin resistance [increased sweating].  These parameters were 
concurrent with the subjective sensation of the flush.  For the six premenopausal 
women studied, the increase in skin temperature and peripheral vasodilatation 
was greater than menopausal women, but not accompanied by tachycardia, and 
the decrease in skin resistance was much smaller, indicative of a lack of 
sympathetic drive in this group.  Later workers closely followed this approach and 
used circulating water pads heated to 42 °C to evoke hot flashes (Germaine and 
Freedman, 1984).  There were no significant differences in any of the  
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Figure 6.  Ambient Temperature-Induced Cutaneous Vasomotor Responses Do Not 
Differ Between Ovariectomized and Sham-Ovariectomized Rats.  Rats were exposed to 
an environmental heating protocol with a heat lamp (shielded) over an open 
experimental chamber.  Ambient temperature was gradually increased over a 30 min 
period (following stable baseline).  There were no statistically significant differences in 
treatment (p=0.21) between OVEX (n=6) and sham-OVEX rats (n=5) or OVEX rats 
treated with estradiol (n=5).  
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physiological parameters (heart rate, finger or cheek temperature, skin 
conductance, EMG, and respiration) between observed spontaneous hot flashes  
and hot flashes evoked with water pads in menopausal women.  Moreover, no 
premenopausal women (n=12, mean age=31.6, range 22-45) had hot flashes 
(objectively defined as the start of tachycardia) whereas 12/14 and 13/14 of the 
symptomatic menopausal women (mean age 50.3, range 44-61) endorsed hot 
flashes in heat stress sessions one and two, respectively.  Their results further 
replicated the tachycardia found by Sturdee; menopausal women exhibited a 
mean increase of 4.93 beats per minute while the premenopausal women’s heart 
rate decreased 1.84 beats per minute to the heat stress procedure.  Anecdotally, 
their participants reported that the evoked hot flashes were indistinguishable from 
spontaneous hot flashes. 
 
3.2.4.  Core body temperature  
 It is possible that ambient temperature affects only a subset of 
symptomatic women, and an unstable, elevated internal temperature may 
precipitate heat loss mechanisms in some cases.  The thermoneutral zone refers 
to the “range of thermal comfort” for an individual (Hartgill et al., 2011), and can 
indicate 1) the range of body temperatures where there is no shivering or 
sweating or 2) the range of ambient temperatures where thermoregulation is 
achieved through “sensible heat loss”, or through vasodilation and 
vasoconstriction to control blood flow.  Beyond the upper threshold, sweating 
also occurs to dissipate heat by evaporative cooling, and below the lower 
threshold, shivering or non-shivering thermogenesis maintains body temperature.  
One leading hypothesis regarding the role of CBT in symptomatic peri- or 
postmenopausal women is that a narrowed-to-virtually negligible thermoneutral 
zone may play a key role in triggering hot flashes.  Freedman and Krell (1999) 
measured the thermoneutral zone in symptomatic women to 0.0 ± 0.11 °C, while 
in asymptomatic women the zone was 0.4 ± 0.18 °C (12 symptomatic women 
and 8 asymptomatic women; CBT as assessed by ingested radiotelemetry pill) 
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(Freedman and Krell, 1999).  Later work demonstrated that estrogen 
replacement widened the thermoneutral zone (Freedman and Blacker, 2002).   
This deviation in the range of tolerable temperatures may play a role in the 
generation of hot flashes, as there are reports in the literature about very small, 
yet statistically significant, increases in core body temperature preceding the 
objectively measured hot flash (Freedman et al., 1995; Freedman and 
Woodward, 1996; Freedman, 1998).  It is difficult to ascertain the precise 
increase in core temperature, but from the data presented in these papers, it 
appears to be about 0.05 °C.  The graphs do not show error bars, and the 
variability observed is unclear.  Interestingly, these increases in core temperature 
occurred in 46/77 (60%) and 24/37 (65%) of hot flashes observed in these 
studies, still leaving a significant minority of women with unchanged core body 
temperature.  Furthermore, the relevance of these core temperature fluctuations 
are unclear, as further work has shown they are not specific to symptomatic 
women, as asymptomatic women have the same variation in temperature 
(Freedman, 2002).  It is possible that these are causally related to hot flashes for 
some women, but a clear demonstration of such causality remains to be 
demonstrated.   
Briefly, from an animal modeling perspective, I have found that core body 
temperature during pharmacological provocations does not increase prior to a tail 
skin temperature increase.  The tail skin temperature increase occurs first, and 
then a core body temperature decrease follows.  A similar series of events may 
occur for women that report that their hot flashes are followed by intense chills.  
However, in other paradigms that I have developed, such as a mild ambient 
temperature induced hot flash (see Fig. 5), core body temperature does not 
change.  While it makes sense that hot flashes could be precipitated by core 
body temperature increases in some cases, this may be more applicable to 
certain circumstances or factors, such as during fever (although Kronenberg 
reports that during a febrile episode, hot flashes for one highly symptomatic 
woman stopped) or ingestion of hot (temperature) or spicy foods or beverages.  
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But as of now, research into delineating different “subtypes” of hot flashes is 
virtually nonexistent.   
 
3.3.  Neuroendocrine Contributions 
 
3.3.1.  Gonadotropins:  LH, FSH, GnRH 
 Given the obvious role of hormonal decline in menopause, it is similarly 
intuitive that other (non-estrogen) reproductive related hormones may play an 
instrumental role in hot flash pathology.  Luteinizing hormone (LH) received 
significant attention in the early hot flash literature as a putative causal factor.  A 
neurohormone released from the anterior pituitary by Gonadotropin Releasing 
Hormone (GnRH), LH acts with Follicle Stimulating Hormone (FSH) in the 
ovaries to cause ovulation.  LH also increases the production of androgens, the 
precursor to estrogens.  Early work demonstrated a fairly tight temporal 
correlation between the onset of a hot flash and a pulsatile release of LH.  The 
first report of neuroendocrine factors appeared to strongly implicate LH; in a 
study of 6 postmenopausal women, 55 hot flashes and 66 pulses of LH were 
recorded (Casper et al., 1979).  The women with the most pulses of LH had the 
greatest number of hot flashes; while 11 pulses were recorded without a cognate 
hot flash, no hot flash was recorded without an LH pulse observed.  FSH was 
also significantly associated with hot flashes but to a lesser degree.  There was 
no change in prolactin or plasma catecholamines, including dopamine, 
norepinephrine, and epinephrine.  The findings of Tataryn et al., (1979) largely 
corroborated Casper’s work; in a study of 6 symptomatic postmenopausal or 
oophorectomized women, they observed 31 pulses of LH in 32 objectively 
measured (finger temperature) hot flashes (Tataryn et al., 1979).  In 26 of the 31 
hot flashes, the pulse of LH “had a close temporal relationship” (range: 0.082-
0.665 per patient; p < 0.01) with the onset of the flush.  In this study, FSH had no 
relationship to hot flashes (range: -0.062-0.63; p = 0.2).  Meldrum and colleagues 
(1984) studied 18 postmenopausal women (natural or surgical) that experienced 
severe hot flashes and assayed several neurohormones (Meldrum et al., 1984).  
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Again, LH was increased (15 min after the temperature increase) with no change 
in FSH or prolactin, though adrenocorticotropic hormone (ACTH) increased 5 min 
after the flush onset and an increase in growth hormone (GH) after 30 minutes 
was also found.  Thyroid stimulating hormone was unchanged.   
All of these studies are, of course, correlational and do not definitively 
indicate a causal role of LH.  Pulses of LH were observed in both premenopausal 
and postmenopausal women (Yen et al., 1972a).  Additionally, women whose 
pituitary glands were removed (hypophysectomized) had low or undetectable 
levels of LH and FSH but still had hot flashes (Mulley et al., 1977).  Women with 
gonadal dysgenesis had intact gonadotropin profiles but low levels of estrogen 
(and never go through puberty) only had hot flashes after withdrawal from 
estrogen treatment (Yen et al., 1972b).  However, these reports do suggest that 
the mechanisms that initiate release of LH may be involved in the neurochemical 
events that initiate hot flashes.   
 
3.4.  Role of the Autonomic Nervous System 
  
Hot flashes are often accompanied by many other symptoms, including a 
pounding heart and blood pressure changes (e.g., lightheadedness), indicating 
broader autonomic changes.  The additional evidence presented below 
demonstrates more globally heightened sympathetic tone that is present in 
symptomatic women, including cardiovascular perturbations.  A discussion of 
autonomic neurochemistry as related to vasodilation and sweating is also 
included.   
 
3.4.1.  Heart rate, norepinephrine, and epinephrine  
As mentioned earlier, tachycardia is often reported during hot flashes, 
providing some evidence that autonomic nervous system activation occurs during 
flashing episodes.  Early laboratory studies of hot flashes using objective 
monitoring of highly symptomatic women confirmed this tachycardia, and even 
found that it slightly preceded the subjectively-defined hot flash sensation onset  
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Figure 7.  Ambient 
Temperature-Induced 
Cutaneous Vasomotor 
Response.  Warm ambient 
temperature (i.e., 24-26 °C) 
increases skin temperature 
(sensed by transient receptor 
potential channels on the 
sensory nerve endings), and the 
signal propagates through the 
dorsal root ganglion and dorsal 
horn of the spinal cord.  It 
decussates at the level of the 
spinal cord and travels up the 
anterolateral system to the 
thalamus or medial preoptic 
area to initiate a motor 
response.  A third order neuron 
sends a collateral to the 
sensorimotor cortex for 
conscious perception of warmth 
while another collateral travels 
to the median preoptic area to 
initiate cutaneous vasomotor 
responses (traveling via the 
perifornical area of the 
hypothalamus).  Cutaneous 
vasodilation makes the skin 
warmer (30-40 °C) which will 
increase temperature 
perception from warm to hot.
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Figure 8.  Divisions and Neurochemicals of the Autonomic Nervous System.  The left 
side of the diagram indicates sympathetic innervation patterns and ganglia, which are 
predominantly preganglionic acetylcholine to postganglionic norepinephrine targets.  An 
important exception to this pattern is observed in the cutaneous vasculature and sweat 
glands, where acetylcholine is also the postganglionic neurotransmitter and causes 
vasodilation and sweating (in concert with other co-transmitters and local transmitters, 
like nitric oxide). The parasympathetic nervous system also uses acetylcholine for 
preganglionic neurotransmission, but in this case, acetylcholine is also the predominant 
postganglionic neurotransmitter.  
  
 52
(Kronenberg et al., 1984).  In this series of studies, assays of plasma 
norepinephrine (NE) and epinephrine (E) revealed increased E but decreased 
NE.  Other groups (Casper et al., 1979; Lightman et al., 1981) measured these 
catecholamines during hot flashes and observed no changes, but may have 
missed changes due to less frequent sampling protocols.  At odds with 
Kronenberg’ findings, (Cignarelli et al., 1989) found a 100% increase in NE and 
unchanged E; however, according to Cutter et al., 1980 (as cited in Cignarelli), 
the levels of E obtained in Kronenberg’s study were below physiological 
thresholds.  Regardless of absolute physiological relevance, this does not 
account for the discrepancies observed in NE between several studies.  
Additional evidence of autonomic activation comes from assays of plasma levels 
of the NE metabolites 3-methoxy-4-hydroxyphenylglycol (MHPG) and 
vanillylmandelic acid (VMA).  MHPG is the brain metabolite of NE, and has been 
reported to increase significantly following hot flashes (Freedman, 1998).  
However, once MHPG is in the peripheral circulation, it can be converted to 
VMA, thus potentially making interpretation of the results unclear.  Subsequent 
studies found that MHPG significantly increased following hot flashes, yet VMA 
levels were unchanged (Freedman, 1998).  It is possible that the different 
patterns observed over many studies may be due to different ‘subtypes’ of hot 
flashes and/or individual variation that reflect differential activation of the 
autonomic nervous system.  For example, Low and coworkers (2008) reported 
some women had decreases in blood pressure while others blood pressures 
remained constant, though all had tachycardia during hot flashes (Low et al., 
2008).   
 
3.4.2.  Blood pressure 
 More global patterns of heightened autonomic activation in symptomatic 
women have been uncovered using ambulatory monitoring techniques.  In 2004, 
James and coworkers studied 20 women for a 24-hour period using ambulatory 
blood pressure and hot flash monitors; women were stratified by current 
symptom status:  symptomatic (hot flashes) during study, historically 
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symptomatic, and asymptomatic (James et al., 2004).  The symptomatic during 
study group had significantly greater systolic blood pressures during work and 
sleep, and the heart rates of currently or previously symptomatic women were 
higher than the asymptomatic group.  A larger 24-hour study of ambulatory blood 
pressure of women ages 18-65 found that those women endorsing hot flashes 
had significantly higher systolic awake and sleeping blood pressures (awake: 
140.8 ± 2.5 vs 131.9 ± 1.7 mmHg for hot flashes vs no hot flashes; during sleep: 
128.9 ± 2.8 vs 119.2 ± 2.0; p = 0.004 and p = 0.007, respectively).  These 
findings maintained significance even when controlling for age, race/ethnicity, 
menopausal status, and conventional risk factors for hypertension, including 
smoking, alcohol, and caffeine consumption.  A similar ambulatory study of 110 
women with a range of hot flash experiences found that women with mild 
essential hypertension were more likely to have hot flashes, and there were no 
differences in age or menopausal status between the hypertensive and 
normotensive participants (Erkal et al., 2014).   
 
3.4.3.  Heart rate variability 
 Yet another autonomic-mediated parameter that has been studied in the 
context of hot flashes is heart rate variability (HRV).  This measure reflects the 
beat-to-beat (R-R interval) or variability in instantaneous heart rate, and can be 
divided into two major components, low frequency and high frequency power.  
High-frequency bands, from 0.15-0.4 Hz, reflect parasympathetic control of the 
heart from the vagus nerve (cranial nerve X).  Low-frequency power is reflected 
by bands from 0.04-0.15 Hz, and very low and ultra low frequencies are below 
that range.  Low-frequency, very low, and ultra low frequencies reflect a mix of 
sympathetic and parasympathetic control of the heart and also the renin-
angiotensin system; therefore, analyses regarding these components are not as 
clear.  Several studies have documented changes in these components of heart 
rate variability in regards to hot flash symptomatology; in one study, women with 
more menopausal symptoms had increased low frequency to high frequency 
power, a measure that reflects the balance between the parasympathetic and 
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sympathetic arms of the ANS (Lee et al., 2011).  Similarly, a study of 45 peri- and 
postmenopausal Japanese women found that those complaining of hot flashes 
and/or night sweats had decreased low frequency, high frequency, and total 
power (Akiyoshi et al., 2011).   
In addition to generalized perturbations of HRV in symptomatic women, 
Hoikkala and Thurston and their respective colleagues both documented the 
change of HRV during hot flashes.  The former group utilized ambulatory HRV 
monitoring and found very low and low frequency power increased while high 
frequency power decreased during hot flashes, indicating greater sympathetic 
activity and lessened parasympathetic activity (Hoikkala et al., 2010).  Curiously, 
these changes did not differ by groups stratified by severity of hot flashes.  
Thurston’s study found significantly decreased high frequency power during a hot 
flash (relative to pre- and post-flash periods) as well as an increase in the LF:HF 
ratio during both physiologically recorded and self-reported hot flashes (Thurston 
et al., 2010).  A later ambulatory monitoring study confirmed this finding; 
additionally, they reported significant interactions with anxiety, age, and 
menopause status (Thurston et al., 2012).  Collectively, these studies 
demonstrate that a perturbed autonomic nervous system (or the mechanisms 
that control the ANS) is likely essential to the mechanisms mediating hot flashes, 
and therefore understanding is a prerequisite to effective treatment strategies. 
 
3.4.4.  Autonomic neurochemistry:  Cutaneous vasodilation and heat perception 
 Both cutaneous vasodilation and sweating (increased skin conductance) 
are objectively measurable indicators of hot flashes.  However, their relative 
importance in producing the sensation of heat is differentiable, as cutaneous 
vasodilation will certainly produce a sensation of heat by activation of TRP 
receptors in the periphery.  While sweating often accompanies hot flashes (the 
neurochemical mechanisms are similar, as elaborated below), sweating in the 
absence of vasodilation would produce a cooling sensation as long as the 
relative humidity is low.  (In environments with low humidity and low ambient 
temperature, sweating with vasodilation could also cause a cooling sensation.)   
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The precise array of neurochemicals that mediate cutaneous vasodilation 
are still being elucidated.  It is clear that human skin possesses an active 
vasodilator component; that is, vasodilation is achieved, in part, through 
activation of a separate acetylcholine system, not just withdrawal of a 
noradrenergic vasoconstriction system (Johnson et al., 1995).  While cutaneous 
vasodilation is achieved by acetylcholine and unknown co-transmitters, including 
histamine, Calcitonin Gene Related Peptide (CGRP), NO, and Substance P, (for 
an excellent review, see [(Holowatz et al., 2010)], it was unclear if the 
menopausal hot flash possessed similar properties.  As discussed already, hot 
flashes are autonomic events, and to address the sympathetic contribution to the 
flush, Low and coworkers (2011) performed a series of studies using botulinum 
toxin (Botox®) to selectively block cholinergic sympathetic nerves (Low et al., 
2011).  In these studies, botulinum toxin was used to block cholinergic 
neurotransmission in the forearm and forehead; hot flashes were induced in 
symptomatic women using mild heat stress (whole body warming using water-
perfused suits).  Both sites had identical attenuation of the hot flash as measured 
by cutaneous vascular conductance, a measure of blood flow that controls for 
blood pressure.  A similar study demonstrated that blockade of NO synthesis 
using the compound L-arginine-N-methyl ester (L-NAME) attenuated the hot 
flash response (either spontaneous or evoked with mild heat stress in 
symptomatic women) (Hubing et al., 2010).  Importantly, they demonstrated that 
skin sympathetic nerve activity (SSNA) increased four-fold immediately prior to 
the hot flash, and returned to baseline after its abatement (Low et al., 2011).   
 
3.4.5.  Autonomic Neurochemistry:  Sweating and evaporative cooling 
While not all hot flashes are accompanied by sweating, a brief overview of 
what is known about sweat physiology is covered here.  As discussed earlier, 
sweating is essential to maintain a normal internal temperature, especially when 
ambient temperature is higher than skin temperature (and, therefore, 
thermoregulation cannot be achieved solely by releasing heat through 
vasodilation).  Sweat, which is 99% water, contains various ions, including 
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sodium, chloride, calcium, potassium, and lactate, and some waste products (i.e. 
urea) and promotes cooling by the evaporation of water, releasing heat.  Eccrine 
glands are the major type of sweat gland and are located across the entire body 
except for the lips (and penis in males) whereas apocrine glands are located in 
hairy areas, including axillary regions and the anogenital region.  For humans, 
the apocrine glands are not a major contributor to thermoregulation, though they 
are important for some species.  Lastly, there exists a mixed type of gland, the 
apoeccrine gland, which is also found in anogenital areas.  It has long been 
recognized that vasodilation and sudomotor sweat responses often paralleled 
each other, suggesting similar molecules mediate both activities.  Like 
vasodilation, sweating is achieved by cholinergic mechanisms and unknown co-
transmitters that overlap with vasodilatory factors (including Substance P, NO, 
CGRP, and VIP) (Shibasaki and Crandall, 2010).  Human sweat glands express 
several nicotinic and muscarinic receptors, including m1-m5, and α3, α7, α9, and 
β2 (Kurzen et al., 2004).  Importantly, a variety of stimuli can elicit sweating, 
including increased ambient temperature, but also stress, anxiety, and other 
emotional states.  There appears to be some dissociability between emotional 
and thermoregulatory sweating and this is discussed further in the commentary. 
 
3.5.  Neurochemical Involvement as indicated by non-hormonal treatments 
  
Despite the relatively modest efficacy of extant non-hormonal therapies, 
these compounds have provided some evidence of key neurochemical systems 
that may be involved in the generation of hot flashes.  Therefore, the following 
section discusses the neurochemical systems currently implicated in hot flash 
physiology, including norepinephrine, serotonin, and GABA.  A graphical 
summary of selected hot flash drug intervention trials is presented in Fig. 9. 
 
3.5.1.  Norepinephrine 
Norepinephrine, the classical sympathetic neurotransmitter underlying the 
fight or flight response, is perhaps the earliest and most well explored 
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neurochemical regarding menopausal flushing.  Early studies demonstrated that 
gonadal removal in rodents (ovariectomy or orchidectomy) increased 
norepinephrine turnover in the brain, suggestive of increased catecholamine 
synthesis following gonadal steroid ablation (Anton-Tay and Wurtman, 1968).  In 
the laboratory, clonidine, an α2-adrenergic receptor agonist, has helped elucidate 
some clues as to the neurochemistry of hot flashes.  Clonidine is thought to be 
relatively specific for presynaptic receptors in vasomotor centers of the brain; 
hence its use to lower blood pressure (for review, see (Slim et al., 2011)).  
Freedman and colleagues (1990) demonstrated that 1) yohimbine (an α2-
adrenergic antagonist) infusions precipitated hot flashes; 2) clonidine 
pretreatment increased the amount of time needed to provoke a hot flash in a 
warm room; and 3) clonidine blocked yohimbine-induced flushing in symptomatic 
menopausal women (Freedman et al., 1990).  Furthermore, in a sample of 
symptomatic postmenopausal women, clonidine raised the sweating threshold, or 
the core body temperature set point in which sweating occurs (Freedman and 
Dinsay, 2000).  While interventional studies have demonstrated significant 
reduction of hot flash frequency and severity, clonidine treatment presents many 
highly unpleasant side effects, including dry mouth, constipation, itchiness, and 
drowsiness, precluding it from a first-line non-hormonal vasomotor symptom 
therapy (Goldberg et al., 1994). 
Alternatively, norepinephrine reuptake inhibitors are used off-label as a 
treatment for hot flashes.  These molecules block the transport of norepinephrine 
across the plasma membrane back into the neuron, which allows for increased 
activity at their synaptic targets.  Their efficacy, as typically measured by self-
reported diaries, is significant, yet plagued by high placebo response rates (and 
often accompanied by underpowered sample sizes).  As reviewed recently, both 
venlafaxine and desvenlafaxine have clinical efficacy, and many trial participants 
often elect to continue on the therapy after the trials end (Handley and Williams, 
2015).  A trial examining venlafaxine that used objective hot flash monitoring 
highlights the difference between objective and subjective monitoring in hot flash 
trials (which are almost entirely dependent on subjective instruments) (Carpenter 
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et al., 2007).  Using ambulatory sternal skin conductance monitors, they 
observed a 22% decrease in hot flash frequency compared to a 0% decrease 
with placebo.  Yet as gauged by diaries, hot flashes decreased 42% for the 
venlafaxine group, and for placebo, decreased 18%.  Like clonidine, there are 
many side effects of NRIs, including dry mouth, decreased appetite, 
sleeplessness, nausea, and constipation.  Additionally, NRIs may increase blood 
pressure, so their use must be carefully considered, and this is especially critical 
for menopausal women, for whom increases in blood pressure are common and 
associated with hot flashes (as described above).   
 
3.5.2.  Serotonin 
3.5.2a.  Selective Serotonin Reuptake Inhibitors 
 Several studies have suggested a prominent role for serotonin in relation 
to menopause.  Serotonin is positively correlated with both plasma estrone and 
estradiol in healthy postmenopausal women (Guicheney et al., 1988) and probing 
the serotonergic system with the serotonin receptor agonist meta-
cholorphenylpiperazine (m-CPP) in postmenopausal women revealed deficits 
that were ameliorated with estrogen treatment (Halbreich et al., 1995).  Clinical 
studies have found significant decreases in serotonin levels in the blood in 
postmenopausal women, and treatment with estrogen restored these levels to 
values comparable to premenopausal women (Gonzales and Carrillo, 1993; 
Blum et al., 1996).  Estrogen replacement also increased urinary 5-HIAA 
excretion, indicating increased serotonin turnover, following estrogen 
replacement in postmenopausal women (Lippert et al., 1996).  Moreover, women 
with moderate or severe climacteric symptoms, as measured by the Kupperman 
Index, had significantly lower plasma 5-HT levels compared to women with only 
mild climacteric symptoms (Slopien et al., 2003).  
Selective serotonin reuptake inhibitors (SSRIs) similarly block the 
reuptake process of serotonin at the synaptic cleft, thereby increasing the 
concentration of serotonin in the synapse and prolonging serotonin’s effects.  
While initially used as a treatment for major depressive disorder, they have found 
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utility for a number of psychiatric conditions, including obsessive-compulsive 
disorder, panic disorder, and premenstrual dysphoric disorder (Stone et al., 
2003).  Initial research into SSRIs as a treatment strategy for hot flashes began 
with breast cancer patients unable to take hormone therapy but has since 
segued into the much larger population of women transitioning through 
menopause.  Ultimately, this has led to the approval of low dose paroxetine as 
the only FDA-approved non-hormonal pharmacotherapy.  Several trials have 
been conducted evaluating the efficacy of many drugs in this class, and, like 
norepinephrine reuptake inhibitors, the main outcome measures are typically 
reduction in hot flash frequency and severity, and sometimes a composite index 
of these measures.  Handley & Williams (2013) reported that paroxetine, 
citalopram, and escitalopram are the most effective SSRIs for vasomotor 
symptoms.  Two trials of fluoxetine (Loprinzi et al., 2002a; Suvanto-Luukkonen et 
al., 2005) had non-significant reductions in hot flash symptoms, and three trials 
describing the effectiveness of sertraline were underpowered (Gordon et al., 
2006; Grady et al., 2007; Wu et al., 2009).  
Paroxetine had three significant trials.  Stearns and coworkers (2003) 
report 62% and 64% reductions in hot flashes compared to a 38% reduction with 
placebo (controlled release formulation), and, in a later report, a 40.6% and 
51.7% reduction (10 mg and 20 mg, respectively) compared to a 13.7% and 
51.7% reduction (Stearns et al., 2003a, 2005).  While these data seem 
impressive, and are statistically significant, the use of percentages can be 
misleading, as the clinical benefit of the drug may not be impressive based on 
raw numbers.  For example, Soares et al., (2008) found a statistically significant 
reduction in number of hot flashes per week, but in this trial, paroxetine reduced 
hot flashes by an average of 6.1 per week, while the placebo reduced hot flashes 
by 2.8 per week (Soares et al., 2008).  In a systematic review and meta-analysis 
of trials of SSRIs for hot flashes, the overall reduction in hot flash frequency was 
approximately 10%, or about 1 hot flash a day in women experiencing ten or 
more hot flashes daily (Shams et al., 2014).  In these types of trials, inclusion 
criteria are especially important, as some women may not be experiencing a 
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great enough and stable enough number of hot flashes to sufficiently gauge 
effectiveness of a medication.  One approach to determining if a woman is 
significantly affected by hot flashes is to use lengthy (2-4 week) placebo-run in 
periods or diary measures prior to starting the test drug.  Another consideration is 
the high attrition rates in many trials, which can be due to side effects of the 
treatment under study, ineffectiveness of the treatment, and other factors; in 
some trials reported in the Handley and Williams’ analysis, attrition was in  
excess of 20%.  This may represent an important source of variability that is lost 
in these studies. 
 
3.5.2b.  Tryptophan Manipulations 
In addition to drug treatments, experimental studies have used tryptophan 
manipulations to study the role of serotonin in hot flashes.  Tryptophan is the 
amino acid precursor of serotonin, and is biotransformed first by tryptophan 
hydroxylase (TPH) into 5-hydroxytryptophan (5-HTP), which is then 
decarboxylated by aromatic L-amino-acid decarboxylase into 5-
hydroxytryptamine/serotonin (5-HT).  TPH is unique in that it is not usually 
saturated, so increased consumption of tryptophan will increase serotonin 
synthesis (Young and Gauthier, 1981).  To that end, two studies have explored 
whether dietary alterations of tryptophan can influence hot flashes.  In a study of 
27 breast cancer survivors, ingesting a concentrated amino acid beverage to 
deplete (outcompete at the amino acid transporters into the brain) tryptophan did 
not change objective or subjective hot flash frequency or self-reported intensity or 
bother (Carpenter et al., 2009).  It could be that these women already had a low 
level of serotonin that this depletion paradigm was unable to further aggravate 
the pathology.  The authors also suggest that there may not be any differences at 
baseline, non-stressed conditions or without any type of challenge.  Another 
small study utilized the opposite approach, tryptophan loading, to study 
objectively measured hot flashes in 24 symptomatic postmenopausal women 
(Freedman, 2010).  Study participants took a 50 mg capsule of 5-HTP three 
times a day, and there were no significant differences in hot flash frequency at 
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the end of the three-week study period.  This study should be interpreted 
cautiously, as the sample was small and the doses used were relatively low, and 
no data is shown regarding the effect of the loading on overall 5-HT tissue 
content (i.e. blood levels).  It could be that much higher doses are required 
observe an effect.  Unfortunately, with the relatively poor quality of such studies, 
making concrete conclusions is troublesome, and these should not be interpreted 
as a lack of a role for serotonin. 
 
3.5.3.  GABA 
 γ-Aminobutyric acid (GABA) is the dominant fast inhibitory 
neurotransmitter in the central nervous system; yet regarding hot flashes, it has 
not received much attention.  GABA mediates its cellular effects through a variety 
of receptors, including heteropentameric, ligand-gated chloride channels (GABAA 
receptors) and G-protein coupled receptors (GABAB receptors).  The particular 
subunit composition of a GABAA receptor determines its affinity for GABA, and 
estrogen levels affect the transcription of GABAA receptor subunits (Herbison and 
Fénelon, 1995).  Specifically, these changes were demonstrated in the BNST, an 
anxiety- and panic-associated brain region.  Adding further complication to the 
relationship between hormones and GABA is that GABAA receptors have been 
shown to be sensitive to changes in progesterone or its metabolite, 
alloprenanolone [as reviewed by (Lovick, 2006)].  In animals, this leads to 
hyperexcitability in the periaqueductal gray, which is a key site in the generation 
of severe anxiety (e.g. panic).  This link between altered GABAergic inhibition 
around the time of decreasing hormone levels may provide a clue as to the 
origins of certain premenstrual symptoms [which can include hot flashes (Hahn et 
al., 1998)].   
As mentioned earlier, gabapentin, a structural analog of GABA, is used 
with some efficacy for hot flashes.  However, its mechanism of action has been 
elusive and does not simply increase GABA concentration by virtue of its 
structure.  It is thought to involve regulation of calcium channels and 
neurotransmitter release, as it binds to the α2δ subunit of voltage-dependent/L-
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type calcium channels (Gee et al., 1996) and inhibits calcium currents in rat 
neurons from the neocortex, striatum, and globus pallidus (Stefani et al., 1998).  
Interestingly, Cai and coworkers (2012) report using 7-Tesla Magnetic 
Resonance Spectroscopy (MRS) to quantify glutamate and GABA levels in the 
brain before and after a 900 mg oral gabapentin [a common dose for use in 
treating hot flashes] challenge in 11 healthy men; GABA levels were significantly 
increased while glutamate levels were unchanged following the challenge (Cai et 
al., 2012).  However, it is unclear how this is occurring mechanistically.  It is 
possible that some of the effectiveness of gabapentin as a hot flash therapy may 
be due to its anxiolytic effects.  In a study of 420 breast cancer patients, 300 and 
900 mg doses of gabapentin were more effective than placebo at reducing state 
anxiety scores at 4 and 8 weeks (Lavigne JE et al., 2012).   
 Despite the aforementioned clinical studies demonstrating some efficacy a 
potential GABA-enhancing drug, more extensive investigation into GABA-
centered therapies, such as benzodiazepines, is almost nonexistent.  A search 
for “benzodiazepine hot flash(es)” or “benzodiazepine hot flush” yielded 0 directly 
relevant results in PubMed on 2/15/2016.  These compounds are widely known 
to allosterically modulate the GABAA receptor to increase the flow of chloride into 
the channel when GABA binds, thus hyperpolarizing the membrane.  A sole 
report in the literature demonstrated some efficacy in reducing climacteric 
symptoms following oöphorectomy in 30 women using the benzodiazepine 
oxazepam compared to the β-adrenergic antagonist propranolol (double-blind, 
cross-over design) (Erkkola et al., 1973).  It is unclear if any newer drugs in this 
class, such as including alprazolam or lorazepam, have any effect on hot flashes, 
but considering their use as anxiolytics, and the afore-described relationship 
between anxiety symptoms and hot flashes, it seems likely that they may have 
some efficacy.   
 Overall, the physiological understanding of hot flashes is relatively limited.  
Major clues to the pathology and neurochemical systems mediating hot flashes 
come from non-hormonal treatments and implicate norepinephrine, serotonin, 
and GABA (potentially).  These treatments are quite limited in efficacy, however,  
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Figure 9.  Reduction in Hot Flash Frequency by Study.  Black bar represents theoretical 
maximal hot flash reduction compared to data from individual studies.  The oral hormone 
therapy trial (bright pink bar) represents data from a meta-analysis of hormone therapy, 
whereas other groupings are individual clinical trials.  Pink bars represent hormone trials, 
orange bars represent serotonin-norepinephrine reuptake inhibitors, green bar 
represents clonidine, blue bars represent selective serotonin reuptake inhibitors, purple 
bars represent gabapentin, and gray bars represent placebo results for each trial.  
Percentages at the top of the bar indicate reduction in hot flash frequency (diary 
measure).  Note the strong placebo response and wide variability between studies. 
 
1Joffe et al., 2014 JAMA Internal Medicine; 2Freeman et al., 2011 JAMA; 3Archer et al., 
2009 American Journal of Obstetrics & Gynecology; 4Speroff et al., 2008 Obstetrics & 
Gynecology; 5Suvanto-Luukonen et al., 2005 Menopause; 6Guttuso et al., 2003 
Obstetrics & Gynecology; 7Stearns et al., 2005 Journal of Clinical Oncology; 8Simon et 
al., 2013 Menopause; 9MacLennan et al., 2004 Cochrane Database; 10Pandya et al., 
2000 Annals of Internal Medicine; 11Butt et al., 2008 Menopause. 
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so building hypotheses concerning the mechanisms of hot flashes around them 
should be undertaken with caution.   
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Part IV:  Animal Modeling 
 
4.1. Animal Modeling of Hot Flashes 
 
 Hot flashes are undeniably complex phenomena that arise in the wake of 
dramatic reduction of the ubiquitous hormone, estrogen.  While clinical 
investigation has attempted to elucidate processes and mechanisms that lead to 
them, preclinical investigation can also contribute.  Now that the features of a hot 
flash, associated neurochemical events, and risk factors have been described, 
this section will focus on the development of a preclinical line of research that 
may contribute to the understanding of hot flash generation and treatment 
strategies. 
 
4.1.1.  Establishing the validity of an animal model 
4.1.1a.  Traditional criteria 
 A full validation of an animal model is a difficult accomplishment, but is 
critical to maximizing its translational potential.  In psychiatry, the most oft-cited 
criteria for validity are the tenets set forth by Willner:  face, construct, and 
predictive validity (Willner, 1984).  He enumerated five subcriteria within each 
category to evaluate an animal model.  Generally, face validity refers to the 
extent that a model recapitulates (“looks like”) the phenotype of the 
condition/disorder being studied, and is often the easiest (and sometimes only) 
accomplishment of a model.  Secondly, construct validity is concerned with the 
extent that the underlying mechanisms of the animal model replicate the biology 
of the human condition; that is, do the same processes (i.e. oophorectomy or 
removal of the ovaries) result in the same or at least similar disease in both the 
model and human.  Lastly, predictive validity is the model’s capacity to accurately 
indicate treatment or progression as the result of a novel intervention that is 
mirrored in the clinical condition (i.e., can this model be used to find new 
treatments for the disease state or condition it represents).   
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4.1.1b.  Updated criteria 
The current emphasis on translational research, either beside-to-bench or 
bench-to-bedside, spurred an elaboration and update to Willner’s criteria 
(Belzung and Lemoine, 2011).  They propose five criteria: 1) homological; 2) 
pathogenic; 3) mechanistic; 4) face; and 5) predictive validity.  Essentially, 
homologic validity reflects the appropriateness of the species and strain for the 
condition under consideration; pathogenic validity considers the role of 
ontological or vulnerability mechanisms (for example, early life stress or 
environmental insults) and “triggers”; and mechanistic validity mirrors construct 
validity.  Face validity is relatively unchanged but incorporates both ethological 
relevance and biomarkers.  Ethological relevance is an important consideration in 
anxiety testing and is elaborated upon below.  Lastly, predictive validity includes 
both induction and remission validity, or the relationship between the precipitating 
factor and treatment, respectively, in both species.  In addition to predictive 
validity, postdictive validity is another feature to consider (Griebel and Holmes, 
2013).  In contrast with Willner’s predictive validity concept, which in the strictest 
interpretation is not immediately useful until a treatment is tested in a clinically 
relevant population, postdictive validity can more readily confirm the validity of a 
model, as it considers how established treatments for a condition (i.e. 
benzodiazepines for anxiety or estrogen replacement for hot flashes) impact the 
behavior or biology of the animal model.  It should be noted that predictive 
validity has often been used the way postdictive validity has been defined, so 
caution is warranted in using these terms.   
 As for the validity of certain tests to assess physiology or behavior, similar 
rules apply.  They should reflect relevant behaviors of the species (i.e. 
thigmotaxis, or wall-hugging behavior exhibited by rodents) and sensitivity to 
known influential factors, such as stress, or developmental abilities of the animal.   
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4.2.  Induction of a Menopausal State 
 
4.2.1.  Ovariectomy 
 With validity in mind, then, how is the best way to study menopause in a 
preclinical species?  The most obvious approach could be to mimic what causes 
menopause in most women—aging.  However, even without respect to 
laboratory constraints (i.e., time and costs involved in aging animals) this is not 
the most feasible option.  Rats do not go through a menopause per se; they may 
become acyclic or in constant estrus, but their estrogen levels never reach those 
as equivalently low to a postmenopausal woman; therefore, naturalistic models 
are extremely limited and could result in a relatively mild or inconsistent 
phenotype.  Rapidly inducing a surgical menopausal state in a rodent is a 
straightforward procedure by bilaterally removing the ovaries.  This model has 
been used for many decades in a variety of fields studying many aspects of 
menopause, and is the preferred model of choice in bone research studying 
osteoporosis, for example (Lelovas et al., 2008).  Certainly, ovariectomy models 
a small percentage of menopausal women and cannot recapitulate every 
menopausal experience; the precipitous loss of ovarian function in this case also 
comes with loss of other hormones.  With regards to oöphorectomized women, 
their experiences are often more dramatic and severe, especially with respect to 
vasomotor symptoms and anxiety (Taylor, 2001; Rocca et al., 2008).  Almost all 
women who undergo oöphorectomy experience acute vasomotor symptoms, 
even those that had no vasomotor symptoms prior to the oophorectomy (Erkkola 
et al., 1973; Kronenberg, 1990).  Therefore, inducing a robust phenotype may 
provide more consistent abnormalities, which could be desirable for treatment 
studies (with the assumption that the phenotype produced by ovariectomy is not 
excessively severe).   
 
4.2.2.  Chemical approaches 
 Another approach that has been developed more recently is the use of 4-
vinyl cyclohexane diepoxide (VCD) to model the perimenopausal stage 
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specifically.  This compound is an ovotoxin that selectively kills follicular cells 
over a period of weeks (for review, see (Kappeler and Hoyer, 2012)).  Unlike 
ovariectomy, it recapitulates the fluctuating hormones observed in this transition 
period rather than abruptly removing all endocrine factors in the ovarian tissue. 
Follicle stimulating hormone levels rise, like naturally aging women, but high 
doses create significant mortality (Frye et al., 2012).  Use of this compound 
requires additional regulatory approval, as the bedding is considered a 
biohazard.  Tamoxifen or other estrogen receptor modulators or aromatase 
inhibitors can also be used in healthy animals to induce a pharmacological 
menopause.  Yet, these methods may also be less reliable than ovariectomy 
insofar as producing a dramatic phenotype (see section 1.3.2.).  
 
4.3.   Modeling of the Hot Flash in Rodents 
 
4.3.1.  Role of the tail as a heat loss organ 
Due to the obviously furred (and therefore highly insulated) nature of the 
rat, heat dissipation occurs in a restricted area—the tail.  Owing to this difference 
in furriness, the tail is the major organ of heat loss in the rat, and while it takes up 
only a small fraction of the rat’s volume, it accounts for approximately 15% of the 
total surface area.  Its highly vascularized skin has the same specialized vessel 
structures called arteriovenous anastomoses (AVA) as human skin.  These non-
nutritive capillary beds formed at the interface of arteries and veins permit a rapid 
flow of blood, and heat is lost to the surroundings through convection.  Rats 
without tails are unable to thermoregulate properly and have prolonged 
responses to pharmacological manipulations that increase core body 
temperature (e.g. injection of β-adrenergic receptor agonist isoproterenol) (Spiers 
et al., 1981).  The following section will summarize the current knowledge of 
neurochemicals that regulate blood flow and tail skin temperature, discuss the 
relevance of cycling hormones in the rat, and existing models of hot flashes in 
rats. 
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4.3.2.  Neurochemical control of tail skin temperature 
4.3.2a.  Acetylcholine 
Despite the anatomical differences between heat exchange appendages 
in rats and humans, there is some evidence that the underlying mechanisms are 
conserved.  The neurochemicals that control the flow of blood and concomitant 
temperature of the tail skin include the classical autonomic neurotransmitters 
acetylcholine (ACh) and norepinephrine, though the former’s involvement has 
been controversial.  In 1978, Cox and Lee reported dose-dependently increased 
tail skin temperature (1-2 °C) and decreased core body temperature (~1-1.5 °C) 
in rats by systemic intraperitoneal (i.p.) injections of oxotremorine, a muscarinic 
cholinergic agonist (Cox and Lee, 1978).  These changes are similar to the 
changes observed by those who have attempted to model hot flashes (see 
below).  However, these manipulations could ultimately be indirectly stimulating 
norepinephrine via the preganglionic acetylcholinergic innervation of 
postganglionic norepinephrine mechanisms controlling vasodilation.  Reports of 
studies utilizing isolated segments of the tail artery are telling.  In isolated rat 
arteries pre-constricted with phenylephrine (which stimulates arterial contraction 
through noradrenergic (α1) mechanisms), acetylcholine and the muscarinic 
receptor agonist pilocarpine both induced endothelium-dependent, dose-
dependent relaxation of isolated rat artery, which was subsequently confirmed by 
another group (Tonta et al., 1994; Geary et al., 1998).  In 2006, Peuler & Phelps 
found that acetycholinesterase inhibitors (neostigmine and metrifonate) 
enhanced the relaxation response of isolated tail artery segments to 
acetylcholine (Peuler and Phelps, 2006).  Isolated tail artery segments from 
ovariectomized rats had significantly impaired relaxation compared to sham 
controls, at the highest dose of acetylcholine (Shuto et al., 2011). 
 
4.3.2b.  Inhibiting presynaptic norepinephrine autoregulation   
Not surprisingly, pharmacological stimulation of noradrenergic targets has 
also indicated an essential role for this neurotransmitter in the regulation of tail 
skin temperature and blood flow.  Redfern and coworkers (1995) performed a 
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series of studies to delineate the roles of various adrenergic receptors.  The α2 
receptors are primarily presynaptically localized, and when stimulated, inhibit 
release of norepinephrine; therefore, antagonizing these receptors would 
increase norepinephrine release (Redfern et al., 1995).  Several α2 antagonists 
caused profound increases in tail skin temperature, including delequamine (RS-
15385-197), yohimbine, and idazoxan, all given at doses of 1 mg/kg.  
Delequamine and yohimbine elicited approximately 9 °C increases while 
idazoxan had a milder effect, increasing TST about 4°C.  The α2 agonist clonidine 
caused a small but significant increase in TST yet also a profound drop in CBT 
(which seems at odds with its potential therapeutic value, though that is quite 
low).  These results parallel induction of hot flashes in symptomatic women with 
yohimbine and its ability to be blocked by clonidine (Freedman et al., 1990; 
Freedman, 1998).  This should be interpreted cautiously, as these drugs are 
capable of having effects at both central and peripheral receptors, and it is 
currently unknown which of these are necessary for inducing hot flashes. 
 
4.3.3.  Role of steroid hormones in temperature regulation in the rat 
4.3.3a.  Relationship of temperature and estrogen status 
Rats tail skin temperature varies across the estrous cycle.  Williams and 
coworkers (2010) demonstrated a distinct diurnal pattern of TST in freely-moving 
animals that it was lower (~6 °C) in the active/dark phase and higher in the 
inactive/light phase (Williams et al., 2010).  Across the estrus cycle, it was only 
significantly changed (decreased compared to other nights) on the night of 
proestrus, when the rat would be ovulating, and both estrogen and progesterone 
levels are high.  A second study demonstrated that ovariectomy abolished this 
phase-dependent decrease in TST, and consequently TST was elevated during 
the active phase.  The ovariectomy-induced increase in TST is consistent with 
many other groups reports (Kobayashi et al., 2000; Berendsen et al., 2001; Pan 
et al., 2001; Opas et al., 2004).  The increase in TST appears to be fairly acute to 
the removal of the ovaries; Berendsen and colleagues observed a 6 °C increase 
three days after surgery and Kobayashi and coworkers found elevated TST  
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Figure 10.  Diurnal Variation in Temperature Between Ovariectomized (OVEX) and 
Intact (Sham) Controls.  Line graphs with error bars (SEM) depicts a) differences in tail 
skin temperature between OVEX and sham rats that occur in the active phase only; b) 
Core body temperature between OVEX and sham rats;  c) Activity as a function of 
phase.  Increased tail skin temperature of OVEX rats is not due to increased activity 
during the active phase. 
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within two weeks.  It is also relatively long-lasting, as Kobayashi observed 
elevated TST from 2--7 weeks after surgery, yet not permanent, as they also 
found that it was not different from sham-ovariectomized rats from 8--20 weeks 
after surgery.  Intriguingly, despite the increase in TST, in most cases, core body 
temperature (CBT) was unaffected; Kobayashi found elevated rectal temperature 
from 8--20 weeks.  I also evaluated core and tail skin temperature alongside 
activity levels using implanted radiotelemetry probes and found similar results.  
Over a several day period of continuous monitoring, I found an active-phase 
dependent elevation in tail skin temperature only in ovariectomized rats that was 
not due to increased activity (activity levels were the same in both groups), 
consistent with these investigators.  This increase in TST after ovariectomy 
suggests that these rats may be vulnerable to stimuli or conditions that may 
produce a hot flash-associated increase in TST (heat dissipation response), but 
does not replicate the episodic nature of the hot flash as described by 
symptomatic women.  This state-dependent elevation of TST has been used to 
investigate novel therapies by examining the ability of a compound or set of 
conditions to restore the active phase decrease in TST.  While studying this 
marker may be valuable, it is perhaps not the ideal model of a “spontaneous” hot 
flash.  
 
4.3.3b.  Utility of variation in tail skin temperature as a hot flash model 
 With respect to the aforedescribed approach to modeling, there is only 
one report of any “spontaneous” fluctuations in TST that mimic the episodic 
nature of hot flashes.  Simpkins observed “pulses” of TST increases in a 
subgroup (9 of 20) intact but anestrus or constant estrus aged rats, yet these 
fluctuations were abolished by ovariectomy (Simpkins, 1984).  The implications 
of this particular study are at odds with the larger literature, and is likely an 
unsuitable modeling approach.   
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4.4.  Existing Neurochemical Modeling of Hot Flashes 
 
An alternative approach to modeling hot flash-related increases in tail skin 
temperature could include administering an agent that reliably provokes a hot 
flash in a vulnerable (i.e. ovariectomized) rat rather than attempting to find 
restoration of normal TST.  Such a probe would represent a threshold difference, 
which contrasts with the ambient temperature-induced flushing paradigm, 
wherein the responses were similar between surgical and estrogen treatments.  
Likewise, a model of this type should also be responsive to estrogen treatment, 
indicating postdictive validity.  Similarly, these substances would also trigger hot 
flashes in symptomatic or menopausal women, but not asymptomatic or non-
menopausal women, or at least to a lesser degree (providing postdictive validity).  
A provocation that reliably triggers a hot flash could then potentially be used in 
screening for novel therapies.  The clinical research community has long 
recognized that a valid animal model of hot flashes is necessary for further 
mechanistic understanding of flushing to guide target development for 
therapeutics (see a summary of an NIH workshop on the state of the science of 
vasomotor symptoms (Miller and Li, 2004a)).  As mentioned previously, inducing 
a menopausal state is relatively easy, but it is how to induce a flush in a valid 
manner that has proven elusive.  To date, there are only two trigger-based 
models in the literature, and only one with relatively extensive publications.  The 
first, and oldest, uses the opioid antagonist naloxone to trigger a hot flash, and 
the second manipulates norepinephrine with yohimbine.   
 
4.4.1.  Opioid antagonist model 
In 1983, the first animal model of a menopause-associated hot flash was 
proposed (Simpkins et al., 1983).  Based on observations that morphine 
withdrawal syndrome is similar to a menopausal hot flash (that is, persons 
complain of intense sensations of heat and chills and tachycardia), Simpkins and 
colleagues administered morphine (subcutaneous pellets) sufficient to produce 
dependence in female rats.  At baseline, they observed a significant CBT 
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elevation of 0.81 °C.  Following the addiction paradigm, they infused naloxone, 
an opioid receptor antagonist, and observed an increase in TST, from ~27 to 33 
°C, and a resulting hypothermia from ~38.5 to 35 °C.  Naloxone also caused a 
nine-fold increase in LH within 10 minutes, and a mild tachycardia—two 
additional signs frequently observed in hot flashes.  Naloxone administration had 
no effect in animals implanted with placebo pellets.  A second set of experiments 
used ovariectomized females following two weeks’ recovery, and they report, 
“The response to NAL treatment was nearly identical, therefore all subsequent 
experiments employed OVX rats.”  The data is not compared directly or shown, 
but based on this statement; it seems that ovariectomy does not confer any 
vulnerability to naloxone-precipitated withdrawal (it does not add construct 
validity).  Subsequent studies demonstrated that the response to this addiction-
withdrawal paradigm is quite similar between male and female rats (Katovich et 
al., 1986).  No differences in the response to naloxone withdrawal were evident 
between intact and castrated male rats.  The only subtle differences between 
sexes were a less pronounced hypothermia in males (only ~1 °C).  This set of 
experiments also measured foot temperature and found that it both increased 
and recovered faster that the tail.   
Despite the evidence that gonadal steroids do not appear to be of any 
particular relevance to the withdrawal response generated by naloxone, chronic 
estrogen replacement (0.5 mg pellet of 17-β estradiol) in ovariectomized rats did 
attenuate the magnitude of the response to naloxone following morphine 
addiction by ~3 °C (Katovich and O’Meara, 1987), thus apparently providing the 
model with postdictive validity.  No benefit of progesterone-only replacement was 
demonstrated, and progesterone did not augment estrogen-only treatment.  A 
subsequent dose-response experiment utilized unopposed estrogen pellets (0.1, 
0.5, 5, 15, and 50 mg) prior to morphine addiction.  Basal rectal temperature was 
only significantly changed (decreased) in the two highest treatment groups.  
While the tail skin temperature increase to naloxone was again similarly 
attenuated, there was no dose-dependency.  This may be due to the extremely 
high dose pellets used:  0.1, 0.5, 5, 15, and 50 mg.  Post-mortem assessments of 
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the plasma estrogen levels in the rats revealed supraphysiological levels, ranging 
from 163.5 ± 28.8 pg/mL (0.1 mg pellet) to 36740 ± 10721.8 pg/mL (50 mg 
pellet).  These levels are far in excess of what has been reported in the literature 
for rat levels of estradiol, which are typically somewhat elevated compared to the 
human; reports range from 36-88 pg/mL for an adult female rat in proestrus (the 
day of the estrus cycle when estradiol levels peak) (Overpeck et al., 1978). 
Unfortunately, the evidence against this model is of the most damning 
type: clinical contradictions.  If it truly replicates a menopause-associated hot 
flash, then administering naloxone to menopausal women should elicit flushing.  
DeFazio and colleagues (1984) tested this question by administering either 
saline or naloxone to 16 postmenopausal women with hot flashes in a crossover 
design and found naloxone “did not change the rate of objectively measured hot 
flashes, mean serum LH or FSH levels, or the frequencies or amplitudes of 
gonadotropin pulses” (DeFazio et al., 1984).  Charney and Heninger (1986) 
found absolutely no effect of naloxone infusion (30 mg) in both healthy male and 
female subjects on hot or cold flushes (Charney and Heninger, 1986).  
Interestingly, these studies stand in contrast to Lightman’s work wherein 6 
menopausal women had decreased hot flashes and LH pulses during 
intravenous naloxone infusion (Lightman et al., 1981).  In all cases, the effect of 
naloxone certainly does not elicit flushing, even when considering the small 
sample sizes of these studies. 
 
4.4.2.  Yohimbine model 
 The other animal model of hot flashes provokes them by administration of 
the α2 adrenergic antagonist yohimbine.  By blocking both presynaptic and 
postsynaptic norepinephrine receptors, yohimbine increases release of 
norepinephrine, and is a known anxiogenic drug in the clinic, and produces hot 
and cold flushes in patients with severe anxiety but not healthy controls (Charney 
et al., 1984; Charney and Heninger, 1986).  Morimoto and colleagues (2011) 
demonstrated a differential flushing response and subsequent decrease in core 
body temperature between ovariectomized and sham-ovariectomized rats at a 3 
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mg/kg (s.c.) dose that was rescued with estradiol replacement (Morimoto et al., 
2011).  This flush was milder in magnitude (2 °C) but greater in duration than the 
flushing observed in the morphine-naloxone model, perhaps reflecting the route 
of administration.  In an initial study, I replicated these results and found that 
ovariectomized rats have a greater response than sham-ovariectomized rats.  
While I used the same dose, I gave i.p. injections and observed a higher 
amplitude flush that occurred faster, likely resulting from faster and greater 
absorption of the drug.   
While this model may be an improvement over naloxone-mediated opioid 
withdrawal, as menopausal women experience hot flashes in response to 
yohimbine (Freedman et al., 1990) [which is attenuated with estrogen 
replacement (Freedman and Blacker, 2002)], the mechanisms are not 
understood.  Yohimbine increases norepinephrine, but increasing norepinephrine 
synaptically by using norepinephrine reuptake inhibitors provides relief from hot 
flashes (see Fig. 9).  Therefore, in the major work presented here (Ch. 2), I used 
a provocation that was better understood neurochemically.  Briefly, FG-7142 is a 
partial inverse agonist at the GABAA receptor, and existing literature has 
delineated the neurochemical sites in which it elicits cellular activity [based on c-
fos responses; see (Singewald and Sharp, 2000; Singewald et al., 2003)].  
Furthermore, our group has mapped where c-fos responses are able to be 
attenuated with pretreatment with an orexin-1 receptor antagonist (Johnson et 
al., 2012a), which proved helpful in analyses of neurochemical circuits in 
ovariectomized rats (Ch. 2, Figs. 18 and 19).   
 
4.4.3.  Emotional trigger of a hot flash?  
 As elaborated in Part III, clinically significant symptoms of anxiety are 
present as a consequence of the menopausal transition and appear to have a 
close relationship with vasomotor symptoms.  Additionally, Freeman and 
coworkers (2005) found that anxiety was the best predictor of the frequency and 
severity of hot flashes (Freeman et al., 2005).  Anxiety and hot flashes were 
directly related such that women with moderate anxiety were three times more 
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likely to report hot flashes, while women with high anxiety were five times more 
likely to report hot flashes.  Interestingly, anxiety preceded the development of 
hot flashes in this cohort.  However, as correlational studies, these findings 
naturally lead to the proposition:  Can anxiety-provoking (“anxiogenic”) stimuli 
elicit hot flashes in vulnerable species, such as ovariectomized rats?  Would 
such a model be better suited to meet criteria for validity?  Increased anxiety-like 
behavior following ovariectomy has been well-documented, in several different 
behavioral paradigms, such as the elevated plus maze and passive avoidance 
task (Mora et al., 1996; Frye and Walf, 2004; Koss et al., 2004).  Prior work in 
this laboratory replicated these results, finding increased time spent in the ‘safe’ 
zones of an open field test (OFT) after ovariectomy (see Ch. 2, Fig. 21).  
Estrogen replacement was highly anxiolytic in this paradigm, suggesting that 
estrogen plays a key role in anxiety, again replicating prior work.   
 
4.4.4.  Similarities between menopausal symptoms and panic attacks 
 Previous work in this laboratory largely focused on the neural substrates 
of anxiety and panic-associated behavior and physiology using animal models.  
Clinically, it is well-established that the majority of patients with Panic Disorder 
(PD), but not healthy controls, will experience a panic attack to a mild 
interoceptive stimulus, such as an intravenous infusion of 0.5 M sodium lactate 
(NaLac) or brief inhalations of high concentrations of carbon dioxide (CO2) (for 
review, please see (Johnson et al., 2014)).  While fear of dying or losing control 
is the prototypical cognitive symptom of a panic attack, a wide range of physical 
symptoms can constitute a panic attack (4 needed of 9 possible symptoms, 
including the cognitive symptoms listed above, though a cognitive symptom is not 
a requirement).  One of these symptoms is strong thermal sensations--hot 
flashes and chills.  Interestingly, PD has a strong gender discrepancy such that 
women are at least twice as likely to develop PD as men.  Anxiety plays a strong 
role in PD; anticipatory anxiety is one of the most consistent symptoms in clinical 
studies.  Moreover, the treatment strategies (use of SSRIs and SNRIs) are 
identical in many cases, as are the neural circuits involved (amygdala,  
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Table 2.  Key Regions of Interest with Respect to Menopausal Symptoms.  Rows 
represent an area of interest.  Columns indicate criteria for relevance of a site to hot 
flashes—expression of estrogen receptors, involvement in thermoregulation, whether an 
area innervates the tail, if the area is implicated in sleep regulation, and if the area is 
implicated in mood regulation.  Filled circles represent that the area fulfills that criteria 
whereas open circles indicate that it does not.  The best candidates for areas involved in 
menopausal symptoms are the perifornical area of the hypothalamus (PeF) and locus 
ceruleus (LC).  Abbreviations:  perfornical area of the hypothalamus (PeF), 
paraventricular nucleus of the hypothalamus (PVN), median preoptic area (mPOA), 
medial amygdala (MeA), basolateral amydala (BLA), central amygdala (CeA), bed 
nucleus of the stria terminalis (BNST), dorsal raphe nucleus (DRN), median raphe 
nucleus (MRN), raphe pallidus (RPa), LPGi, and locus ceruleus (LC).   
 
  
 79
hypothalamus, insula), and associated neurochemical systems (serotonergic and 
noradrenergic).  Key brain areas of interest and relevance to menopausal 
symptoms (that are also implicated in panic) are detailed in Table 2, and 
prominent panic-generating systems also meet many criteria for involvement in 
hot flashes and other menopausal symptoms.  Comparisons between these 
conditions were well-described in a review article (Hanisch et al., 2008).  
However, direct, non-correlational evidence for the role of anxiety-provoking 
stimuli in hot flashes is lacking. 
Our laboratory has a long history of using telemetric probes implanted in 
the abdominal cavity to measure the autonomic/physiological components of a 
panic-associated response to various anxiogenic or panicogenic stimuli.  Aside 
from measuring heart rate, blood pressure, and locomotor activity, these probes 
also measure temperature.  Some stimuli/provocations used to elicit panic 
responses in vulnerable rodents also caused a profound drop in core body  
temperature.  Tail skin temperature was never measured in these studies, yet the 
weight of the evidence strongly suggested activation of a heat dissipation 
response.  Considering the prominence of anxiety in women in the menopausal 
transition, similarities between hot flashes and panic attack symptoms, and the 
self-reported factors to hot flashes, it seemed that this might be a feasible 
method of inducing a hot flash-like response.  Therefore, preliminary studies 
were conducted to verify that these stimuli were causing hot flash-associated 
increases in tail skin temperature (Ch. 1), and to explore the possibility that these 
stimuli may provide a useful and novel means of modeling hot flashes. 
 
4.4.5.  Criteria for a validated animal model of a hot flash 
 A fully validated animal model of hot flashes would meet the following 
criteria:  1a) rapid increase in tail skin temperature following clinically-relevant 
provocation agent and 1b) subsequent decrease in core temperature (fulfilling 
face validity); 2) vulnerability (differential or exaggerated response) to 
provocation following induction of a menopausal state (meeting construct 
validity); 3) amelioration of the tail skin temperature increase with systemic 
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estrogen replacement (post-dictive validity); and 4) ability to identify new 
therapies that are ultimately successful in preventing or reducing hot flashes in 
symptomatic women (predictive validity). 
 
4.4.6.  Goals of the Dissertation 
 The overarching goals of the dissertation are to develop a valid animal 
model of hot flashes—specifically, one that shows a vulnerability to clinically-
relevant provocation agents following a treatment that causes or simulates 
menopause.  The model will then be used to elucidate the neural circuitry and 
neurochemicals that mediate the hot flash-associated response, to 1) increase 
basic knowledge of the circuitry and associated neurochemicals that mediate the 
response and 2) potentially find novel, non-hormonal targets for treatments that 
are safe for not only naturally menopausal women but also breast cancer 
patients.  Ultimately, if successful, the model will be used to screen for novel 
targets for treatment for hot flashes. 
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Materials and Methods 
 
Animals and Housing Conditions 
Adult male (300-350 g) or female (225-250 g) Sprague-Dawley rats were 
purchased from Harlan Laboratories (Indianapolis, IN USA) and housed 
individually in plastic cages under standard housing conditions (maintained at 22 
°C) for at least 5 days prior to experimental procedures.  Rats with heterozygous 
expression of the serotonin transporter (SERT+/-) were purchased from Charles 
River Laboratories (Wilmington, MA USA) and bred in-house on a Wistar 
background.  These rats possess a null mutation of the SERT generated by N-
methyl-N-nitrosurea-mutation as described previously (Homberg et al., 2007).  
Female Wistar rats (225-250 g) were purchased (Harlan) as wildtype controls 
due to insufficient numbers of littermates in relevant experiments.  Rats had ad 
libitum access to food and water and were maintained on a 12:12 light/dark cycle 
(lights on at 0700h).  All experiments were conducted in accordance with the 
Guide for the Care and Use of Laboratory Animals, Eighth Edition (Institute for 
Laboratory Animal Research, The National Academies Press, Washington, DC, 
2011) and the guidelines of the Indiana University-Purdue University, 
Indianapolis Institutional Animal Care and Use Committee. 
 
Surgical Procedures 
Ovariectomy (OVEX) and Sham OVEX Surgeries 
All surgical procedures were conducted under sterile conditions.  Rats 
were anesthetized under isoflurane delivered through a nose cone (2-3% by 
volume MGX Research Machine, Vetamac, Rossvile, IN dissolved in medical air, 
Praxair, Indianapolis, IN).  Animals were checked for corneal and paw-withdrawal 
reflexes to ensure adequate anesthesia before commencing surgical procedures.  
The skin was shaved on each side between the ribcage and hindlimbs and 
sterilized with iodine solution.  A small (1-2 cm) incision was made to expose the 
lateral muscle wall, which was then opened and the ovaries were visualized.  The 
ovaries are a prominent, spherical, reddish-pink structure that are readily seen 
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from the incision site.  In the event that the ovaries were not readily visible, a 
cotton swab was used to carefully move overlying tissue to expose them.  For 
OVEX rats, after visualization, the ovary was gently pulled up and the fallopian 
tube was clamped 3-5 mm under the ovary with a hemostat.  A length of suture 
was used to tie off the tube under the clamp, and the ovary was removed with a 
scalpel.  The tissue was inspected for bleeding and re-tied if necessary.  Silk 
sutures were used to close the muscle wall and the skin was closed with surgical 
staples.  The entire procedure was then repeated on the other side.  For sham 
operated control rats, after ovary visualization, the muscle wall and skin were 
closed as for OVEX rats and procedure repeated on the other side.  Following 
surgery, all rats were given pain medication (buprenorphine, Indiana University 
School of Medicine Laboratory Animal Resources) and monitored until 
consciousness was restored.  Animals then recovered for the next 12 days in the 
animal housing facilities, and were monitored daily.   
 
Radiotelemetry Probe Implantation 
Rats were anesthetized under isoflurane (2-3% by volume, MGX 
Research Machine, Vetamac, Rossville, IN USA dissolved in medical air; Praxair 
Inc., Indianapolis, IN) under sterile conditions.  The ventral skin was shaved and 
an incision made of approximately 2 cm.  The muscle wall was opened and a 
radiotelemetry probe with an internal thermistor (model C50PXT or HD-S11, Data 
Sciences International, St. Paul, MN USA) was fitted into the peritoneal cavity.  
The probe contains a perorated rib to affix it in place, and non-dissolving silk 
suture was used to secure the probe.  The skin was stapled, rats were given pain 
medication, and were monitored until consciousness was restored.  Animals then 
recovered for at least 5 days in the animal housing facilities and were monitored 
daily.  
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Assessments of temperature 
Methodology 
Two methods of temperature assessment were performed.  For 
measurement of core body temperature, data acquisition was accomplished 
using DSI DataQuest® software in continuous sampling mode.  For assessments 
of tail skin temperature, a thermistor (Omega Precision Fine Wire 
Thermocouples, part no. 5SRTC-TT-K-30-36; Omega Engineering, Stamford, CT 
USA) was secured 1 cm from the tail base on the ventral side using 3M 
Durapore® medical tape.  The thermistor was attached to a T-type pod and 
connected to a Powerlab data acquisition system running LabChart software 
(ADInstruments, Colorado Springs, CO USA) for continuous monitoring of 
temperature.  As an additional verification of temperature change, infrared 
thermal images were acquired using a FLIR T440 thermal imaging camera (FLIR 
Systems, Boston, MA USA) with standard settings taken at a height of 1 meter.  
Analysis of images was performed using FLIR Tools to standardize scaling 
between images.   
 
Calibration 
 Radiotelemetry probes from Data Sciences International are calibrated by 
the manufacturer prior to implantation.  Thermistors were measured against air 
temperature (recorded on a digital thermometer) prior to commencing 
experimentation and readings were always within ±0.5 ºC.  Thermistors were 
replaced with each series of experiments or more frequently if necessary.  To 
determine with greater precision any differential between thermistors and 
changing temperature, a calibration experiment was performed.  Thermistors 
were placed in a 700 mL water bath at 21 ºC and temperature was warmed to 40 
ºC over a twenty minute period.  Measurements were taken every 30 seconds 
with a glass thermometer at the same depth of the thermistors.  Averages were 
computed and there was no difference between thermistor temperature and 
temperature measured with the thermometer; p=0.45 as shown in Fig. 11.  
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Figure 11.  Accuracy of Thermal Data Acquisition.  Calibration of thermistors reveals no 
difference between measured temperature and thermometer readings.   
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Provocations  
General Protocol 
 All experiments were performed in a temperature-controlled laboratory at 
20-22 °C.  Animals were handled daily to reduce the novelty of the experimenter 
and environment.  Four plastic cages were set up and cleaned with 10% 
Coverage Plus prior to testing for each rat.  Cages were free of bedding and 
other debris.  Rats were weighed and placed into the cages and then either 
thermistors were taped to the ventral part tail (using 3M Durapore® tape) and/or 
radiotelemetry probes were activated and recording commenced.  Baselines had 
to be stable (less than 0.5 °C fluctuation) for a minimum of 10 minutes prior to 
injections (for both pre-treatments and hot flash provocations).  Pre-treatment 
drug kinetics determined the waiting period between pretreatment and hot flash 
provocation, but in all cases a stable baseline had to be re-obtained if it changed 
after handling.  After hot flash provocations, recordings continued for a minimum 
one hour (for all pharmacological provocations).   
 
Pharmacological Challenges in Male Rats 
Once a stable baseline was established for TST, rats were injected 
(intraperitoneally) with either vehicle or one the following compounds:  FG-7142, 
a benzodiazepine receptor partial inverse agonist (7.5 mg/kg dissolved in 10% 
DMSO/90% ddH2O); yohimbine, α2 adrenoceptor antagonist (5 mg/kg dissolved 
in 10% DMSO/90% ddH2O); or d-fenfluramine (10 mg/kg dissolved in 0.9% 
saline).  Separate groups of animals were used for each drug treatment.  A 
counterbalanced, crossover design was utilized such that all rats received both 
vehicle and panicogenic drug with 48h between treatments.  All reagents were 
purchased from Sigma Aldrich, St. Louis, MO USA.  A second experiment was 
performed identical to the first, except CBT was assessed in a separate cohort of 
rats.  I took this approach to first determine what changes were occurring in the 
tail (i.e., to determine if we were successfully inducing a heat dissipation 
response) and then measured internal temperature.   
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CO2 Challenge  
Flow cages (12 in. width x 12 in. height x 24 in. length) were custom-built 
using Plexiglas®.  When the lid of the cage was latched, gases could only enter 
the cage through an inlet connector (for the gas infusion) and could only exit the 
cage through an outlet connector.  The gas flow into the cages was controlled 
using a 2-stage regulator (Praxair, Inc., Danbury, CT, USA) at a pressure of 0.6 
Bar.  We previously validated the consistency of the rate of CO2 delivery using 
state-of-the-art infrared CO2 (ProCO2) and electrochemical O2 (ProO2) sensors 
(Johnson et al., 2005).  Specifically, concentrations of O2 remain at 21% 
throughout the gas infusion in the control and experimental cages [see (Johnson 
et al., 2005)].  The CO2 concentration remains constant at < 1 % in the control 
cage during exposure of rats to atmospheric air (< 1% CO2 / 21% O2/ 79% N2).  
Infusion of the premixed normoxic, hypercarbic gas (20% CO2 / 21% O2/ 59% N2) 
results in a rapid increase in CO2 concentration from < 1% CO2 up to 20% CO2 at 
the 5 min time point.  After terminating gas infusion and opening the cages, the 
concentration of CO2 rapidly decreases from 20% CO2 to < 2.5% CO2 during the 
following 5 min.  Using a portable iSTAT gas analyzer (HESKA, Des Moines IA) 
we have also determined that this hypercapnic, normoxic challenge leads to 
arterial pCO2/pH levels of ~130mmHg/7.01 during the challenge that are back to 
normal physiological range (~50mmHg/7.37) within 2 min post challenge 
(unpublished data).   
Atmospheric air was infused from the start of the experimental session.  
After obtaining a stable baseline TST in atmospheric air, rats were exposed to 
hypercapnic or atmospheric gas for 5 min in a counter-balanced manner, and 
then atmospheric air was infused again for 10-15 min following the challenge (for 
male rats in Ch. 1 and female rats in Ch. 3).  A crossover design was utilized 
such that all rats received either 20% CO2 or atmospheric air with 48h between 
treatments.  A second experiment, using a separate cohort of rats, was 
performed identical to the first, except that CBT was measured (for male rats in 
Ch. 1).  
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Atmospheric Air Control Experiment 
To determine if the experimental environment alone caused a change in 
tail skin temperature, the above experiment was performed, but only atmospheric 
air was infused for the duration of the experiment (Ch. 3).  After obtaining a 
stable baseline, the air was turned off and immediately turned back on to mimic 
the gas change during a CO2 infusion.  Rats recovered in atmospheric air for 10 
min following the challenge.   
 
Thermal Imaging of the Tail 
 In order to determine if the increase in tail skin temperature was occurring 
along the entire length of the tail, hot flash provocations (pharmacological and 
CO2) were repeated in male rats.  In this case, thermal images were acquired at 
baseline and after hot flash provocation and closely followed the timeline of the 
results in Ch. 1 (i.e., selecting when to image based on the peak response time).  
This experiment was done in a small number of animals and requires replication 
prior to publication.  
 
Subthreshold Panicogenic Drug Effect on TST of OVEX Rats ± Estrogen  
 Twelve days post surgeries, OVEX rats received daily subcutaneous (s.c.) 
injections of either sesame oil vehicle (0.2 ml, sham-OVEX received this as well) 
or 17-β estradiol (0.25 mg/kg in 10% DMSO/90% sesame oil; Sigma Aldrich, St. 
Louis MO) for 5 days prior to testing.  Once a baseline was established for TST, 
rats were injected with either vehicle or a low dose of the FG-7142 (3 mg/kg, i.p., 
dissolved in 10% DMSO/90% ultrapure H2O).  The experiment utilized a 
counterbalanced, crossover design such that all rats received either vehicle or 
panicogenic drug with 48 hours between treatments.  
 
Benzodiazepine Pretreatment Effect on TST of OVEX Rats  
 OVEX rats were pretreated with either the benzodiazepine alprazolam (3 
mg/kg, i.p., dissolved in 10% DMSO/90% ddH2O) or vehicle.  This is a dose we 
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have previously shown to be anxiolytic (Johnson et al., 2015).  Once a baseline 
was established for TST, rats were injected with FG-7142 (3 mg/kg, i.p.).    
 
Subthreshold Panicogenic Drug Effect on TST and CBT in OVEX Rats 
 Once baselines for TST and CBT were established, OVEX rats were 
injected with either vehicle or FG-7142 (3 mg/kg, i.p.).  The experiment utilized a 
counterbalanced, crossover design such that all rats received both FG-7142 and 
vehicle with 48 hours between treatments. 
 
Neurochemical System Cellular Responses in OVEX Rats treated with a 
Panicogenic Drug 
OVEX and sham-OVEX rats were injected with either vehicle or a low 
dose of FG-7142 (1 mg/kg, i.p.).  Ninety minutes post-injection, rats were 
anesthetized with isoflurane and transcardially perfused with 4% 
paraformaldehyde in 0.1 M sodium phosphate buffer (PB).  Brains were 
removed, post-fixed in the same fixative for 12 h, rinsed twice in PB (12 h), and 
placed in 0.1 M PB containing 30% sucrose for 12 h.  Brains were blocked using 
a standard adult rat brain matrix (model RBM-4000C, ASI Instruments, Warren, 
MI) and frozen using liquid isopentane cooled on dry ice.  Serial coronal sections 
(30 µm) were cut using a Leica freezing microtome and were immediately placed 
in cryoprotectant consisting of 27% ethylene glycol and 16% glycerol in 0.05 M 
PB to yield six alternative sets of sections.  Sections were stored at -20 °C until 
immunohistochemical processing.  All solutions used had pH level of 7.4.   
Immunohistochemical staining for c-Fos, in the presence or absence of 
other neurochemical markers, was used to identify specific brain regions involved 
in responses to the anxiogenic drug.  Immunostaining of nuclear c-Fos 
expression is a useful method of identifying functional cellular responses to 
anxiety-related stimuli (Johnson et al., 2012a).  Four of the six alternate sets of 
30 µm coronal brain sections were immunostained, one set each for c-Fos (full 
brain), or c-Fos (day 1) then on day 2 the tissue was immunostained with the 
cytoplasmically expressed OXA (hypothalamus); tyrosine hydroxylase (TH, 
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brainstem), or tryptophan hydroxylase (TPH, brainstem).  Immunostaining of 
OXA, TH, and TPH were done to identify orexin, noradrenergic, and serotonergic 
neurons, respectively.  Specifically, free-floating sections were washed in 0.05 M 
PBS for 30 min, then incubated in 1% H2O2 in PBS for 20 min.  Sections were 
then washed 10 min in PBS and 20 min in PBS with 0.3% Triton X-100 (PBST).  
Sections were then incubated 12-16 hr in PBST with the primary antibody 
solution at room temperature [i.e., day 1: c-Fos (rabbit anti-c-Fos polyclonal 
antibody, cat. no. sc-52, Santa Cruz Biotech., Santa Cruz, CA; diluted 1:10,000); 
day 2: OXA (rabbit anti-OXA-polyclonal, affinity-purified antibody, cat. no. H-003-
30, Phoenix Pharmaceuticals, Burlingame, CA; diluted 1:8,000); TH (rabbit anti-
TH polyclonal affinity-purified antibody cat. no. AB152, Millipore, Billerica, MA; 
diluted 1:800; or TPH (sheep anti-TPH polyclonal affinity-purified antibody, cat. 
no. 9260-2505, AbD Serotec; diluted 1:1,000 for midbrain/pons and 1:2000 for 
medulla)].  After a 30 min wash in PBST, sections were incubated 2 hr in the 
appropriate secondary antibody:  biotinylated goat anti-rabbit IgG (c-Fos, OXA, 
TH; cat no. BA-1000, Vector Laboratories, Burlingame, CA; diluted 1:200), 
biotinylated rabbit anti-sheep IgG (TPH; cat. no BA-6000; Vector Laboratories, 
1:200 dilution).  Sections were washed again for 30 min in PBST then incubated 
1.5 hr in an avidin-biotin complex provided in a standard Vector Elite kit (cat no. 
PK-6100, Vector Laboratories; diluted 1:500).  Substrates for chromagen 
reactions were SG (c-Fos; SK-4700, Vector Laboratories) or 0.01% 3,3’-
diaminobenzidine tetrahydrochloride (DAB; OXA, TH; TPH) (D-5637, Sigma, St. 
Louis MO, USA) in PBS containing 0.003% H2O2, pH 7.4.  Substrate reactions 
were run for ~10-15 min.  All sections were mounted in 0.1% gelatin dissolved in 
ultrapure water on glass slides, dried overnight, dehydrated and mounted with 
coverslips using DPX mounting medium (BDH Laboratory Supplies, Poole, U.K.).  
All washes and incubations were done in 12 well polystyrene plates with low 
frequency shaking on an orbital shaker.   
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Orexin, Glutamate, GABA gene expression in the PeF of OVEX Rats 
Ovariectomized and sham-ovariectomized rats were anaesthetized under 
isoflurane and rapidly decapitated. Brains were removed and flash frozen in 
isopentane precooled with dry ice then stored at -80 °C until processing.  The 
PeF region was bilaterally dissected from two consecutive 300 µm coronal 
sections and tissue was processed for absolute qRT-PCR for Orexin mRNA 
using methods previously described (Johnson et al., 2010), or for glutamate and 
GABA-related genes using the custom-designed TaqMan Low Density Array 
(TLDA) as previously described (Truitt et al., 2015).  Orexin gene expression 
analysis was normalized to beta-actin as previously described (Johnson et al., 
2010).  The glutamate and GABA-related gene expression panel was normalized 
using geNorm approach as previously described in detail (Truitt et al., 2015).   
 
Behavioral Testing Following Ovariectomy 
SB-334867 
Following 12 days, OVEX and sham-OVEX rats were injected i.p. with a 
control vehicle [0.2 ml/100 g volume dimethyl sulfoxide (DMSO)] or a 30 mg/kg 
dose of the single OX1R antagonist (SORA1) SB334867 (cat. no. 1960, Tocris 
Bioscience, Bristol, UK, in 0.2 ml/100 g volume DMSO) which has selectivity of 
50X for the OX1 receptor compared to the OX2 receptor; occupies 100% of 
central OX1Rs within 30 min post systemic injection (Bonaventure et al., 2015); 
and attenuates FG-7142 (7.5 mg/kg, i.p.) induced anxiety-like behavior and 
panic-associated cardioexcitatory responses without inducing somnolence 
(Johnson et al., 2012a).  Therefore, we tested rats in an accepted test of anxiety-
associated behaviors (i.e., open field test which was videorecorded and scored 
by Anymaze software, Stoelting, Woods Dale, IL) 60 min following injections.  
The experiment utilized a crossover design such that all rats received both 
vehicle and SORA1 with 48 hours between treatments.   
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Estradiol  
Following 12 days, OVEX rats received daily subcutaneous injections of 
either sesame oil vehicle (0.2 ml, sham-OVEX received this as well) or 17-β 
estradiol (0.25 mg/kg) for 5 days prior to testing in the open field. 
 
Effects of Orexin Receptor Antagonists on TST Responses to a Subthreshold 
Panicogenic Drug in OVEX Rats 
 
Following 12 days, all OVEX rats were pretreated systemically with highly 
selective and centrally active OXR antagonists (details for each experiment 
follow) prior to receiving an injection of FG-7142 (3 mg/kg, i.p.).  These 
experiments utilized a counterbalanced, crossover design such that all rats 
received both vehicle or an OXR antagonist with 48 hours between treatments.  
Five days prior to experiments, rats were handled for 5 min and trained with 
either i.p or s.c injections or mock gavages.  Tail skin temperature was assessed 
as previously described.   
 
Dual Orexin Receptor Antagonist (DORA; DORA-12)  
On the experimental day, rats received an oral gavage of a control vehicle 
(0.2 ml/100 g volume 20% vitamin E/TPGS) or 30 mg/kg of a dual OXR 
antagonist, DORA-12 (Merck & Co.) with balanced potency for OX1R and OX2R; 
good brain exposure; 47% oral bioavailability; and a favorable brain to plasma 
ratio of 0.4-0.6.  The 30 mg/kg p.o. dose of DORA-12 being used here achieves 
a plasma Cmax of 2.02 µM with CSF exposure of 66 nM and ex vivo occupancy 
of 97%, and has been shown to promote sleep in rats (Gotter et al., 2013).  
 
Single Orexin-1 Receptor Antagonist (SORA1; SB-334867)   
On the experimental day, rats received an i.p. injection of a control vehicle 
(0.2 ml/100 g volume DMSO) or a 30 mg/kg dose of SB-334867 i.p.  Following 
this experiment, concerns about SB-334867 were raised, including hydrolytic 
instability (McElhinny et al., 2012) and target specificity.  In a binding panel of 
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170 enzymes, transporters, and receptors, SB-334867 was found to have 
significant activity at monoaminergic targets, including the 5HT2B and 5HT2C 
receptors; adenosine A2A and A3 receptors; and monoamine, norepinephrine, 
and adenosine transporters (Winrow et al., 2012).  Consequently, to ensure that 
the effects I observed were due to antagonizing the orexin-1 receptor, I repeated 
this experiment with a more selective drug, the SORA1 Compound 56 described 
below.  
 
Single Orexin-1 Receptor Antagonist (SORA1; Compound 56).  
All rats were injected s.c. with a control vehicle (0.2 ml/100 g volume 
DMSO) or the highly selective SORA1, Compound 56 (10 mg/kg, dissolved in 
30% SBE-β-cyclodextrin/70% ddH2O supplied by Janssen Research & 
Development, LLC., La Jolla, CA, which has 44X selectivity for the OX1R 
compared to the OX2R, and the 10 mg/kg systemic dose occupies ~90% of 
central OX1Rs within 30 min (Bonaventure et al., 2015).  While SB-334867 has 
been shown to have off-target affinities for non-OXRs, in a binding assay panel of 
50 receptors, ion channels, and transporters, Compound 56 did not exhibit a 
significant affinity to anything other than the OX1R (Bonaventure et al., 2015).  
 
Single Orexin 2 Receptor Antagonist (SORA2; JNJ10397049) 
     All rats were injected s.c. with a control vehicle (0.2 ml of 10% pharmasolve, 
5% solutol, and 85% dextrose in water) or a dose of JnJ10397049 (10 or 30 
mg/kg, Tocris Bioscience, Bristol, UK, in 0.2 ml) which has selectivity of 630X for 
the OX2R compared to the OX1R and the 30 mg/kg systemic dose occupies 
~80% of central OX2Rs within 30 min (Dugovic et al., 2009).   
 
Single Orexin 2 Receptor Antagonist (SORA2, TCS OX2 29)  
     All rats were injected i.p. with a control vehicle (0.9% saline) or TCS OX2 29 
(30 mg/kg, Tocris Bioscience, in 0.2 ml), a SORA2 that displays >250-fold 
selectivity for OX2Rs over OX1Rs (Bonaventure et al., 2015). 
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Statistical Analyses 
Dependent variables for analyses of tail skin temperature (TST) were 
analyzed using a one-way ANOVA with repeated measures, using drug 
treatment or gas infusion as the between-subjects factor and time as a within-
subjects factor.  In the presence of significant main effects or main effect x time 
interactions, Fisher’s Least Significant Difference (LSD) test was used for post 
hoc testing between-subjects comparisons.  Analyses of behavior (SORA1), and 
TST responses in females were analyzed using an ANOVA with drug treatments 
and/or surgical treatments as main factors (i.e., independent variables) and time 
as a repeated measure.  In the presence of a significant drug effect or drug x 
time interaction, an ANOVA was run at each time point in combination with a 
Fisher’s LSD test post hoc test to detect within subject differences.  Analyses of 
OXA gene expression and behavior (estrogen) were performed with an 
independent two-tailed t-test or a nonparametric Mann-Whitney Rank Sum Test 
U if unequal variance was detected with a Shapiro-Wilk normality test p<0.05.  
Expression of each glutamate/GABA-related gene was calculated relative to the 
sham treatment group using the delta Ct method.  These values were then 
converted to log10 (log10(ΔΔCt)) for statistical analyses with an ANOVA and 
Fisher’s LSD for post hoc testing.  Analyses of cell counts were analyzed with an 
ANOVA with drug treatment and surgical treatments as main factors and a 
Tukey’s post hoc test.  Levene's Test of Equality of Error Variance was also done 
to determine equal variances in the groups to determine if nonparametric testing 
was needed.  The alpha level was set at 0.05 in all cases.  All statistical analyses 
were carried out using SPSS 21.0 (SPSS Inc., Chicago, IL, USA), and all graphs 
were generated using SigmaPlot 12.0 (SPSS Inc.) and an illustration program 
(CorelDraw X5, Ontario, Canada).   
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Chapter 1:  Select Panicogenic Drugs and Stimuli Induce Increases in Tail 
Skin Temperature and Decreases in Core Body Temperature  
 
Panic attacks (PA) are discrete episodes of intense fear or discomfort, and 
are accompanied by a variety of somatic and psychological sensations.  Isolated 
PAs (without diagnosis of Panic Disorder and/or agoraphobia) occur relatively 
frequently, estimated at 22.7% [US National Comorbidity Survey Replication, a 
nationally representative sample of 9282 participants (Kessler et al., 2006)].  
According to the Diagnostic and Statistical Manual of Mental Disorders, (DSM-
IV), a PA must produce at least any 4 of 13 symptoms:  racing or pounding 
heart/palpitations, chest pain, trembling/shaking, dizziness, sweating, dyspnea 
(feeling of suffocation), choking sensation, paresthesias (tingling), nausea, 
flushing or chills, fear of dying, fear of losing control, and derealization or 
depersonalization (Craske et al., 2010).  While cardiac symptoms (e.g., racing 
heart) are the most commonly reported event in 86.1-97% of cases (Cox et al.; 
Brown et al., 1995), all of the symptoms are relatively common and overall 
endorsed in 36.4-96.6% of panic attacks (Ietsugu et al., 2007).  As may be 
expected, some symptoms are regarded with more gravity than others; for 
example, patients presenting to emergency centers with (potentially life-
threatening) chest pain are given priority.  However, other symptoms, such as 
paresthesias or choking, are associated with more intense (self-reported) panic 
attack severity (Ietsugu et al., 2007).  While thermal sensations (hot flashes or 
chills) are not commonly thought of as a symptom of a panic attack, they are a 
reliable marker of a panic attack of moderate (as compared to mild or intense) 
severity (Ietsugu et al., 2007) and are present in about 43% of panic attacks 
[study of 1276 panic attacks from 94 patients over a 6-12 week period (de Beurs 
et al., 1994)].   
Animal models of panic-associated physiology and behavioral responses 
have been employed for decades in an attempt to understand neurochemical 
mechanisms underlying adaptive and maladaptive panic in order to identify new 
treatment strategies.  Recapitulating the physiological signs associated with 
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somatic symptoms of panic attacks in animals is possible by administering 
clinically-relevant, panic-provoking pharmacological agents (i.e. yohimbine) or 
interoceptive challenges (such as carbon dioxide exposure) [for review, see 
(Johnson et al., 2014)].  Physiological assessments of panic in animals reveal 
cardiovascular activation (increased heart rate and pressor responses) and 
behavioral flight-associated increases in locomotion in response to these same 
challenges and are similarly sensitive to panicolytic treatments like 
benzodiazepines (Bhattacharya et al., 1997; Johnson et al., 2015b).  Though 
some symptoms may be unmeasurable in rodents (i.e., nausea or tingling 
sensations), thermal changes are objectively measurable yet underexplored in 
the context of panic. 
Panic is an adaptive response to cope with an imminent threat where 
cardiovascular and respiratory responses are mobilized to initiate an optimal fight 
or flight behavioral response, but heat dissipation is also an important adaptive 
aspect of panic.  The rat tail serves in part to regulate internal temperature 
(Stricker and Hainsworth, 1971; Spiers et al., 1981), and increases in 
temperature dissipate heat to the surroundings due to its highly vascularized 
nature and lack of insulation.  Therefore, increases in tail skin temperature (TST) 
may reflect a hot flush/flash or heat sensation.  We hypothesized that threshold 
panicogenic challenges would cause strong heat dissipation responses and 
resulting decreases in internal temperature.  Therefore, in the following series of 
studies, we test the ability of a diverse array of panicogenic challenges to elicit 
CBT and TST changes:  FG-7142 (partial inverse GABAA receptor agonist), 
yohimbine (α2 adrenoceptor antagonist), d-fenfluramine (serotonin agonist), and 
20% CO2 exposure (to induce acidosis).  All of these challenges have previously 
been reported to elicit panic-associated behavioral and/or physiology at or below 
the doses we used; please see (File and Pellow, 1984; Baldwin et al., 1989; 
Johnson et al., 2012c, 2012d, 2015a).    
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Results  
 
Pharmacological Challenges 
Panicogenic Drugs Elicited Increases in Tail Skin Temperature 
An ANOVA with drug as main factor and time as a repeated measures 
(also protected by post hoc testing) revealed that systemically injecting male rats 
with panicogenic doses of FG-7142 (n=5,6), yohimbine (n=8/group) and d-
fenfluramine (n=5/group) produced a marked 7-9 °C increases in TST [Fig. 12a-
c, left panel]; Representative thermal imaging; [Fig. 14a-d] - FG-7142: treatment 
x time interaction F(69,821)=13.3, p<0.001; yohimbine: treatment x time interaction 
F(65,900)=11.3, p<0.001; d-fenfluramine: treatment x time interaction F(70,560)=12.5, 
p<0.001].  One vehicle-treated rat was removed from FG-7142 experiment due to 
a high baseline temperature. 
 
Panicogenic Drugs Elicited Decreases in Core Body Temperature.  
Systemically injecting male rats with panicogenic doses of FG-7142 
(n=12/group), yohimbine (n=7,8) and d-fenfluramine (n=5/group) led to a 
decrease in CBT [Fig. 12a-c, right panel, - FG-7142: treatment x time 
interaction F(69,1518)=10.1, p<0.001; yohimbine: treatment x time interaction 
F(65,845)=11.3, p<0.001; d-fenfluramine: treatment x time interaction F(70,560)=41.3, 
p<0.001].  One yohimbine-treated rat was removed from the experiment due to a 
faulty radiotelemetry probe. 
 
Interoceptive Challenge   
Panicogenic Hypercapnic Gas Elicited Increases in Tail Skin Temperature and 
Decreases in Core Body Temperature 
An ANOVA with gas as main factor and time as a repeated measures 
(also protected by post hoc testing) revealed that exposing male rats to 20% CO2 
(normal O2) compared to atmospheric air (n=8/group) produced a marked 7-9 °C 
increases in TST and ~1 °C decrease in core body temperature [Fig. 13a-b– 
20% CO2: treatment x time interaction F(19,247)=13.7, p<0.001; Fig. 13c treatment 
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x time interaction F(19,247)=22.2, p<0.001.  Representative thermal imaging; Fig. 
14e].   
 
Discussion  
 
In a series of studies using a neurochemically diverse array of panicogenic 
challenges (affecting serotonergic, GABAergic, and noradrenergic systems, 
among others), we demonstrate rapid, high amplitude (7-9˚C) increases in tail 
skin temperature followed by substantial (1-3 ˚C) decreases in core body 
temperature.  These results provide face validity and support our hypothesis that 
thermal changes occur during panic-associated challenges in rodents to help 
dissipate heat during periods of intense arousal and activity and increased 
metabolism.  To the best of our knowledge, these are novel findings, though 
previous reports had demonstrated temperature perturbations with d-
fenfluramine at high doses or under non-thermoneutral conditions [see review by 
(Clark and Clark, 1980) and (Subramanian and Vollmer, 2004)].  Importantly, all 
of the provocations used herein--20% CO2, d-fenfluramine, FG-7142, and 
yohimbine are known to induce severe anxiety or panic symptoms in healthy 
persons or precipitate panic attacks in persons with Panic Disorder [as reviewed 
by (Bourin et al., 1998) and see also (Dorow et al., 1983; Charney et al., 1984; 
Woods et al., 1988; Targum and Marshall, 1989; Kaye et al., 2004)], providing 
postdictive validity in this modeling approach.  Furthermore, prior studies have 
demonstrated that these provocations also elicit strong self-reported thermal 
sensations in humans, providing additional face validity to the results that we 
observed (Dorow et al., 1983; Charney et al., 1984; Freedman et al., 1990; Kaye 
et al., 2004).  Future studies will determine the efficacy of established panicolytic 
treatments on thermal changes (both core and tail) relative to other panic 
symptoms, such as cardiovascular profile or behavioral outputs.   
Thermal imaging affords a noninvasive tool to quickly assess tail skin 
temperature and could augment existing experimental protocols relatively easily.  
Thermal imaging has recently been used as the exclusive measure of tail skin 
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temperature, and this method has the inherent advantage of capturing multiple 
sites along the tail at once (Luong and Carrive, 2012).  This method could be 
useful in determining a greater range of panicogenic or panicolytic properties of 
novel compounds.  
The diversity of neurochemical mechanisms that produced similar thermal 
changes implicates common underlying neural sites/circuits.  Indeed, all of the 
panicogenic pharmacological or CO2 challenges we administered have been 
shown to increase cellular activity (e.g., c-fos immunoreactivity) in critical panic-
generating brain areas such as the perifornical/dorsomedial hypothalamic nuclei 
(PeF/DMN) and dorsal periaqueductal gray (DPAG) (Singewald and Sharp, 
2000; Singewald et al., 2003; Johnson et al., 2011, 2012a).  Specifically, 
stimulation of the posterior hypothalamus and adjacent areas (including the 
DMN/PeF) in humans evokes cognitive and somatic symptoms strongly 
associated with panic attacks (e.g., fear of dying, anxiety, panic, tachycardia, 
thermal sensations, nausea, and paresthesias) (Rasche et al., 2006; Wilent et 
al., 2010, 2011).  Studies using electrical stimulation of homologous areas in rats 
and rabbits reported similar defensive responses (Hess, WR Brugger, 
1943)(Markgraf et al., 1991; McCabe et al., 1994; Duan et al., 1996) though it 
should be noted that electrical stimulation can elicit its effects through a variety of 
pathways and targets due to its nonspecific stimulation of fibers of passage.  
Chemical stimulation (achieved through disinhibition with the GABAA antagonist 
bicuculline methiodide) of the posterior hypothalamus in rats also elicits escape 
behavior and cardiovascular responses (DiMicco et al., 1986; Shekhar and 
DiMicco, 1987).  Electrical stimulation of the DPAG also leads to marked 
defensive and fear responses, including tachycardia and pressor responses, in 
both human and animal studies, but temperature was not assessed (Nashold et 
al., 1969; Young, 1989; Schenberg and Lovick, 1994; Bittencourt et al., 2004).  
Stimulation of the dorsal and ventral PAG in rats with the glutamate receptor 
agonist n-methyl-D-aspartate also increased heart rate and mean arterial 
pressure, but also increased core body temperature (de Menezes et al., 2009).  
Interestingly, prior activation of GABAA receptors with muscimol in the DMH 
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prevented all of these responses (de Menezes et al., 2009).  Importantly, the 
DMN/PeF areas are also heavily implicated in thermoregulatory effector 
pathways, see review by (Morrison and Nakamura, 2011).   
 
Conclusions 
These studies support the idea that thermal sensations—hot flashes and 
chills--can be elicited by a variety of panic provocations in animals, and studying 
this sign can complement the existing panic literature. 
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Figure 12.  Panicogenic Drugs Elicit Profound Hot Flash-Associated Cutaneous 
Vasomotor Responses in Male Rats.  Effects of panicogenic compounds on tail skin and 
core body temperature of male rats.  a) indicates representative thermal images of rats 
respectively treated systemically (intraperitoneal) with vehicle; a benzodiazepine partial 
inverse agonist (beta carboline FG-7142, 7.5 mg/kg, n=12/group); an alpha 2 receptor 
antagonist (yohimbine, 5 mg/kg, n=8/group); or a serotonin reuptake inhibitor and 
vesicular storage disruptor (d-fenfluramine, 10 mg/kg, n=5/group).  Line graph with error 
bars (SEM) in b-d) indicate mean tail and core body temperature activity in Celsius in 
freely moving male rats over a 10 min baseline and 60 min following treatment with b) 
FG-7142, c) yohimbine, or d) d-fenfluramine.  Tail and core body temperature was 
respectively assessed with a tail thermistor taped to ventral surface of tail base and 
intraperitoneal implanted radiotelemetry probes, both of which were interfaced with data 
acquisition systems.  * denotes indicates significance with a one-way ANOVA with drug 
as independent variable and time as a repeated measures p<0.05, and significant 
differences between groups using a Tukey's HSD post hoc test p<0.05, protected by an 
ANOVA at each time point.    
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Figure 13.  Hypercapnic Gas Exposure Elicits Profound Hot Flash-Associated 
Cutaneous Vasomotor Response in Male Rats.  Effects of 20% CO2 exposure (normal 
O2) on tail skin and core body temperature of male rats. a) Line graph with error bars 
(SEM) indicates mean tail skin temperature (˚C) in freely-moving male rats over a 5 min 
baseline, 5 min atmospheric or hypercarbic gas exposure and 10 min recovery in 
atmospheric air.  b) Line graph with error bars (SEM) indicates core body temperature 
(˚C) in freely moving male rats (n=8/group) over a 5 min baseline, 5 min atmospheric or 
hypercapnic gas exposure and 10 min recovery in atmospheric air.  Tail skin and core 
body temperature were respectively assessed with a tail thermistor taped to ventral 
surface near the base of the tail and intraperitoneal implanted radiotelemetry probes, 
both of which were interfaced with data acquisition systems.  *indicates significance with 
a one-way ANOVA with gas as independent variable and time as a repeated measures 
p<0.05, and significant differences between groups using a Tukey's HSD post hoc test 
p<0.05, protected by an ANOVA at each time point.   
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Figure 14.  Hot Flash Provocations Result in Increased Temperature Along the Entire 
Length of the Tail.  Thermal images were acquired at the peak height of the response 
(see Figs. 12-13).  Images represent an animal from a) vehicle injection, b) FG-7142 
(7.5. mg/kg, i.p.), c) yohimbine (5 mg/kg, i.p.), d) d-fenfluramine (10 mg/kg, i.p.), and e) 
20% CO2 exposure.  
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Chapter 2:  Hypothalamic Orexin’s Role in Exacerbated Cutaneous 
Vasodilation Responses to an Anxiogenic Stimulus in a Surgical 
Menopause Model 
 
 Menopause occurs following loss of ovarian function during natural aging, 
and a simulated menopausal state follows some breast and ovarian cancer 
treatments [e.g., surgical oophorectomy, or estrogen inhibition therapies 
(Carpenter and Andrykowski, 1999; Gallicchio et al., 2006b)].  Common 
symptoms during menopausal states include vasomotor symptoms (hot flashes 
and night sweats), anxiety and mood disruption, and sleep disturbances 
(Kronenberg, 1990).  Hot flashes are the cardinal symptom, and 75% of 
postmenopausal women surveyed reported repeated hot flash episodes over an 
average of 4-7 years, but some over 10-13 years (Politi et al., 2008; Avis et al., 
2015) following onset of menopause.  Hot flash symptom presentations correlate 
well with objectively measurable, sympathetically-induced increases in cutaneous 
blood flow that raises skin temperature (Low et al., 2008).   
 Hormone replacement therapy [HRT, containing estradiol (E2) in 
combination with estrone (E1) and progesterone (P)] remains the most effective 
therapy for reducing hot flash symptomatology by ~75% treating in peri and post 
menopausal women [see systematic review (Maclennan et al., 2004)].  Yet, E2 
replacement therapy (ERT) alone is as effective as HRT at moderate doses (1-2 
mg) (Baerug et al., 1998; Greendale et al., 1998) which restore plasma estrogen 
levels to 85-100% of pre-menopausal levels, respectively (Waaseth et al., 2008).   
Although ERT effectively alleviates hot flashes [even at lower doses of 0.5 mg 
(Joffe et al., 2014)], not all women are interested in taking ERT since initial use of 
E2 is associated with side effects such as uterine bleeding and breast tenderness 
(Maclennan et al., 2004), and long-term ERT also increases the risk for estrogen 
positive breast cancer (Beral, 2003; Bolland et al., 2015).  Additionally, ERT is 
contraindicated for postmenopausal women with estrogen receptor positive 
breast cancer, and hot flashes are the primary reason for noncompliance with 
estrogen inhibition therapies (Kemp et al., 2014), which increases mortality 
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(Hershman et al., 2011).  Collectively these side effects and identified risks may 
explain a significant decline in HRT prescription and compliance (Zbuk and 
Anand, 2012) and an increase interest in non-hormonal therapies.  Unfortunately, 
the few existing non-hormonal therapies are much less effective than ERT 
(Nelson et al., 2006).  For instance, ERT reduces hot flash symptomatology by 
by ~75% [see systematic review (Maclennan et al., 2004)], whereas clonidine or 
serotonin/norepinephrine reuptake inhibitors (SSRI/NRI) are ~46% and 30% 
effective, respectively and are only marginally better than placebo responses that 
typically range from 20-50% (Nelson et al., 2006).  These therapies are also 
commonly associated with side effects such as headaches, nausea, decreased 
sexual function, and insomnia, which can reduce adherence.  The lack of 
effective, non-hormonal treatments is largely due to the limited understanding of 
the mechanisms that underlie menopausal symptoms.  Menopausal symptoms 
are clearly induced by estrogen withdrawal; yet, how loss of estrogens leads to 
menopausal symptoms is largely unknown (Miller and Li, 2004a).   
One mechanistic pathway that has not been explored is the orexin (OX 
and its two forms, OXA and OXB) neuropeptide system, which is unique in that 
OX-synthesizing neurons are restricted to the perifornical hypothalamic (PeF) 
region of rodents (Peyron et al., 1998) and humans (Thannickal et al., 2007).  
Estrogen receptors are expressed in the PeF (Laflamme et al., 1998), and 
stimulating the PeF in humans also produces symptoms associated with 
menopause [e.g., feelings of anxiety, racing heart, and hot flashes or chills 
(Wilent et al., 2011)].  Additionally, in female rats, E2 administration decreases 
OXA content within the hypothalamus as well as at postsynaptic target CNS sites 
(Russell et al., 2001).  More importantly, menopausal women have 300% higher 
plasma OX levels compared to reproductive controls, which is restored following 
Prempac, comprised primarily of equine estrones, and norgestrel, a form of 
progestin (El-Sedeek et al., 2010)].  This dramatic increase in OX activity during 
menopause is likely contributing to disrupted sleep since OX’s most prominent 
role is to promote wakefulness (Sakurai, 2007), and higher OXA concentrations 
in cerebrospinal fluid have been demonstrated in individuals with poor sleep 
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quality (Allen et al., 2002).  But there is also emerging evidence that a 
hyperactive OX system contributes to anxiety states and panic-associated 
sympathetic activity in rodents (Johnson et al., 2010, 2012a, 2015b), and that 
central OX levels are elevated in patients with increased anxiety symptoms 
(Johnson et al., 2010).  These findings, combined with the building evidence that 
anxiety and stress are strongly associated with more severe and persistent hot 
flashes in large cohort studies (Avis et al., 2015), and that stressful stimuli can 
increase objective hot flashes (Swartzman et al., 1990) led to our current 
hypothesis that the OX system plays a critical role in menopause-related 
symptoms such as hot flashes, anxiety, and sleep disruption.  We further posited 
that anxiety states and panicogenic-related stimuli may contribute to hot flash 
severity and frequency, and could help explain the presence of hot flashes in 
thermoneutral environments.   
To test these hypotheses, we:  1) determined whether a panicogenic 
compound would elicit exacerbated tail skin temperature (TST: a correlate of a 
hot flash) responses in a surgical ovariectomy (OVEX) model of a menopausal 
state; 2) assessed cellular responses in OX neurons and efferent 
neurochemically identified targets that regulate arousal, anxiety, and 
thermoregulation; and 3) assessed orexin gene expression in the PeF, and 
determined if systemically treating OVEX rats with highly selective and brain-
penetrant antagonists that target the two cognate OX receptors at optimal 
pharmacokinetic timelines would attenuate panicogenic drug induced TST 
responses. 
 
Results 
 
Experiment 1:  OVEX Rats Have Exacerbated TST Responses to a Low Dose of 
a Panicogenic Drug that is Blocked by Estrogen Replacement.  
Compared to sham-OVEX controls, systemically injecting female OVEX 
rats with a low dose of the panicogenic drug FG-7142 (n=7,5,5) produced a 
marked 6-7 °C increase in TST, which was blocked with estrogen replacement 
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(Fig. 15a-Representative thermal imaging; Fig. 15b - treatment x time interaction 
F(55,770)=3.4, p<0.001). 
 
Experiment 2:  Alprazolam Pretreatment Prevents Increases in TST in OVEX 
Rats 
 Compared to vehicle-treated OVEX controls, alprazolam treatment (3 
mg/kg, i.p.) attenuated an increase in TST induced by FG-7142 (3 mg/kg, i.p.) 
(F(10,70)=14.62, p<0.0001; n=3,6), Fig. 16.  
 
Experiment 3:  FG-7142 induced Increases in TST precedes a decrease in Core 
Body Temperature (CBT) Decrease in OVEX Rats  
Compared to vehicle treated OVEX controls, FG-7142 treated OVEX rats 
had a dramatic increase in TST within 3 min (F(55,825)=18.7, p<0.0001, n=8,9, see 
thermal imaging of tail in Fig. 17a, and TST response on bottom line graphs in 
Fig. 17b) which was followed by a decrease in CBT that occurred 11 min post 
injection (F(55,825)=11.2, p<0.001, n=8,9, see CBT response on top line graphs in 
Fig. 17b).  
 
Experiment 4:  Neural Circuits of OVEX Rats that Display Hyperactive 
Responses Following a Low Dose of a Panicogenic Drug 
Among the brain regions implicated in menopause-related symptoms (see 
Fig. 18a for convergent evidence for brain region involvement and Fig. 18b for 
coronal illustration of brain regions assessed), the following brain regions of 
OVEX rats showed exacerbated cellular c-Fos responses to the low dose of a 
panicogenic drug FG-7142 (i.e., OVEX x FG-7142 interaction, Fig. 18c):  1) PeF 
[n=7,7,7,7, F(1,24)=4.5, p=0.044]; 2) central amygdala [CeA, n=7,7,6,7 (area 
damaged unilaterally on one rat), F(1,23)=16.1, 0.001]; 3) dorsolateral region of 
dorsal raphe nucleus [DRVL, n=6,6,7,7, (area damaged unilaterally on two rats), 
F(1,22)=6.6, p=0.018]; 4) locus ceruleus [LC, n=7,7,7,7, F(1,24)=6.1, p=0.021]; 5) 
raphe pallidus [RPa, n=7,7,7,7, F(1,24)=7.4, p=0.012]; 6) rostroventrolateral 
medulla [RVLM, n=7,7,7,7, F(1,24)=4.4, p=0.048].  Cellular responses were not 
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significantly different in the periventricular hypothalamic nucleus (PVN), medial 
preoptic hypothalamic area (mPOA), basolateral, lateral, or medial amygdala 
(BLA, LA, MeA), bed nucleus of the stria terminalis (BNST), dorsomedial or 
dorsolateral periaqueductal gray (dmPAG, dlPAG), ventral or dorsal part of the 
dorsal raphe nucleus (DRV or DRD), median raphe nucleus (MRn), or raphe 
magnus (RMg).  
 
Experiment 5:  Neurochemical Circuits of OVEX Rats that Display Hyperactive 
Responses Following a Low Dose of a Panicogenic Drug 
Neurochemical phenotyping of c-Fos responses in OXA-ir neurons in the 
PeF and adjacent lateral hypothalamus (LH) revealed that OX neurons in the 
PeF, but not LH had exacerbated responses to FG-7142 in OVEX rats 
(n=6,6,7,7) [PeF: OVEX x drug interaction, F(1,22)=4.1, p=0.055; OVEX effect, 
F(1,22)=4.1, p=0.055; FG-7142 effect F(1,22)=4.5, p=0.046; LH data not shown: 
OVEX x drug interaction, F(1,22)=1.1, p=0.306; OVEX effect, F(1,22)=2.0, p=0.169; 
FG-7142 effect F(1,22)=0.5, p=0.482] (Fig. 19a).  This difference in the number of 
c-Fos-ir OXA positive neurons was unlikely due to differences in numbers of 
OXA-ir neurons counted since there was no difference in the PeF [see gray bars 
in Fig. 19a: PeF: OVEX x drug interaction, F(1,22)=0.9, p=0.770; OVEX effect, 
F(1,22)=0.3, p=0.601; FG-7142 effect F(1,22)=0.9, p=0.770; LH: OVEX x drug 
interaction, F(1,22)=1.3, p=0.258; OVEX effect, F(1,22)=3.2, p=0.086; FG-7142 
effect F(1,22)<0.01, p=0.997].   
Neurochemical phenotyping of c-Fos responses of tyrosine hydroxylase-ir 
(TH)- noradrenergic neurons in the LC revealed that these neurons had 
exacerbated responses to FG-7142 in OVEX rats [Fig. 19b, OVEX x drug 
interaction, F(1,22)=3.8, p=0.064; OVEX effect, F(1,22)=7.2, p=0.014; FG-7142 
effect F(1,22)=10.1, p=0.004].  Neurochemical phenotyping of c-Fos responses 
TPH-ir serotonergic neurons in the DRVL and RPa revealed that these neurons 
had exacerbated responses to FG-7142 in OVEX rats [Fig. 19c, n=6,6,7,7,OVEX 
x drug interaction, F(1,23)=9.4, p=0.006 (area damaged unilaterally on two rats); 
Fig. 19d, n=7,6,7,6, OVEX x drug interaction, F(1,22)=14.7, p=0.001 (area 
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damaged on two rats)].  No difference was noted in the total number of TH or 
TPH-ir neurons counted between groups (see gray bars in Fig. 19c-d).  
 
Experiment 6:  Orexin, Glutamate, GABA Gene Expression in the PeF of OVEX 
Rats 
Gene expression analyses in the PeF region (see Fig. 20a for convergent 
evidence of PeF region involvement) revealed that compared to sham-OVEX 
controls, OVEX rats had 200% higher expression of prepro-orexin (n=7,6, see 
Fig. 20a for illustration of area micropunched; Fig. 20b, t(14)=-2.1, p=0.029).  A 
Taqman Low Density Array (TLDA) custom designed for GABA and glutamate-
related genes revealed that compared to sham-OVEX rats, OVEX rats had had a 
1.81 fold increased gene expression of GAD1 (aka GAD67, p=0.040) and 
decreased expression of Grm4 (-1.83 fold; p=0.003) and Grin2a (-1.63 fold; 
p=0.024) (see volcano plot in Fig. 20c). 
 
Experiments 6-7:  Systemic Pretreatment with a SORA1 or estrogen is Anxiolytic 
in OVEX rats 
Compared to sham-OVEX controls, OVEX rats spent less time exploring 
the center region of an open field test (indicating an anxiety-like behavioral 
response, Fig. 21a).  Furthermore, pretreating OVEX rats with a SORA1 blocked 
the OVEX-induced anxiety-associated behavior [SORA1 effect, F(1,35)=7.1, 
p=0.012, n=10,10,9,10, an outlier detected and removed from OVEX/vehicle 
group, Grubb’s test z=2.3, p<0.05].  In a second experiment, compared to OVEX 
rats treated with vehicle, OVEX rats with estrogen replacement spent more time 
exploring the center of the open field [Fig. 21b, n=9,7, failed Shapiro-Wilk 
normality test p<0.05, Mann-Whitney Rank Sum Test U=5.0, p=0.006].   
 
Experiments 8-12:  Systemic Pretreatment with an OX1R, OX2R, or Dual OX 
Antagonist Attenuates TST Responses to a Panicogenic Drug in OVEX Rats 
Here the highest dose of DORA-12 blocked the TST response to the 
panicogenic drug FG-7142 (Fig. 22a; drug x time interaction, F(108,1458)=1.4, 
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p=0.006, n=9,10,10].  In the SORA1 experiments, both SB-334867 and 
Compound 56 attenuated the TST response to the panicogenic drug FG-7142 
(Fig. 22b; no drug x time interaction F(55,715)=1.1, p=0.247, but there was a 
significant drug effect, F(1,13)=7.6, p=0.016, n=5,10; Fig. 22c, drug x time 
interaction F(54,648)=2.2, p<0.001, F(1,13)=7.6, p=0.016, n=7,7].  Initially, we 
administered a SORA2 (TCS OX2 29, 5 and 10 mg/kg, i.p.) which, compared to 
vehicle group, did not alter FG-7142 induced TST responses in OVEX rats (data 
not shown, drug x time interaction F(130,2535)=0.5, p=1.00, drug effect F(2,39)=0.5, 
p=0.600, n=14,14,14).  We later learned that this compound only achieves about 
~50% OX2R occupancy and quickly dissociates and is not brain penetrant (P. 
Bonaventure, personal communication).  In a subsequent experiment using a 
brain penetrant SORA2 called JnJ10397049, which achieves greater (~75%) and 
sustained (8 h) receptor occupancy an attenuation of the TST response to the 
panicogenic drug FG-7142 (3 mg/kg, i.p.) was observed at both doses [Fig. 22d; 
drug x time interaction F(100,1950)=37.4, p<0.001, n=14,14,14]. 
 
Discussion 
 
 Here we first ovariectomized female rats to model a surgical menopausal 
state, which increased baseline anxiety-associated behaviors, and when 
challenged with a low dose of the panicogenic compound FG-7142, OVEX rats 
had an exacerbated hot flash-associated TST responses >7 °C that preceded a 
decrease in CBT (suggesting a heat dissipation response), thus providing face 
validity.  Furthermore, ER, which also attenuated anxiety-associated behaviors, 
almost blocked the TST responses.  Thus, predictive validity is provided since 
ER effectively treats hot flashes and FG-7142 is known to cause hot flashes 
and/or chills in humans, and also elicits anxiety (Dorow et al., 1983).  Alprazolam 
pretreatment (a benzodiazepine) attenuated an increase in TST following FG-
7142, demonstrating that the TST response is specific to drug action at the 
benzodiazepine site.  These data also suggest that there is a loss of GABAergic 
inhibitory signaling following loss of ovarian function.  Consistent with this 
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hypothesis is that in one clinical study the benzodiazepine oxazepam was 
effective in reducing hot flashes in a cohort of premenopausal women who 
underwent oophorectomy (Erkkola et al., 1973).  Collectively, these clinical 
studies and our preclinical studies may explain part of the effectiveness of these 
treatments for hot flashes.  Finally, since this method of inducing hot flash-
associated TST responses also produces strong anxiety at higher doses, it 
suggests that some stress-related stimuli and or existing anxiety states could 
contribute to hot flash severity and prevalence.   
 The link between anxiety and stress with hot flashes has been controversial.  
For instance, although a recent systematic review concluded that anxiety 
symptoms were low during the menopause transition, they noted that the majority 
of studies utilized brief and largely non-validated measures of anxiety symptoms 
(Bryant et al., 2011).  Bryant and colleagues further stated that studies that 
utilized accepted diagnostic assessments did observe an increase in anxiety in 
postmenopausal women [see (Cagnacci et al., 1997; Pimenta et al., 2012)] that 
is alleviated with ERT+P (Cagnacci et al., 1997).  Furthermore, greater presence 
of anxiety predicts more frequent and/or severe hot flashes (Freeman et al., 
2005), and is also positively correlated with hot flash severity (Gibson et al., 
2011).  Additionally, women with premenstrual syndrome, which includes high 
levels of anxiety, are more likely to have hot flashes (Freeman et al., 2004) and 
hot flashes are common symptom associated with panic attacks that occur in 
severe anxiety disorders (DSM-V).  Perhaps more compelling is that in a recent 
large (n=3302) multiracial/multiethnic longitudinal investigation [the Study of 
Women's Health Across the Nation], greater perceived stress, anxiety symptoms, 
depressive symptoms, and decreased socioeconomic status were associated 
with more persistent and frequent vasomotor symptoms (Avis et al., 2015).  
Thus, these data are supportive of the hypothesis that anxiety and stress, which 
are associated with more severe and persistent hot flashes, may also contribute 
to hot flash severity and prevalence.  This hypothesis is also consistent with a 
hypothetical review that observed similarities between hot flashes and severe 
anxiety/panic attacks that included:  symptom presentation; neurochemical 
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circuitry; pharmacotherapy; and psychological treatments (Hanisch et al., 2009) 
and also suggests that neurochemical systems implicated in generating anxiety-
associated emotional, behavioral, and physiological responses may represent 
novel targets for treating symptoms associated with menopause.  
 Our subsequent experiments sought to determine if the hypothalamic OX 
system might represent one such novel therapeutic target.  In a series of 
experiments, we demonstrated that rats with a surgical menopausal state have a 
two-fold increase in prepro-OX mRNA expression within the PeF region, and 
exacerbated OX neuronal responses to a subthreshold panicogenic drug that 
excites this system (FG-7142) (Johnson et al., 2012a).  We further demonstrated 
that efferent targets of OX neurons heavily implicated in hot flash etiology 
(Freedman et al., 1990; Stearns et al., 2005) also showed exacerbated cellular 
responses.  These included limbic structures such as the amygdala, as well as 
noradrenergic neurons in the locus ceruleus, and serotonergic neurons in the 
dorsal raphe nucleus and raphe pallidus.  Artificially increasing central OX activity 
in rodents with intracerebroventricular injections of OXs disrupts sleep (Espana 
et al., 2002); increases anxiety-associated behaviors (Suzuki et al., 2005); 
induces thermoregulatory changes (Yoshimichi et al., 2001); elicits cardio-
excitation (Samson et al., 1999), and stimulates corticosteroid release (Brunton 
and Russell, 2003), which is related to greater hot flash symptomatology in 
menopausal women (Woods et al., 2006a)].  These data are consistent with 
preclinical data showing that estrogen inhibits OX expression in rodents (Russell 
et al., 2001), and clinical data showing OX activity is dramatically elevated 
following menopause (El-Sedeek et al., 2010).  Thus, a hyperactive OX system 
seen here in our surgically-induced menopausal state in rodents and mirrored in 
postmenopausal women (El-Sedeek et al., 2010) could be contributing to multiple 
core symptoms that occur during and/or following menopause.  An outstanding 
question for future studies, would be determining if the interactions observed 
between orexin and estrogen are indirect or direct (e.g., determining if the 
prepro-orexin gene has an estrogen response element, or whether expression of 
ERα and/or ERβ are colocalized with orexin neurons).   
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 In a final series of experiments, we systemically treated OVEX rats with 
highly selective and brain-penetrant OXR antagonists at optimal pharmacokinetic 
timepoints to determine if antagonizing this system would decrease hot-flash 
associated increases in TST.  There are two forms of OXs, OXA and OXB, and 
two known receptors.  The OX1R has greater affinity for OXA than OXB by an 
order of magnitude, while the OX2R has similar affinity for both OXA and OXB 
(Sakurai, 2007).  Both receptors are G-protein coupled, and are either co-located 
or selectively located in specific brain areas (Marcus et al., 2001), suggesting 
differentiated roles.  Here we show that a dual OXR antagonist, DORA-12, 
blocked the TST response elicited by FG-7142, whereas antagonizing either 
receptor alone partly attenuated hot flash-associated TST responses.  This 
suggests that these drugs may provide a novel non-hormonal treatment strategy 
for hot flashes in menopausal women.  Interestingly, suvorexant, a DORA, was 
recently FDA-approved with an indication for insomnia.  Sleep problems, broadly 
defined, are a known problem at midlife and at the menopause (Burleson et al., 
2010), and many have posited that hot flashes during sleep contribute to 
nighttime awakenings/sleep problems.  Therefore, it seems reasonable to 
postulate that targeting either symptom may lead to improvement in the other.  
The sleep-promoting properties of DORAs are primarily through antagonism of 
OX2Rs which are exclusive to histaminergic neurons in the tuberomammillary 
nucleus, which is a brain region that plays a critical role in wake promotion 
(Huang et al., 2001; Marcus et al., 2001), but also plays a role in regulating 
thermogenic activity (Yasuda et al., 2004) which could partially explain the ability 
of the OX2R antagonist to attenuate TST responses.  The anxiolytic effects of 
DORAs may be preferentially through antagonism of OX1Rs (Johnson et al., 
2010, 2012a, 2015b; Bonaventure et al., 2015), but also potentially OX2Rs (Li et 
al., 2010).  Anatomically, OX1Rs appear to be more selectively expressed in 
panic and anxiety-associated neural circuits such as the bed nucleus of the stria 
terminalis, amygdala, cingulate cortex and exclusively in noradrenergic neurons 
in the locus ceruleus [(Marcus et al., 2001), see review (Johnson et al., 2012b)], 
which also play a role in sympathetic mobilization.  Yet, anxiolytic effects of 
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ORX2R antagonism have been demonstrated in the paraventricular thalamus (Li 
et al., 2010).  Thus, DORAs may alleviate sympathetically-mediated hot flashes 
and or hot flashes resulting from pre-existing anxiety states or in responses to 
some stress-related stimuli.   
 
Conclusions 
 Collectively, our previous and current data support the hypothesis that 
estrogen tonically inhibits the orexin arousal system, and dramatic loss of 
estrogen tone during menopausal states leads to a hyperactive orexin system 
that contributes to the cardinal menopausal symptoms such as recurrent hot 
flashes, insomnia, and anxiety.  Additionally, our data suggests that OXR 
antagonists, possibly in combination with lower doses of ERT, may represent a 
novel non-hormonal therapy for treating all of these symptoms, with minimal side 
effects.  
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Figure 15.  Rats Modeling Surgical Menopause are Vulnerable to Displaying Hot Flash 
Associated Cutaneous Vasomotor Responses to a Low Dose of a Panicogenic Drug.  
Effects of a low dose of FG-7142 (3 mg/kg) on tail skin temp of female sham-OVEX rats 
given daily 0.2 ml s.c. injections of sesame oil control vehicle (n=7), or in OVEX rats 
given daily s.c. injections of control vehicle (n=5) or 0.25 mg/kg 17-β estradiol (n=5).  a) 
Thermal images of rats 20 min after FG-7142 injection from each treatment group with 
scale bar to right.  b) Line graph with error bars (SEM) represents the mean tail skin 
temp prior to and following a 3 mg/kg i.p. injection of FG-7142 in each treatment group 
assessed with a thermistor at base of tail.  * denotes significance with a one-way 
ANOVA with drug as an independent variable and time as a repeated measures p<0.05, 
and significant differences between groups using a Fisher’s LSD post hoc test protected 
by an ANOVA at each time point, p<0.05. 
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Figure 16.  Alprazolam Pretreatment Attenuates Cutaneous Vasomotor Response to a 
Low Dose of a Panicogenic Drug.  Effects of a low dose of FG-7142 on tail skin 
temperature of OVEX rats pretreated with either vehicle (n=3) or alprazolam (n=6; 3 
mg/kg, i.p.).  Line graph with error bars (SEM) represents the mean tail skin temperature 
of OVEX rats prior to and following systemic injections of FG-7142 (3 mg/kg, i.p.).  
*denotes significance with a one-way ANOVA with drug as independent variable, 
p<0.05.  Though not shown, there were no baseline differences prior to alprazolam 
treatment. 
  
 116
 
Figure 17.  Panicogenic Drug-induced Cutaneous Vasomotor Responses Precede a 
Decrease in Core Body Temperature in Rats with Surgical Menopause.  Effects of a low 
dose of FG-7142 (3 mg/kg) on tail skin temp and core body temperature of female OVEX 
rats.  a) Representative thermal images of OVEX rats 10 min after vehicle or FG-7142 
injection from each treatment group with scale bar to right.  b)  Line graph with error bars 
(SEM) represents the mean tail skin temp and core body temperature of OVEX rats prior 
to and following systemic injections of either vehicle (n=8) or 3 mg/kg FG-7142 (n=9).  * 
denotes significance with a one-way ANOVA with drug as an independent variable and 
time as a repeated measures p<0.05, and significant differences between groups using 
a Fisher’s LSD posthoc test protected by an ANOVA at each time point, p<0.05.  
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Figure 18.  Rats with Surgical Menopause Display Hyperactive Cellular Responses 
Following a Low Dose of a Panicogenic Drug in Neural Circuits Heavily Implicated in 
Menopausal Symptoms.  a) Table with convergent evidence of neurochemical circuit 
involvement in hot flash-associated cutaneous vasomotor responses.  Columns 
respectively represent brain regions and additive criteria to strengthen the likelihood that 
a particular brain region will be impacted by loss of estrogen, but also involved in 
menopause-related symptoms.  Closed circles means the region meets the criterion, 
open circles mean the region does not meet the criterion.  Yellow shaded rows meeting 
most criterion, with orange and purple shaded rows meeting less. See results section for 
anatomical abbreviation definitions.  Effects of vehicle or a dose of FG-7142 (that evokes 
hot flashes in OVEX, but not sham rats) on cellular responses (c-Fos immunoreactive, ir) 
in brain regions from OVEX and Sham-OVEX rats from Table 1 (n=6,6,7,7).  b) 
illustrates coronal brain sections of a rat at different rostrocaudal levels, with yellow 
circles indicating brain regions where OVEX rats showed hyperactive responses to FG-
7142 compared to sham-OVEX rats.  Purple circles indicate areas that were counted but 
had no significant differences between groups.  Bars in c) represent mean number of 
single c-Fos-ir cells +/-SEM.  * denotes significant differences between groups using a 
Tukey's HSD post hoc test protected by 2-way ANOVA, p<0.05.  
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Figure 19.  Neurochemical Circuits of Rats with Surgical Menopause that Display 
Hyperactive Responses Following a Low Dose of a Panicogenic Drug.  Effects of vehicle 
or FG-7142 injection (that evokes hot flashes in OVEX, but not sham rats) on cellular 
responses (c-Fos immunoreactive, ir) in brain regions from OVEX and Sham-OVEX rats 
from Table 1 (n=6,6,7,7).  Bars in a) represent c-Fos+OX labeled neurons in the 
PeF/DMN and LH.  Bars in b) represent c-Fos+tyrosine hydroxylase (TH) in 
noradrenergic neurons in the locus ceruleus (LC).  Bars in c-d) represent c-
Fos+tryptophan hydroxylase (TPH) in serotonergic neurons in the ventrolateral region of 
the dorsal raphe nucleus (DRVL/VLPAG), and in the raphe pallidus (RPa), respectively.  
* denotes significant differences between groups using Tukey's HSD post hoc test 
p<0.05, protected by a 2-way ANOVA.  Photographs in a-d) represent high magnification 
brain sections illustrating dark nuclear immunostaining of c-Fos +/- brown cytoplasmic 
immunostaining of OX-ir neurons in the PeF, TH-ir neurons in the LC, and TPH-ir 
neurons in the DRVL/VLPAG and RPa from Sham and OVEX rats treated with FG-7142, 
respectively.  Scalebar in d = 20 µm.   
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Figure 20.  Surgical Menopause Enhances Baseline Hypothalamic Orexin/Glutamate 
Gene Expression. a) illustration of a coronal section of rat hypothalamus with the 
PeF/DMN and LH with representative distribution of OX neurons (black dots) and areas 
where micropunches were done (orange dashed circles) in a 300 µm fresh frozen tissue 
section for gene expression data in b-c) and where cell counts were done (purple 
dashed lines) in Fig. 18-19).  b) indicates expression of prepro-OX mRNA in sham and 
OVEX rats.  * indicates p<0.05 unpaired t-test.  c) A volcano plot of hypothalamic mRNA 
levels of OVEX rats relative to Sham rats, determined by a custom designed Taqman 
Low Density Array (TLDA).  Plotted on the Y-axis are p values from Fisher’s LSD test 
(each gene) and ±fold difference (Log10) on the x-axis.  Genes with p < 0.05 are 
indicated by solid circles and all others are open circles.  Horizontal red line is p=0.05 
and vertical dotted lines represent a ±2 fold change in expression (0.0301 on log10 
scale).  
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Figure 21.  Systemic Pretreatment with a SORA1 or Estrogen is Anxiolytic in OVEX 
Rats.  a) Bar graphs illustrate the time spent in the center region of an open field test 30 
min after injection of vehicle or the SORA1 SB334867 (30 mg/kg, i.p.) in sham-OVEX 
controls or OVEX rats.  b) Bar graph illustrates the duration OVEX rats spent in the 
center region of an open field test following daily subcutaneous injections of estrogen 
replacement [0.25 mg/kg of 17-β estradiol or 0.2 ml vehicle].  * p<0.05.  All testing was 
done 12-13 days after sham-OVEX or OVEX surgeries.  Bars represent mean and error 
bars represent SEM.   
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Figure 22.  Systemically Treating Ovariectomized Rats with Centrally Active Orexin 1 
and/or 2 Receptor Antagonists Attenuates Hot Flash-Associated Cutaneous Vasomotor 
Responses to a Low Dose of a Panicogenic Compound.  a) Effects of FG-7142 (3 
mg/kg) on tail skin temp of female OVEX rats orally pre-treated with vehicle or a dual 
OXR antagonist (DORA-12. 10 and 30 mg/kg p.o.); b-c) Effects of FG-7142 (3 mg/kg) on 
tail skin temp of female OVEX, or sham-OVEX rats systemically pre-treated with vehicle 
or an OX1R antagonist (b: SB-334867 30 mg/kg i.p.; c: Compound 56, 3 mg/kg s.c.);.  d) 
Effects of FG-7142 (3 mg/kg) on tail skin temp of female OVEX, or sham-OVEX rats 
systemically pre-treated with vehicle or an OX2R antagonist (JnJ-10397049, 10 and 30 
mg/kg s.c.).  * denotes significant differences between groups using a two-tailed 
Dunnett’s post hoc test against vehicle protected by a one-way ANOVA with drug as 
main factor and time as repeated measures, and a Fisher’s LSD post hoc test protected 
by a one-way ANOVA at each time point, p<0.05.  All OX receptor antagonist doses, 
routes, and treatment timelines were done based on published pharmacokinetic 
information (e.g., brain penetrance, OX1R and OX2R occupancy in the brain, and Cmax 
in plasma and brain). 
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Chapter 3:  Anxiogenic CO2 Stimulus Elicits Exacerbated Hot Flash-like 
Responses in a Rat Menopause Model  
 
Hot flashes are intense heat sensations that occur primarily in the chest 
and face and affect the vast majority of women at midlife or following estrogen 
inhibition therapies or oophorectomy (Kronenberg, 1990; Gallicchio et al., 
2006b).  In the laboratory setting, the subjective hot flash sensation (as indicated 
with button press or self-report) correlates well with objectively measured, 
sympathetically-mediated increases in cutaneous vasodilation which pools 37 °C 
blood to the skin.  This in turn interacts with peripheral thermal sensors in skin to 
signal heat.  Sweating sometimes also occurs during a hot flash, but this induces 
an evaporative cooling sensation.  Under normal circumstances, both cutaneous 
vasodilation and sweating are effective means of dissipating heat to maintain 
core body temperature (Tc) in hot environments.  While environmental 
temperature is often thought to affect hot flash parameters (i.e., frequency, 
severity, duration), many studies have found weak or inconsequential 
relationships to ambient temperature (Voda, 1981; Stefanopoulou et al., 2014a, 
2014b) and in a self-reported survey of hot flash precipitants, temperature was 
identified less frequently than other stimuli (Stubbs et al., 2008).  While exact 
figures are unavailable, these data suggest that many women may experience 
hot flashes in thermoneutral environments with no clear identifiable trigger.  In 
these circumstances, the collective heat dissipation mechanisms that occur 
during a hot flash could lead to decreases in Tc which does occur and could 
explain chills that also occur in menopausal women [(Low et al., 2008)and see 
review (Freedman, 2005)].   
While there are many variables that influence hot flashes, recent findings 
from large longitudinal studies have identified the presence of anxiety, early life 
stress, and lower socioeconomic status as key risk factors for more severe and 
problematic hot flashes (Thurston et al., 2008a; Avis et al., 2015).  Notably, 
anxiety has been identified as the best predictor of hot flashes, even when 
controlling for typical confounds, and women with greater anxiety levels 
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experience more severe hot flashes (Freeman et al., 2005; Avis et al., 2015).  
Additionally, many women report that stressful stimuli in everyday life precipitate 
hot flashes (Stubbs et al., 2008), and stressful stimuli in a laboratory setting have 
been shown to increase objectively measured hot flashes (Swartzman et al., 
1990).  Taken together, there is evidence that stressful events may provoke hot 
flashes, and that pre-existing anxiety states or traits may contribute to increased 
symptoms.  However, the mechanisms by which anxiety and stress-related 
factors contribute to hot flashes remain poorly understood.  
One contributing factor to the poor understanding of the mechanisms 
mediating hot flashes is a scarcity of appropriate, validated animal modeling 
(Miller and Li, 2004b).  Previous models such as the morphine withdrawal model 
(Simpkins et al., 1983) elicit robust cutaneous vasomotor responses in the tail, 
but lack an obvious relevance to causes and triggers of hot flashes (Lightman et 
al., 1981; DeFazio et al., 1984).  Consequently, the use of models for 
mechanistic investigation into the central and peripheral neural circuitry and 
associated pathways mediating hot flashes has suffered.  Recently, we found 
profound decreases in Tc in rats following an acute 20% carbon dioxide (CO2) 
exposure, which signals air hunger and produces anxiety-associated behavior 
and sympathetic associated cardioexcitation (Johnson et al., 2011, 2012c, 2015).  
In human studies, 20% CO2 inhalation induces anxiety symptoms, and in one 
study the subjects reported having strong heat sensations (Kaye et al., 2004).  
However, it was unknown if this would have relevance to menopause-associated 
symptoms.   
Therefore, we designed a series of studies to determine if CO2 exposure 
represented a novel and valid method of provoking hot flashes.  Thus, in a rodent 
model, we hypothesized that 20% CO2-induced decreases in Tc were due to 
cutaneous vasomotor responses in the tail which would increase the tail skin 
temperature (TST) to dissipate heat in a thermoneutral environment.  We further 
posited that the TST response would be exacerbated in ovariectomized (OVEX) 
rats, modeling surgical oophorectomy-induced menopause, which is linked to 
more severe hot flashes (Gallicchio et al., 2006b; Benshushan et al., 2009).  
 124
Secondly, recent work has begun to elucidate some of the genetic contributions 
to increased or problematic hot flashes.  The short (‘s’) version of the serotonin 
transporter (SERT) gene, whose protein product mediates the termination of 
serotonin signaling, leads to reduced transcriptional efficiency and less protein, 
and is linked to anxiety-associated traits in humans (Heils et al., 1996; Lesch et 
al., 1996; Gonda et al., 2007, 2009) as well as increased climacteric symptoms in 
menopausal women (Grochans et al., 2013).  Therefore, we then hypothesized 
that OVEX rats with a heterozygous null mutation of the SERT gene (SERT+/-) 
which leads to similar reduced transcriptional efficiency, would have exacerbated 
and/or prolonged hot flashes (increased TST) in response to CO2 compared to 
wildtype (WT) OVEX controls. 
 
Results 
 
Experiments 1-2:  Ovariectomized rats exhibit exacerbated hot flash-associated 
increases in tail skin temperature in response to hypercapnic gas infusion while 
atmospheric air infusion does not change tail skin temperature 
An ANOVA with ovex surgery and hypercapnic gas/CO2 as main factors 
and time as a repeated measure revealed that hypercapnic gas infusion 
produced an exacerbated increase in tail skin temperature in ovex rats while 
atmospheric air caused no changes in temperature [Fig 23a-Representative 
thermal image; Fig. 23b- CO2 tail skin temperature (n=15/group) overall CO2 
effect F(1,38)=45.9, p<0.0001, overall ovex effect F(1,38)=5.3, p=0.027, and overall 
CO2 by time interaction F(114,532)=20.1, p<0.0001 but no ovex by time interaction 
F(14,532)=0.23, p=0.999 or ovex by CO2 by time interaction F(14,532)=0.34, p=0.989].  
Fisher’s Least Significant Difference Test was used for post hoc testing to 
determine specific time point differences between groups, and Dunnett’s test was 
used to determine significance of specific time points against t-1.  
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Experiment 3:  Ovariectomized SERT+/- rats exhibit prolonged hot flash-
associated increases in tail skin temperature in response to hypercapnic gas 
infusion 
An ANOVA with genotype as the main factor and time as a repeated 
measure revealed that hypercapnic gas infusion produced a prolonged increase 
in tail skin temperature in ovex rats [Fig 24a-Representative thermal image; Fig. 
24b- CO2 tail skin temperature (n=7,8) overall time effect F(13,392)=47.8, p<0.0001 
and overall genotype x time interaction F(15,180)=2.1, p=0.013].  Fisher’s Least 
Significant Difference Test was used for post hoc testing to determine specific 
time point differences, and Dunnett’s test was used to determine significance of 
specific time points against t-1.   
 
Discussion  
  
These studies have demonstrated that an anxiogenic stimulus can 
precipitate a hot flash-associated increase in TST responses in OVEX rats that is 
not an artifact of experimental environment.  Our studies provide potential 
insights into triggers of hot flashes in thermoneutral environments and evidence 
that anxiety or anxiety-generating stimuli may have a causal relationship to hot 
flashes, not merely an associative one.  Earlier clinical provocations used the 
drug yohimbine to facilitate hot flashes (Freedman et al., 1990), which, at high 
doses, elicits strong anxiety (Charney et al., 1984; Charney and Heninger, 1986), 
and also produces robust TST responses in OVEX rats (Morimoto et al., 2011), 
and thus yohimbine may represent a pharmacological model preclinically and 
clinically.  Other studies have previously documented that stress-related stimuli, 
including mental arithmetic or emotionally salient films, can increase the rate of 
objective and subjective hot flashes (Swartzman et al., 1990) and self-reports 
implicate stressful stimuli (e.g. interpersonal family conflict or social stress) 
precipitate hot flashes in breast cancer patients (Stubbs et al., 2008).  These 
data complement the emerging literature relating to the role of anxiety and 
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stress-related factors in hot flashes and may help to start addressing a critical 
gap in knowledge of hot flash triggers. 
In our preclinical rodent experiments, the results exhibit validity in three 
domains:  1) face validity, as the increase in TST is a rapid heat loss mechanism 
(cutaneous vasodilation) analogous to and what would be expected during a hot 
flash; 2) construct validity, as the TST change is exaggerated in ovariectomized 
rats, which is a model of surgical/oophorectomy-induced menopause in women 
(a condition with more severe hot flashes (Gallicchio et al., 2006b; Benshushan 
et al., 2009)); and 3) predictive validity, as the same stimulus causes an 
exacerbated response in ovariectomized SERT+/- rats, which mimic a common 
human polymorphism that was recently linked to increased hot flash pathology 
(Grochans et al., 2013).  A small study of 20% CO2 exposure in symptomatic 
menopausal women by collaborators in the IU School of Nursing (Dr. Janet 
Carpenter and colleagues) demonstrated that this stimulus also causes self-
reported and objectively-verified (sternal skin conductance) hot flashes (see 
Table 2 and Fig. 25 in Commentary for greater discussion), adding additional 
validity to our modeling approach. 
This modeling approach is unique in that the provocation does not use 
pharmacological manipulations; rather, it triggers an endogenous challenge to 
homeostasis by provoking air hunger through CO2 exposure (which causes 
acidosis).  Currently, the role of blood pH in hot flashes is largely unknown, as 
only one small study demonstrated a statistically significant, yet very slight, pH 
reduction following spontaneous hot flashes (Aktan et al., 1998).  Paced 
respiration (which could moderate blood pH) such as controlled breathing of 6-10 
breaths per minute, is often recommended as a non-pharmacological treatment 
for reducing hot flashes, yet clinical trials have not demonstrated significantly 
greater efficacy than usual treatment or active comparators (Carpenter et al., 
2013; Sood et al., 2013; Huang et al., 2015).   
Here our challenges utilized systemic administration through 
environmental exposure, necessitating inhalation leading to systemic exposure.  
Dissection of the central and peripheral components of the CO2-induced hot 
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flashes and TST responses in rats is beyond the scope of this investigation, but 
the paradigms we used most likely triggered central mechanisms, as previous 
applications were used to elicit and study anxiety in humans and in rodents that 
are accompanied by sympathetic associated cardiovascular responses.  
Evidence for a central role comes from ex vivo assessments of cellular 
responses in rodents where 20% CO2 exposure increases activity in anxiety and 
thermoregulatory associated brain circuitry such as the hypothalamus (Johnson 
et al., 2005, 2011), and noradrenergic and serotonergic neurons in the midbrain 
pons and medulla (Johnson et al., 2005).  However, CO2 has also been shown to 
have local cutaneous vasodilatory action in both humans and rodents (Diji, 1959; 
Ito et al., 1989) (40, 41).  Thus, there are likely central and peripheral 
contributions to hot flashes (Shuto et al., 2011).  
Our third study also contributes to an emerging literature concerning the 5-
HTTLPR on climacteric symptoms and anxiety trait vulnerability.  Short form ‘s’ 
carriers (s/s or s/l genotype) of the 5-HTTLPR experience higher rates of 
psychiatric disorders later in life, including anxiety and depression (Lesch et al., 
1996; Hauser et al., 2003; Gonda et al., 2009), which are two conditions that 
have been linked to increased hot flashes (Avis et al., 2015; Gallicchio et al., 
2015).  Analyses from the multiethnic Study of Women’s Heath Across the Nation 
Mental Health Study found that early life stress (childhood abuse or neglect) also 
predicted later vasomotor symptoms  (Thurston et al., 2008a).  Menopausal 
women with the short form (‘s’ carrier) of the 5-HTTLPR also experience 
increased climacteric symptoms (Grochans et al., 2013), which could be related 
to increased anxiety traits associated with this polymorphism.  This animal model 
could contribute mechanistic insight into the interactions between early life 
events, genetic contributions, and later anxiety and physiological phenotypes, 
including hot flash-associated responses, which may ultimately lead to a better 
understanding of the role of serotonin and its complement of proteins to 
menopausal symptoms.   
Indeed, this is an important research area in women’s health at midlife, as 
drugs that target the serotonin transporter are among the most frequently used 
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pharmacotherapies for vasomotor symptom relief and currently represent the 
only FDA-approved non-hormonal treatment for hot flashes (Simon et al., 2013; 
Orleans et al., 2014). Despite this indication, SSRIs do not fully alleviate hot 
flashes and treatment switching is common due to tolerability issues (Handley 
and Williams, 2015).  Some of this variability in response and side effects may be 
due to differences in SERT genotype, as persons with the s/s genotype have 
been shown to have a poor response to SSRIs (for treating anxiety disorders) 
(Stein et al., 2006).  Specifically, s/s carriers are at greater risk for treatment-
emergent side effects from these medications (Perlis et al., 2003).  Investigations 
into 5-HTTLPR genotype by hot flash treatment efficacy could prove useful in 
advancing personalized medicine by informing treatment strategies, though to 
our knowledge, no such studies have been performed.  This is likely to be a 
substantial challenge, as there is evidence that the effect of the polymorphism 
can be complex and modulated by ethnic background; for example the ‘l’ allele, 
as opposed to the ‘s’ allele, confers increased risk for anxiety in a Chinese 
population (Long et al., 2013).   
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Figure 23.  Rats Modeling Surgical Menopause Have Exacerbated Hot Flash- 
Associated Tail Skin Temperature Responses.  Effects of ovariectomy or sham surgery 
on baseline tail skin temperature in response to hypercapnic or atmospheric air infusion.  
a) Representative thermal images with scale (to the right) of a sham-OVEX (top) or 
OVEX rat (bottom) after 5 min exposure to atmospheric air (left) or 20% CO2 (right).   b) 
Line graph with error bars (SEM) represents mean tail skin temperature prior to and 
following atmospheric air or hypercapnic gas challenge in OVEX or sham-OVEX groups 
assessed with a tail thermistor at the base of the tail (n=15/group for CO2 challenge and 
n=6/group for atmospheric air challenge).  *denotes significance of surgical treatment at 
specific time points in (b) with Fisher’s Least Significant Difference test protected by an 
ANOVA, and + denotes significant differences over time from t-1 as measured by 
Dunnett’s test.   
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Figure 24.  Rats with a Heterozygous Null Mutation of the Serotonin Transporter 
(SERT+/-) have Prolonged Hot Flash-Associated Tail Skin Temperature Responses to 
Hypercapnic Gas Infusion.  Effects of ovariectomy in SERT+/- and WT rats tail skin 
temperature in response to hypercapnic gas infusion.  a) Representative thermal image 
with scale (to the right) of a WT-ovex (top) or SERT+/- rat (bottom) after 5 min exposure 
to 20% CO2.  b) Line graph with error bars (SEM) represents mean tail skin temperature 
prior to and following hypercapnic gas challenge in ovex SERT+/- or WT rats assessed 
with a tail thermistor at the base of the tail (n=8,7).  *denotes significant effect of 
estrogen treatment with a two-way ANOVA p=0.001 in (a).  *denotes significance of 
genotype at specific time points in (c) with Fisher’s Least Significant Difference test 
protected by an ANOVA, and + denotes significant differences over time from t-1 as 
measured by Dunnett’s test.   
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Commentary 
 
Overall statement of significance 
 Hot flashes are a beguiling phenomenon, and research to date has yet to 
determine how estrogen loss leads to hot flashes and how estrogen replacement 
relieves them (Kronenberg, 2010).  Undoubtedly, the mechanisms that mediate 
these effects are likely to be complex, and elucidating such complexity through 
clinical investigation exclusively is likely to be unsuccessful, if not impossible, and 
certainly untimely.  Therefore, an alternative tool is needed, and that is where 
animal modeling can contribute to understanding not only hot flashes, but other 
menopausal symptoms.  My studies demonstrate key roles for anxiety-
associated pharmacological stimuli/triggers and anxiety states in animal models 
that meet key criteria for validity.  The elucidation of potentially critical brain 
structures and novel neurochemical systems provides many avenues for future 
investigation to better understand how dramatic loss of sex steroid hormones 
leads to hot flash vulnerability, and these findings could lead to the development 
of novel non-hormonal treatment strategies for women that desperately need 
them.  Furthermore, while striking similarities between panic, anxiety, and hot 
flashes have been identified in the literature, direct evidence was lacking.  The 
studies in this work provide evidence that anxiety or panic-provoking stimuli 
(depending on the dose) can elicit rapid and profound hot flashes in a model of 
simulated/surgical menopause.  These findings further strengthen the link 
between anxiety and hot flashes that has been reported in many well-controlled 
longitudinal studies, and it is my hope that future clinical studies will stringently 
examine this link in order to elucidate the details mediating this relationship. 
  
Brief recapitulation of studies  
Based in part on early observations of hypothermia occurring during panic 
provocations, and later verification of surface/tail temperature changes, I 
explored the relevance of anxiety-associated factors in hot flash induction in 
ovariectomized rats.  The studies in the major part of this work have focused on 
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understanding the neural circuits and associated neurochemicals through a novel 
hot flash provocation, a low dose of an anxiogenic drug, the beta carboline FG-
7142 (a GABAA receptor partial inverse agonist at the benzodiazepine allosteric 
site).  My studies demonstrated this provocation leads to a rapid and profound 
increase in tail skin temperature and concomitant drops in core body temperature 
in ovariectomized rats, but not sham controls or estrogen-replaced rats, providing 
evidence of face, construct, and post-dictive validity.  Importantly, FG-7142 
provokes anxiety and hot flashes in humans [for review, see (Evans and Lowry, 
2007) and (Dorow et al., 1983)], though menopausal women’s sensitivity to it is 
unknown.  Furthermore, this approach implicated GABA in hot flashes.  As 
discussed in the introduction, GABA has not been a major target of basic 
research in hot flashes, and clinical investigation is extremely limited.  A handful 
of small studies have examined the efficacy of the GABA analogue gabapentin 
(largely in cancer patients), which may increase GABA content in the brain, for 
the amelioration of hot flashes and found efficacy.  However, only one study 
examined the effectiveness of a benzodiazepine on hot flashes in a cohort of 
women with oophorectomy and used an early benzodiazepine (oxazepam); there 
have been no subsequent studies of any benzodiazepine in a larger sample of 
naturally menopausal women or cancer patients.   
 To elucidate the neurochemistry and circuitry involved in mediating the hot 
flash-associated response, I performed a series of immunohistochemical studies.  
The results of the initial study (single labeled c-fos) revealed hyperactivity in 
drug-treated ovariectomized rats in key sites, including the 
dorsomedial/perifornical hypothalamus, locus ceruleus, raphe pallidus, 
rostroventrolateral medulla, and dorsoventral-ventrolateral periaqueductal gray, 
key thermoregulatory structures in animals (Morrison and Nakamura, 2011).  
Brainstem structures have been shown to activate before the perception of a hot 
flash, but resolving the precise nuclei is currently beyond the limits of detection, 
as the voxel size (spatial resolution) currently exceeds some small nuclei 
(Diwadkar et al., 2014).  Therefore, it is possible that the raphe pallidus and 
rostroventrolateral medulla are activated, but this is another unknown.  Drug 
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effects in both ovariectomized and sham-ovariectomized rats revealed 
heightened activity in the central nuclei of the amygdala, which has also been 
implicated in animal models of thermoregulation, and may be particularly relevant 
in the context of emotion-related flushing (Yu and Blessing, 2001).  Secondary 
neurochemical phenotyping studies confirmed the noradrenergic identity of A6 
locus ceruleus neurons and serotonergic neurons in the RPa and RVLM, further 
adding to the construct validity of the model.  The c-fos hyperactivity in the 
dorsomedial/perifornical area of the hypothalamus, a thermoregulatory and 
panic-generating site, co-expressed orexin-A, and thus revealed the orexin 
peptide system as a potential novel target in hot flash-associated tail skin 
temperature responses.   
Subsequent experiments targeted the orexin system by blocking receptors 
with systemically administered antagonists to determine if this could decrease 
both flushing and anxiety behaviors.  Pre-treatment with a dual orexin receptor 
antagonist (DORA-12), completely blocked the response to FG-7142.  Blockade 
of either the orexin-1 receptor (OX1R) or orexin-2 receptor (OX2R) with selective, 
well-characterized, brain-penetrant antagonists prior to hot flash provocation 
partially attenuated the increased tail skin temperature.  An initial assessment of 
anxiety-related behaviors in ovariectomized rats found that pretreatment with the 
selective orexin-1 receptor antagonist (SORA1) SB-334867 attenuated 
ovariectomy-induced anxiety.  Further experiments using an improved SORA1 
(Compound 56, donated by Janssen Research and Development) or DORA-12 
that were successful in attenuating hot flash-associated responses also proved 
anxiolytic, yet in these cohorts there were no differences in baseline anxiety 
behaviors between ovariectomized and intact rats.  Difficulties in assessing sex-
specific behaviors are discussed below. 
A final series of studies utilized a different type of anxiety induction, 
hypercarbic gas, which elicits hypercapnia (decreased blood pH/acidosis), in 
conjunction with animals predisposed to greater levels of anxiety behaviors.  This 
approach models an interoceptive stimulus, or one that does not reach conscious 
appreciation under baseline conditions.  A 5 min challenge of 20% CO2-enriched, 
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normal oxygen content air elicited a profound increase in tail skin temperature 
that was greater in ovariectomized rats compared to intact controls.  Importantly, 
atmospheric air did not change tail skin temperature, so the effects observed 
were not due to the novelty of the experimental environment.  To validate this 
modeling approach and determine if the sensations evoked were consistent with 
a naturally-occurring hot flash, our collaborators (Dr. Janet Carpenter, Sarah 
Dorsey, and Connie Krier) tested two similar CO2 inhalation paradigms in a small 
sample of highly symptomatic menopausal women.  Overall, 5/6 women 
experienced a mild hot flash in response to breathing 20% CO2 (40 sec) or taking 
two vital capacity inhalations of 35% CO2, as shown in Fig. 25.  Participants 
reported that these sensations were consistent with a hot flash, and all 
subjectively reported hot flashes were verified with an objective hot flash monitor 
(sternal skin conductance).  Interestingly, the subjective intensity of the hot flash 
response and anxiety rating following CO2 inhalation positively correlated with 
diary-reported daily hot flash frequency.  Lastly, and as another validation of CO2 
hot flash induction, I tested for increased hot flashes in ovariectomized (serotonin 
transporter) SERT+/- and SERT+/+ rats, and found a prolonged response to 20% 
CO2.  This deletion mimics a human polymorphism of the SERT that is linked to 
increased anxiety and increased climacteric symptoms in menopausal women 
(Grochans et al., 2013).  This series of studies represents some of the first 
evidence that direct manipulation of anxiety leads to hot flashes, and may be a 
useful method of provoking hot flashes in the clinical setting.  
 
Critique of modeling approach 
 
Methodological considerations 
Ovariectomy 
 Animal models, like all models, have limitations, and this one is no 
exception.  The induction of menopause by ovariectomy is highly clinically  
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Table 3 and Figure 25.  Schematic of Clinical Study of Hot Flash Provocation with CO2 
Challenges in Highly Symptomatic Women and Participant Characteristics.  a) Depicts 
the timeline for the study procedures.  b) Table illustrates subjects assigned number, 
age, total number of hot flashes during the day and night for a seven day period prior to 
the study, average number of hot flashes per day, baseline STAI and NRS anxiety, NRS 
anxiety post control air, NRS hot flash and anxiety (respectively) severity post 20% and 
35% CO2 inhalation, followed by the NRS Anxiety and STAI anxiety at rest.  Participants 
are ranked in order of increasing daily hot flashes.  Three of the four participants with 
confirmed inhalations of 20% CO2 reported hot flashes within 5 min of the challenge, and 
two of the three participants with confirmed inhalations of 35% CO2 reported a hot flash 
within 5 min of the challenge; hot flashes were rated from mild to moderate.  Numbers 
below NRS hot flashes or anxiety (columns 9 and 10, respectively) post CO2 respectively 
represent 20% CO2 and 35% CO2 with the parenthetical number representing the mean 
of the confirmed inhalations (“-” indicates no confirmed inhalation for respective 
challenge).  Correlation analyses revealed that the frequency of daily hot flashes (total 
per 24h day) was positively correlated with the c) mean severity of the hot flash post 
confirmed CO2 inhalations and d) mean severity of the anxiety response post confirmed 
CO2 inhalations.  Correlation analysis also demonstrated that the e) mean hot flash 
severity following verified CO2 inhalation was positive correlated with the mean anxiety 
rating following verified CO2 inhalation. 
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relevant, as women that undergo this procedure for a variety of medical reasons, 
including cancer prevention and/or treatment, have rapid and severe hot flashes.  
From this perspective, it has high utility.  In the United States, an estimated 
2,000,000 women reach menopause every year; about 300,000 of these women 
have ovarian removal (half for ovarian cancer prevention, half for “benign 
disease”), so approximately 15% of menopausal women are acutely menopausal 
(Parker et al., 2005; Rocca et al., 2006).  Furthermore, for translational reasons, I 
elected to use freely cycling, sham-ovariectomized rats as controls in the majority 
of my experiments.  This choice was more relevant clinically, as 
oophorectomized women are not frequently given estrogen replacement.  
However, freely cycling controls were a source of greater and often unequal 
variability because I did not assess stage of estrous to perform testing at 
particular stages.  Future studies could control for stage of the estrous cycle, 
determine differential responses relating to phase of estrus.  Recent work in this 
laboratory has shown this is especially relevant for behavioral studies, which 
sometimes include an estrogen replacement group.   
 
Timing and Treatment Rationale 
All of my testing was done within a set time frame following recovery from 
ovariectomy, starting 12 days after surgery.  Estrogen loss is accomplished 
within 48 hours following ovariectomy, but this longer time frame was chosen 
based on previous work in these laboratories that demonstrated an induction of 
anxiety at this time frame.  The initial focus of this project was anxiety, not hot 
flashes, and decisions were made in this context at first.  Then, initial attempts at 
modeling hot flashes with CO2 were successful at this time point, and so were 
continued in subsequent experiments for consistency.  Yet, based on the clinical 
literature, hot flashes eventually subside for most women.  It would be of great 
interest and further validate the model if vulnerability to these provocations were 
assessed over time and found to subside as time from ovariectomy increased.   
Similarly, the doses of estrogen used in the initial study that established 
vulnerability to FG-7142 were supraphysiological (0.25 mg/kg/day), and were, 
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chosen in the context of efficacy for relief of ovariectomy-induced anxiety 
behaviors from previous work in the laboratory.  Therefore, I used this dose in the 
model, and it blocked the increase in tail skin temperature in this provocation.  
While it is high, it parallels studies of estrogen replacement in symptomatic 
women.  The current guidelines for hormonal therapy recommend the lowest 
possible dose for the shortest period of time (North American Menopause 
Society position statement), and clinical studies have examined the effectiveness 
of different doses of estrogen therapies.  While lower doses (e.g., 0.30 and 0.45 
mg/day) of estrogen replacement reduce hot flashes greater than placebo, the 
standard dose (0.625 mg/day) is still more effective at reducing hot flashes 
(compared to both doses), and is the only treatment that provided complete relief 
(Utian et al., 2001). 
 
Provocation Techniques 
 
Pharmacological Provocations 
 My methods of provocation are mostly pharmacological (yohimbine, FG-
7142, d-fenfluramine) with the exception of CO2.  While these provocations may 
seem artificial, all have demonstrated to induce anxiety responses and flushing 
ability in humans, and symptomatic menopausal women exhibit vulnerability to 
yohimbine (Dorow et al., 1983; Charney et al., 1984; Freedman et al., 1990).  
Furthermore, the pilot study of CO2 challenges described in Ch. 3 in symptomatic 
menopausal women in Dr. Carpenter’s laboratory provide evidence that an 
interoceptive stimulus may be a real trigger of hot flashes; the women reported 
that CO2 inhalations “felt just like a hot flash”.   
Interestingly, I also challenge the SERT+/- rats with FG-7142 (3 mg/kg, i.p.) 
and d-fenfluramine (5 mg/kg, i.p.) and found no genotype differences to either 
challenge.  It may be that the SERT+/- rats are sensitive to some, but not all, 
anxiogenic stimuli, and the defect in their serotonergic system could underlie that 
difference.  Serotonin neurons are known to be chemosensitive and responsive 
to CO2 (Hodges and Richerson, 2010), and so this difference may represent a 
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proclivity toward stimulus-dependence.  Furthermore, and unlike the first series 
of studies using Sprague-Dawley rats, these rats were pair-housed with  
littermates (due to the breeding procedures), and so perhaps the lack of 
differences is due to reduction of isolation stress, to which these rats may be 
particularly vulnerable.    
 
Measurement Technique 
During the provocations, the animals were non-restrictively tethered with a 
thermistor for many of the physiological experiments, which permitted a quick, 
inexpensive, and easy to use assessment of tail skin temperature.  Because 
these experiments were not assessing behavioral responses, this type of 
tethering is a minor concern.  Experiments where I used implanted telemetric 
probes with internal thermistors (allowing the animals to move completely freely 
and monitor core and tail temperature simultaneously) provided comparable 
flushing results.  These probes would be ideal for both long-term periodic 
assessment of provocation vulnerability and continuous monitoring over several 
days or even weeks.  The current design of the probe, even with customized 
modifications, can slip out of the tail and provide a measurement of core 
temperature; methodological refinement or more sophisticated implants may 
eliminate the need for tethering with thermistors.   
 
Difficulties in assessing anxiety behaviors 
There are several critical problems to assessing anxiety behaviors in animals, 
and additional complications in working with female rats.  First, the tests most 
commonly used to assess anxiety are dependent upon locomotion, which can 
easily be confounded.  For example, high doses of caffeine are anxiogenic, and 
an experiment in our lab administered a large dose of caffeine to rats.  The rats 
were placed in the center of the open field arena, and did not move for the 
duration of the test.  Conventions of the test dictate that the greater time spent in 
the center and away from the walls of the box indicate less anxiety-related 
behavior, yet this is a known anxiogenic drug.  These types of testing only 
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provide fairly crude measures and cannot measure internal state or emotions, 
only overt evidence of them.  Second, there are critical sex differences that make 
testing anxiety behaviors more or less feasible in female vs. male rats.  For 
example, one of the more sensitive anxiety tests (in males) is the Social 
Interaction tests, wherein two rats are placed in an arena, and the duration and 
nuances of time spent interacting (scoring the test rat) is quantified.  However, 
this test is difficult to perform in females because of interference from the estrous 
cycle (Frye et al., 2000), requiring that stage of estrous is controlled for, which 
eliminates natural sources of variability that were not controlled for in different 
experiments.  There is also conflicting evidence that estrogen is actually 
“anxiogenic” in the SI test, or at least when measured by spatial parameters 
(Koss et al., 2004).  Another example is the assessment of conditioned fear, 
measured by the time spent freezing after a tone (conditioned by a subsequent 
mild shock); females exhibit less freezing behavior when re-exposed to the 
conditioning chamber (Maren et al., 1994).  Additional groups have demonstrated 
that both contextual freezing and cue-induced freezing is estrus-stage dependent 
(Markus, 1997; Milad et al., 2009).  Finally, in my hands, the anxiety state 
induced by ovariectomy proved to be inconsistent (or at least was not always 
adequately reproduced in the behavioral tests that I used).  Initial studies 
demonstrated a decrease in exploratory behaviors in the open field test (and was 
prevented by SB-334867), but further studies failed to find anxiety-like behavior 
consistently, with some tests showing differences in anxiety between surgical 
groups but other tests were the same.  While other orexin receptor antagonists 
tested in these studies were anxiolytic, there were no interactions with surgical 
treatment.  All tests were performed within the same time frame after surgery, 
and so observed differences in anxiety could have been due to experimenters 
and/or any handling procedures between experiments.   
Recent work in the laboratory (by Aline Abreu Rezende) has focused on 
developing more sophisticated behavioral analyses; specifically, the elevated T 
maze (ETM) and defensive burying.  The first test can give measures of escape 
and avoidance behaviors, and is a multi-day, multi-trial protocol commonly used 
 140
to assess panic-associated behavior.  Early evidence for ETM’s use in assessing 
behavior in females looks quite promising (see Figure 26 on next page), and has 
shown estrus stage-dependent effects.  Another more ethologically relevant test 
is also being developed for use in females, defensive burying.  This test 
examines active (burying) versus passive (avoidance) coping by placing a shock 
probe in a cage of bedding, and quantifying time spent avoiding the probe and/or 
burying the probe.   
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Figure 26.  The Elevated T-maze Test of Anxiety-Associated Behaviors in Female Rats 
Across the Estrus Cycle.  
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Future Directions 
 
Manipulation of neurochemical systems 
While these models exhibit critical face, construct, predictive, and postdictive 
validity (estrogen replacement), additional validation should be performed.  As 
mentioned above, assessing the long-term vulnerability to the FG-7142 challenge 
and other neurochemical challenges would add to the validity of the model, 
particularly if there is a time-dependent vulnerability.  The immunohistochemical 
studies that I performed using c-fos and neurochemical phenotyping 
demonstrated construct validity by implicating the serontonergic and 
noradrenergic systems, but these systems have not yet been systematically 
manipulated and tested for effects on hot flash-associated responses.   
Future studies should determine what foci of these systems are necessary for 
hot flash provocation or if stimulation of any particular sites are sufficient to cause 
a hot flash on their own.  This could be achieved with neurochemical lesioning 
techniques (i.e. saporins targeting the serotonergic system) in a site-specific 
manner (i.e. the raphe pallidus or dorsal raphe nucleus) followed by baseline 
assessment and pharmacological provocation.  Specifically, the targets that were 
indicated by the immunohistochemical studies could be removed, including the 
perifornical hypothalamus, rostral raphe pallidus, rostroventral lateral medulla, 
and dorsal raphe.  Following this, baseline temperature assessment should be 
performed, and the ability of a particular provocation (i.e. FG-7142, CO2, or a 
thermal provocation, for example) could be determined.  Presently, these 
techniques are being validated in this laboratory for different research questions 
involving panic and anxiety, and implications for hot flash vulnerability are as yet 
unanswered.   
 
Refinement of Orexin’s Role in Hot Flash Associated Responses 
Based on prior evidence in this laboratory, it seems that orexin’s role in 
thermoregulation may be complicated.  Results from panic studies indicate that 
antagonizing the orexin system prior to panic provocation with sodium lactate or 
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CO2, respectively, can attenuate both an increase and decrease in core body 
temperature.  These studies both had dramatic increases in orexin levels, either 
by the provocation itself (CO2) or as a mechanism (by decreased GABA in the 
PeF through an inhibitor of GAD (Johnson et al., 2010).  Extant literature reports 
similarly divergent effects on core temperature and tail skin temperature when 
directly injecting orexin into the brain.  For example, a 2 µg i.c.v. injection of 
orexin-A in cold-adapted, conscious female rats elicited significant hypothermia 
and an increase in tail skin temperature to approximately 30 °C in a 15 °C room 
with no change in metabolic rate (Balasko et al., 1999).  Unfortunately, the data 
analysis was limited, with only a representative trace shown and no reporting of 
group data or the statistical significant of tail skin temperature changes.  Another 
group, after injection of 280 pmol of OX-A i.c.v., induced a 1.3 °C hypothermia in 
conscious, male rats 60 min following injection, but did not assess tail skin 
temperature (Jaszberenyi et al., 2002).  Perhaps the strongest evidence that 
supports the role of OX-A in eliciting hypothermia and consequent flushing 
comes from a microinjection study wherein a 30 pmol injection of OX-A into the 
raphe pallidus (in conscious rats) elicited a strong tail flush within 60 minutes 
(Luong and Carrive, 2012) and no overt change in body temperature (measured 
primarily with thermography).  
However, a number of other studies have demonstrated hyperthermia 
following i.c.v. OX-A injection (Monda et al., 2001, 2003a, 2003b, 2004, 2005).  
In contrast to Luong and Carrive’s study, a study of OX-A microinjections into the 
raphe pallidus (under cool body and skin conditions) elicited increased BAT 
thermogenesis and sympathetic nerve activity, and increased core body 
temperature (Tupone et al., 2011).  In this particular case, TST did increase 
significantly, but baseline values were in excess of 35 °C, so it is impossible to 
discern the magnitude of the contribution of OX-A to TST.  Importantly, these 
studies were performed under anesthesia and on a heating pad, so it is possible 
that these conflicting reports could be due to the experimental procedures.  
Another important point is the handling (picking the rats up) and data 
fragmentation involved in many of these studies, due to relatively crude 
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measures of assessing core temperature using rectal probes instead of 
implanted, telemetric devices for continuous measurement.  These factors are 
likely causing stress-induced hyperthermia that could be confounding the 
meaning of the results.  Most importantly, some of the conflict could be due to 
dose; Monda’s group consistently used 1.5 nmol/5 µL injections (and male rats) 
whereas Balasko’s group used 2 µg/5 µL injections; perhaps at very high doses, 
hypothermia occurs; according to Monda, his dosing regimen produces a sub-
maximal dose for hyperthermia.  An important series of experiments to address 
these discrepancies include 1) replicating an OX-A flush in both normal male and 
female rats (across the estrus cycle, ideally) in a dose-response design; and 2) 
determining whether ovariectomized rats have an exacerbated TST response to 
an OX-A infusion compared to sham or estrogen-replaced controls. Collectively, 
it seems clear that orexin regulates tail skin vasomotion, and future studies will 
be necessary to determine precisely how this is occurs under normal 
physiological conditions and following precipitous hormone loss.  
 
Identification of key nodal sites for orexinergic activity in hot flash responses 
Results from neurochemical studies consistently implicated the orexin system 
and its output sites as hyperactive in ovariectomized rats treated with FG-7142.  
Thoughout this work, every attempt has been made to use selective orexin 
receptor antagonists with high brain penetrance/receptor occupancy that are 
relatively sustained.  As I have always delivered these drugs systemically in 
testing their potential therapeutic efficacy, I have not delineated the sites within 
the orexin system (e.g. perifornical hypothalamus versus raphe pallidus or dorsal 
raphe) that are critical for the tail skin temperature response.  One approach to 
determining the necessity of a given site could be an orexin-conjugated saporin, 
though previously available molecules have been removed from the market.   
 
Identification of hypothalamic mechanisms 
This project has not yet definitively identified critical mechanistic targets in the 
hypothalamus.  An initial microarray analysis of GABA and glutamate-related 
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genes were performed (with tissue punched from the perifornical hypothalamus 
in ovariectomized or sham-ovariectomized rats), and significantly altered targets 
revealed the 2A subunit of the NMDA-type glutamate receptor (up-regulated in 
ovex rats) and mGluR4 (a Group III mGluR; down-regulated in OVEX rats).  I 
performed a pre-treatment study with the NMDA receptor antagonist memantine, 
and a moderate dose (5 mg/kg, i.p.) appeared to attenuate flushing induced by 
FG-7142.  Interestingly, in a few rats, this treatment combination elicited seizure-
like events, with hyperlocomotor activity and what can best be described as 
backflips, consistent with prior work [see (Loscher and Honack, 1990)].  
Importantly, memantine is a nonselective drug and has effects at multiple targets.  
It is an antagonist at 5-HT3 receptors and nicotinic acetylcholine receptors (α7) 
and an agonist at the dopamine D2 receptor in vitro (Rammes et al., 2001; 
Aracava et al., 2005; Seeman et al., 2008).  Stimulation of these targets probably 
mediates some of these effects.   
Secondly, to examine the contribution and/or potential therapeutic efficacy of 
augmenting metabotropic glutamate receptors in hot flash provocation, I 
performed a study using a systemically-administered mGluR2 (a Gi-coupled, pre- 
and postsynaptic receptor that can also couple with ERα) positive allosteric 
modulator, CBiPES.  This was a treatment that our laboratory had previously 
shown to be effective in reducing sodium lactate-induced panic-associated 
physiological and behavioral responses in an animal model (Johnson et al., 
2013).  Intriguingly, systemic CBiPES pre-treatment caused an immediate, high-
amplitude increase in tail skin temperature in OVEX rats; yet, after returning to 
baseline, the hot flash-associated response provoked with FG-7142 was 
attenuated in the CBiPES-treated group.  The distribution pattern of mGluR2 may 
provide some clues.  mGluR2 is heavily expressed in several nuclei of the 
amygdala, including the basolateral, basomedial, and terminals of the central part 
of the lateral amygdala also express mGluR2 (Ohishi et al., 1993, 1998; Gu et 
al., 2008).  As demonstrated in Ch. 2, Fig. 18c, the central amygdala was 
responsive to hot flash provocation, which suggests that this area may contribute 
to emotionally-relevant flushing.  This latter point suggests that future studies 
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should use site-specific treatments to modulate mGluRs within the amygdala 
and4 finely explore the relevance of these receptor systems with respect to 
thermoregulation, which would answer more basic, rather than translational, 
questions.  
Indeed, the role of the amygdala in thermoregulatory responses overall may 
be especially meaningful in light of emotionally-relevant stimuli.  A neuroimaging 
study of 12 volunteers exposed to fearful faces (and non-face scenes of the 
same emotional valence, in additional to geometric shapes controls) found that 
skin conductance (the most commonly measured clinical indicator of a hot) and 
blood-oxygen level dependent (BOLD) fMRI responses in the amgydala 
increased in response to the faces only (Hariri et al., 2002).  The amygdala 
response to fearful faces can be potentiated with a subthreshold dose of the 
anxiogenic drug, dextroamphetamine (Hariri et al., 2002b).  It appears that 
thermoregulatory sweating (sweating induced by temperature increase) is 
dissociable from emotional sweating, which occurs predominantly on the palms 
and soles.  In patients with Idiopathic Pure Sudomotor Failure, a condition in 
which thermoregulatory sweating is absent, emotional sweating is preserved 
(Nakazato et al., 2004).  Conversely, a case report of a 21-year old woman with 
limbic encephalitis/mesial temporal lobe lesions found reduced emotional 
sweating in response to tasks including mental arithmetic, exercise, or tactile 
sensation that was recovered as she improved clinically (Asahina et al., 2011).  
Similarly, patients with Urbach-Wiethe Disease, a rare condition in which the 
amgydala is calcified, exhibit blunted skin conductance responses in anticipation 
of a CO2 inhalation (Feinstein et al., 2013).  The distinction between emotional 
and thermoregulatory sweat responses in hot flashes is an outstanding and 
unanswered research question.  The localization and distinction between 
different inductions of sweating could be highly relevant to clinical studies of hot 
flashes, as skin conductance is often assayed in discrete areas, often the chest.  
Measuring skin conductance on the palms or soles of the feet could reveal 
significant information about the nature of hot flashes induced by different 
paradigms (i.e., CO2 inhalation compared to warming techniques).  Further, this 
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could be related to the affective dimensions of hot flashes, such as through 
standardized assessments of anxiety given after each of a series of challenges.  
 
Tamoxifen 
Lastly, because hot flashes are a serious side effect of some cancer 
treatments, this project could branch into exploring hot flash pathology in 
menopause induced by tamoxifen treatment.  Prior work in this lab demonstrated 
anxiety-like behavior following a short course of tamoxifen treatment in female 
rats (unpublished data), but this work was discontinued as the animals lost 
weight and appeared to be unwell.  However, improved methods of 
administration with subcutaneous pumps and refinement of dosing may improve 
outcomes.  This investigation could explore differences in the neural circuitry and 
neural mechanisms between the two models, and any sensitivity to the current 
pharmacological flushing agents would add validity to the vulnerability to 
challenges in rats with ovariectomy.  It may be that there are particular 
differences that would lead to more specialized targets despite precipitous 
estrogen loss of function in both cases; for example, in tamoxifen-treated women, 
the circadian periodicity to hot flashes has not been found (Carpenter et al., 
2001).  Additionally, though, there are groups working on developing endoxifen 
directly, so non-hormonal treatment options may be greater for cancer patients if 
these efforts are successful.     
 
Gaps in knowledge:  Clinical literature 
Hot flashes have only been subject to serious investigation for about the last 
25-30 years, and much of the early literature was highly descriptive and involved 
small numbers of participants.  It was not until the early 1990s that large, 
prospective cohort studies (such as the WHI and SWAN) started to be 
assembled and studied over many years.  Clearly, such studies are expensive 
and require coordination of multiple investigators over many sites to ensure that 
representative samples are recruited and adherence to standardized 
methodology is met.  Many of the early studies focused predominantly on 
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Caucasian women, and there does appear to be a few consistent associations 
with race or ethnicity as discussed in the introduction.  The factors mediating 
these differences have yet to be elucidated.  In fact, the mechanisms by which 
most of the known risk factors increase risk of hot flashes is unclear, and the 
precise mechanisms underlying estrogen’s role in ameliorating hot flashes is 
similarly murky.  Many studies have failed to find any correlation or have found 
only weak correlations between estrogen levels and hot flashes, which suggests 
that other hormones, neurochemicals, and/or proteins are involved.  Because of 
this gap, treatment strategies have similarly failed to advance much beyond 
estrogen derivatives.  Importantly, knowledge of estrogen’s mechanisms would 
inform treatment in other aspects of women’s health, especially post-menopausal 
bone loss and increased risk of cardiovascular events and stroke and cognitive 
complaints.   
There is also bias in some studies for participant selection, like those that 
include women who experience hot flashes in situations of increased ambient 
temperature or direct heating paradigms.  Certain studies that have examined the 
relationship between ambient or outdoor temperature have failed to find any 
significant associations (see the introduction for details), and the inclusion of 
these women to the exclusion of others creates the opportunity to only study one 
type of hot flash, if there are multiple ‘types’ of hot flashes.  It could be that there 
are ‘subtypes’ of hot flashes, each with distinct physiology and etiological factors.  
This is an area that needs systematic investigation, and studies with larger 
numbers of women are needed.  Imaging studies of hot flashes at present are 
extremely limited, which has hindered understanding of the neural mechanisms 
underlying these events.  At present, the voxel size in magnetic resonance 
imaging is larger than small subnuclei in the hypothalamus or brainstem regions 
(Diwadkar et al., 2014), and advancements in spatial resolution could greatly 
improve our understanding of the brain regions mediating hot flashes in women.   
Recent large cohort studies have used standardized assessments, and this is 
a great boon to the literature.  Many studies that examined anxiety in menopause 
used non-standardized or non-validated measures (see (Bryant et al., 2012)), 
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which had led to the contention that anxiety is not a symptom of menopause.  
More current literature has demonstrated that anxiety and stress-related stimuli 
are important factors in the hot flash experience, and further studies to finely 
elucidate how these factors contribute to hot flashes are essential.  It is unclear 
whether it is the experience of the hot flash(es) that contributes to anxiety, or if 
anxiety states heighten the probability of having hot flashes.  The study by 
(Swartzman et al., 1990) suggests that it may be the latter, as stressful stimuli 
increased the likelihood of having hot flashes in a laboratory setting.  However, 
this may be artificial, and long-term ambulatory monitoring would be helpful in 
trying to fine-tune this relationship.   
The strong placebo effect in hot flash trials is intriguing.  The placebo 
response rate for hot flashes is among the highest of all conditions studied, with 
rates ranging up to 58% in trials of estrogen replacement (Maclennan et al., 
2004).  Comparisons between studies demonstrate that, in some cases, a 
placebo is more effective in reducing hot flashes than the test compound.  A 
pooled analysis of treatment studies demonstrated the time course for placebo 
for hot flashes, and, like estrogen, the effects accumulated each week, which is 
curious since the compound is, by definition, inactive (Freeman et al., 2015).  
Strikingly, the factors that predicted response to placebo had substantial overlap 
with those factors that have demonstrated risk for hot flashes, including African-
American race, cigarette smoking, and greater hot flash severity.  Presently, it is 
unknown whether the mechanisms by which estrogen and placebo ameliorate 
hot flashes are the same or differ, and furthermore, it is not well understood if 
placebo mechanisms are the same between conditions (i.e. does the placebo 
work differently when used for chronic pain than hot flashes?).  Understanding 
the mechanism(s) underlying the placebo response could provide new treatment 
strategies that potentially have less risk of harm, or may provide strategies to 
enhance the placebo response and avoid using drug treatments altogether.   
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Reliance on self-report and question of measurement 
The vast majority of studies investigating hot flashes have used self-report 
diary-type measures, either paper or electronic versions wherein a woman notes 
the time and characteristics of a hot flash (i.e. intensity, duration).  The use of 
self-report measures has several drawbacks, including failure to report hot 
flashes due to time constraints or interference with daily activities or 
forgetfulness.  Objective physiological monitoring has used a few different 
methodologies, including monitoring of skin temperature, core temperature, and 
skin conductance or sweat rate, and the best correlations with subjective 
sensation were found with skin conductance (Tataryn et al., 1979).  Using both 
subjective and objective assessments of hot flashes allows for multiple 
dimensions of the hot flash experience to be studied.  Initially, studies of 
objective monitoring in the laboratory provided evidence that the association 
between an increase in sweating and the subjective label of a “hot flash” was 
quite high, approaching 100% (Freedman, 1989).  However, the use of these 
monitors in ambulatory settings has not replicated this concordance (Carpenter 
et al., 1999, 2004), and there may be important cultural differences in these 
measures (Sievert et al., 2002, 2008; Brown et al., 2009).  These monitors, while 
effective, can be bulky and rather conspicuous, and the thermal effects of 
clothing can interfere with monitoring; advancements in monitoring could greatly 
expand our knowledge of typical thermoregulatory patterns and hot flashes 
overall.  As Sievert discovered, there are important cultural or ethnic variations in 
sweating patterns during hot flashes among symptomatic women, and measuring 
sternal skin conductance to the exclusion of other sites, such as the back of the 
neck, may preclude the detection of a hot flash.  Furthermore, while these 
measures are useful in determining frequency, the magnitude of the sweat 
response does not provide an objective indicator of intensity or distress 
(Carpenter et al., 2005).  
So the question then becomes, what exactly is a hot flash?  Is it the sensation 
alone, or must it be accompanied by an increase in temperature and sweat rate?  
Sievert reports that not all hot flashes are accompanied by sweating, and 
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sweating in the absence of cutaneous vasodilation would lead to a cooling 
sensation (under conditions of appropriate relative humidity).  If not sweating, 
than an increase in skin temperature or blood flow?  Again, the magnitude of the 
increase or total duration of the increase does not correlate very well the 
subjective sensation.  So what psychological factors are involved in labeled a 
feeling of heat of varying amplitude, with or without sweating, as a hot flash?  
These are outstanding key questions in this field, (as summarized by (Miller and 
Li, 2004)).  The answers as to what neurochemicals and hormones contribute to 
certain components of hot flashes is a complex problem, and careful dissection 
of the systems implicated insofar using animal modeling may provide new 
avenues for treatment. 
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